

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

U.S. PTO

JC931

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR § 1.53(b))</i>		<i>Attorney Docket No</i>	1735.0410002/RWE/BEC
		<i>First Inventor</i>	John A Drewe et al
		<i>Title</i>	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof
		<i>Express Mail Label No</i>	

APPLICATION ELEMENTS
*See MPEP chapter 600 concerning utility patent application contents***ADDRESS TO:**
Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 142]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 5]
5. Oath or Declaration [Total Pages 2]
 a. Newly executed (original or copy)
 b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
 i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b)
6. Application Data Sheet. See 37 CFR 1.76.
7. CD-ROM or CD-R in duplicate, large table or Computer Program
(Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
 i. CD-ROM or CD-R (2 copies); or
 ii. paper
- c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
11. English Translation Document *(if applicable)*
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Other: Authorization under 37 C.F.R. § 1.136(a)(3)
 Other: _____

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

Continuation Divisional Continuation-in-Part (CIP)
Prior application information. Examiner _____ of prior application No: _____ / _____
Group/Art Unit. _____

For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label *(Insert Customer No. or Attach bar code label here)* or Correspondence address below

NAME	STERNE, KESSLER, GOLDSTEIN & FOX PLLC Attorneys at Law			
ADDRESS	Suite 600, 1100 New York Avenue, N W			
CITY	Washington	STATE	DC	ZIP CODE
COUNTRY	USA	TELEPHONE	(202) 371-2600	FAX
NAME (Print/Type)	Robert W. Esmond		Registration No (Attorney/Agent)	32,893
SIGNATURE	<i>Robert W. Esmond</i>		Date	November 6, 2000

Burden Hour Statement. This form is estimated to take 0 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT	(\$2,296.00)	Complete if Known
--------------------------------	---------------------	--------------------------

METHOD OF PAYMENT (check one)		FEE CALCULATION (continued)																																																																																																																																																																																																													
<p>1. <input type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:</p> <p>Deposit Account Number 19-0036</p> <p>Deposit Account Name Sterne, Kessler, Goldstein & Fox P L L C</p> <p><input type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17</p> <p><input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27</p>		<p>3. ADDITIONAL FEES</p> <table border="1"> <thead> <tr> <th>Large Entity</th> <th>Small Entity</th> </tr> </thead> <tbody> <tr> <td>Fee Code</td> <td>Fee (\$)</td> <td>Fee Code</td> <td>Fee (\$)</td> <td>Fee Description</td> <td>Fee paid</td> </tr> <tr> <td>105</td> <td>130</td> <td>205</td> <td>65</td> <td>Surcharge - late filing fee or oath</td> <td></td> </tr> <tr> <td>127</td> <td>50</td> <td>227</td> <td>25</td> <td>Surcharge - late provisional filing fee or cover sheet</td> <td></td> </tr> <tr> <td>139</td> <td>130</td> <td>139</td> <td>130</td> <td>Non-English specification</td> <td></td> </tr> <tr> <td>147</td> <td>2,520</td> <td>147</td> <td>2,520</td> <td>For filing a request for ex parte reexamination</td> <td></td> </tr> <tr> <td>112</td> <td>920*</td> <td>112</td> <td>920*</td> <td>Requesting publication of SIR prior to Examiner action</td> <td></td> </tr> <tr> <td>113</td> <td>1,840*</td> <td>113</td> <td>1,840*</td> <td>Requesting publication of SIR after Examiner action</td> <td></td> </tr> <tr> <td>115</td> <td>110</td> <td>215</td> <td>55</td> <td>Extension for reply within first month</td> <td></td> </tr> <tr> <td>116</td> <td>390</td> <td>216</td> <td>195</td> <td>Extension for reply within second month</td> <td></td> </tr> <tr> <td>117</td> <td>890</td> <td>217</td> <td>445</td> <td>Extension for reply within third month</td> <td></td> </tr> <tr> <td>118</td> <td>1,390</td> <td>218</td> <td>695</td> <td>Extension for reply within fourth month</td> <td></td> </tr> <tr> <td>128</td> <td>1,890</td> <td>228</td> <td>945</td> <td>Extension for reply within fifth month</td> <td></td> </tr> <tr> <td>119</td> <td>310</td> <td>219</td> <td>155</td> <td>Notice of Appeal</td> <td></td> </tr> <tr> <td>120</td> <td>310</td> <td>220</td> <td>155</td> <td>Filing a brief in support of an appeal</td> <td></td> </tr> <tr> <td>121</td> <td>270</td> <td>221</td> <td>135</td> <td>Request for oral hearing</td> <td></td> </tr> <tr> <td>138</td> <td>1,510</td> <td>138</td> <td>1,510</td> <td>Petition to institute a public use proceeding</td> <td></td> </tr> <tr> <td>140</td> <td>110</td> <td>240</td> <td>55</td> <td>Petition to revive - unavoidable</td> <td></td> </tr> <tr> <td>141</td> <td>1,240</td> <td>241</td> <td>620</td> <td>Petition to revive - unintentional</td> <td></td> </tr> <tr> <td>142</td> <td>1,240</td> <td>242</td> <td>620</td> <td>Utility issue fee (or reissue)</td> <td></td> </tr> <tr> <td>143</td> <td>440</td> <td>243</td> <td>220</td> <td>Design issue fee</td> <td></td> </tr> <tr> <td>144</td> <td>600</td> <td>244</td> <td>300</td> <td>Plant issue fee</td> <td></td> </tr> <tr> <td>122</td> <td>130</td> <td>122</td> <td>130</td> <td>Petitions to the Commissioner</td> <td></td> </tr> <tr> <td>123</td> <td>50</td> <td>123</td> <td>50</td> <td>Petitions related to provisional applications</td> <td></td> </tr> <tr> <td>126</td> <td>240</td> <td>126</td> <td>240</td> <td>Submission of Information Disclosure Stmt</td> <td></td> </tr> <tr> <td>581</td> <td>40</td> <td>481</td> <td>40</td> <td>Recording each patent assignment per property (times number of properties)</td> <td>40</td> </tr> <tr> <td>146</td> <td>710</td> <td>246</td> <td>355</td> <td>Filing a submission after final rejection (37 CFR 1.129(a))</td> <td></td> </tr> <tr> <td>149</td> <td>710</td> <td>249</td> <td>355</td> <td>For each additional invention to be examined (37 CFR 1.129(b))</td> <td></td> </tr> <tr> <td>179</td> <td>710</td> <td>279</td> <td>355</td> <td>Request for Continued Examination (RCE)</td> <td></td> </tr> <tr> <td>169</td> <td>900</td> <td>169</td> <td>900</td> <td>Request for expedited examination of a design application</td> <td></td> </tr> <tr> <td colspan="6">Other fee (specify)</td> </tr> <tr> <td colspan="6">Other fee (specify) :</td> </tr> <tr> <td colspan="6">*Reduced by Basic Filing Fee Paid</td> </tr> <tr> <td colspan="6">SUBTOTAL (3) (\$ 40.00)</td> </tr> </tbody> </table>						Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee paid	105	130	205	65	Surcharge - late filing fee or oath		127	50	227	25	Surcharge - late provisional filing fee or cover sheet		139	130	139	130	Non-English specification		147	2,520	147	2,520	For filing a request for ex parte reexamination		112	920*	112	920*	Requesting publication of SIR prior to Examiner action		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		115	110	215	55	Extension for reply within first month		116	390	216	195	Extension for reply within second month		117	890	217	445	Extension for reply within third month		118	1,390	218	695	Extension for reply within fourth month		128	1,890	228	945	Extension for reply within fifth month		119	310	219	155	Notice of Appeal		120	310	220	155	Filing a brief in support of an appeal		121	270	221	135	Request for oral hearing		138	1,510	138	1,510	Petition to institute a public use proceeding		140	110	240	55	Petition to revive - unavoidable		141	1,240	241	620	Petition to revive - unintentional		142	1,240	242	620	Utility issue fee (or reissue)		143	440	243	220	Design issue fee		144	600	244	300	Plant issue fee		122	130	122	130	Petitions to the Commissioner		123	50	123	50	Petitions related to provisional applications		126	240	126	240	Submission of Information Disclosure Stmt		581	40	481	40	Recording each patent assignment per property (times number of properties)	40	146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))		149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))		179	710	279	355	Request for Continued Examination (RCE)		169	900	169	900	Request for expedited examination of a design application		Other fee (specify)						Other fee (specify) :						*Reduced by Basic Filing Fee Paid						SUBTOTAL (3) (\$ 40.00)					
Large Entity	Small Entity																																																																																																																																																																																																														
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee paid																																																																																																																																																																																																										
105	130	205	65	Surcharge - late filing fee or oath																																																																																																																																																																																																											
127	50	227	25	Surcharge - late provisional filing fee or cover sheet																																																																																																																																																																																																											
139	130	139	130	Non-English specification																																																																																																																																																																																																											
147	2,520	147	2,520	For filing a request for ex parte reexamination																																																																																																																																																																																																											
112	920*	112	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																																																											
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																																																											
115	110	215	55	Extension for reply within first month																																																																																																																																																																																																											
116	390	216	195	Extension for reply within second month																																																																																																																																																																																																											
117	890	217	445	Extension for reply within third month																																																																																																																																																																																																											
118	1,390	218	695	Extension for reply within fourth month																																																																																																																																																																																																											
128	1,890	228	945	Extension for reply within fifth month																																																																																																																																																																																																											
119	310	219	155	Notice of Appeal																																																																																																																																																																																																											
120	310	220	155	Filing a brief in support of an appeal																																																																																																																																																																																																											
121	270	221	135	Request for oral hearing																																																																																																																																																																																																											
138	1,510	138	1,510	Petition to institute a public use proceeding																																																																																																																																																																																																											
140	110	240	55	Petition to revive - unavoidable																																																																																																																																																																																																											
141	1,240	241	620	Petition to revive - unintentional																																																																																																																																																																																																											
142	1,240	242	620	Utility issue fee (or reissue)																																																																																																																																																																																																											
143	440	243	220	Design issue fee																																																																																																																																																																																																											
144	600	244	300	Plant issue fee																																																																																																																																																																																																											
122	130	122	130	Petitions to the Commissioner																																																																																																																																																																																																											
123	50	123	50	Petitions related to provisional applications																																																																																																																																																																																																											
126	240	126	240	Submission of Information Disclosure Stmt																																																																																																																																																																																																											
581	40	481	40	Recording each patent assignment per property (times number of properties)	40																																																																																																																																																																																																										
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))																																																																																																																																																																																																											
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))																																																																																																																																																																																																											
179	710	279	355	Request for Continued Examination (RCE)																																																																																																																																																																																																											
169	900	169	900	Request for expedited examination of a design application																																																																																																																																																																																																											
Other fee (specify)																																																																																																																																																																																																															
Other fee (specify) :																																																																																																																																																																																																															
*Reduced by Basic Filing Fee Paid																																																																																																																																																																																																															
SUBTOTAL (3) (\$ 40.00)																																																																																																																																																																																																															
<p>Total Claims <u>82</u> - 20** = <u>62</u> X <u>18</u> = <u>1,116</u></p> <p>Indep. Claims <u>5</u> - 3** = <u>2</u> X <u>80</u> = <u>160</u></p> <p>Multiple Dependent <u>270</u> = <u>270</u></p> <p>Large Entity Small Entity Fee Description Fee Paid</p> <table border="1"> <thead> <tr> <th>Large Entity Fee Code (\$)</th> <th>Small Entity Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>103</td> <td>18</td> <td>203</td> <td>9</td> <td>Claims in excess of 20</td> <td></td> </tr> <tr> <td>102</td> <td>80</td> <td>202</td> <td>40</td> <td>Independent claims in excess of 3</td> <td></td> </tr> <tr> <td>104</td> <td>270</td> <td>204</td> <td>135</td> <td>Multiple dependent claim</td> <td></td> </tr> <tr> <td>108</td> <td>80</td> <td>209</td> <td>40</td> <td>**Reissue independent claims over original patent</td> <td></td> </tr> <tr> <td>110</td> <td>18</td> <td>210</td> <td>9</td> <td>**Reissue claims in excess of 20 and over original patent</td> <td></td> </tr> </tbody> </table> <p>SUBTOTAL (2) (\$ 1,546.00)</p>		Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	103	18	203	9	Claims in excess of 20		102	80	202	40	Independent claims in excess of 3		104	270	204	135	Multiple dependent claim		108	80	209	40	**Reissue independent claims over original patent		110	18	210	9	**Reissue claims in excess of 20 and over original patent		<p>Complete if applicable</p> <p>SUBMITTED BY</p> <table border="1"> <tr> <td>Name (Print/Type)</td> <td>Robert W. Esmond</td> <td>Registration No (Attorney/Agent)</td> <td>32,893</td> <td>Telephone</td> <td>202-371-2600</td> </tr> <tr> <td>Signature</td> <td><i>Robert W. Esmond</i></td> <td>Date</td> <td colspan="3">11/06/00</td> </tr> </table>						Name (Print/Type)	Robert W. Esmond	Registration No (Attorney/Agent)	32,893	Telephone	202-371-2600	Signature	<i>Robert W. Esmond</i>	Date	11/06/00																																																																																																																																																												
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid																																																																																																																																																																																																												
103	18	203	9	Claims in excess of 20																																																																																																																																																																																																											
102	80	202	40	Independent claims in excess of 3																																																																																																																																																																																																											
104	270	204	135	Multiple dependent claim																																																																																																																																																																																																											
108	80	209	40	**Reissue independent claims over original patent																																																																																																																																																																																																											
110	18	210	9	**Reissue claims in excess of 20 and over original patent																																																																																																																																																																																																											
Name (Print/Type)	Robert W. Esmond	Registration No (Attorney/Agent)	32,893	Telephone	202-371-2600																																																																																																																																																																																																										
Signature	<i>Robert W. Esmond</i>	Date	11/06/00																																																																																																																																																																																																												

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

** or number previously paid, if greater. For Reissues, see above.



STEVE KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, D.C. 20005-3934

www.skgf.com

PHONE (202) 371-2600 FACSIMILE (202) 371-2540

JC931 U.S. PRO
109/705840
11/06/00

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL Q. LEE

STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*

HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. McCALL
TERESA U. MEDLER

JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
MATTHEW M. CATLETT*
NATHAN K. KELLEY*
ALBERT J. FASULO II *
W. BRIAN EDGE*

KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
ANDREA J. KAMAGE**
NANCY J. LEITH**
TARJA H. NAUKKARINEN**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

November 6, 2000

WRITER'S DIRECT NUMBER:

(202) 371-2560

INTERNET ADDRESS:

resmond@skgf.com

Commissioner for Patents
Washington, D.C. 20231

Box Patent Application

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
Appl. No. (to be assigned); filed (herewith)
For: **Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof**
Inventors: Drewe *et al.*
Our Ref: 1735.0410002/RWE/BEC

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. Fee Transmittal (Form PTO/SB/17) (in duplicate);
2. Utility Patent Application Transmittal (Form PTO/SB/05);
3. U.S. Utility Patent Application entitled:

Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof

and naming as inventors:

John A. Drewe
Sui Xiong Cai
Yan Wang

Commissioner for Patents
November 6, 2000
Page 2

the application consisting of:

- a. A specification containing:
 - i. 99 pages of description prior to the claims;
 - ii. 42 pages of claims (claims 1-78); and
 - iii. 1 page abstract;
 - b. Five (5) sheets of drawings (Figures 1A-1B; 2-3; 4A-4B; 5A-5C and 6A-6C); and
 - c. An executed Declaration for Patent Application;
4. Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate);
5. Recordation Form Cover Sheet (Form PTO-1595);
6. An executed Assignment to Cytovia, Inc., recordation of which is hereby respectfully requested;
7. An executed Power of Attorney from Assignee;
8. A Certificate under 37 C.F.R. § 3.73(b) from Assignee with a copy of Assignment attached;
9. Two (2) return postcards; and
10. Our check No. 39361 for \$2,296.00 to cover:

\$ 710.00 Basic filing fee (37 C.F.R. § 1.16(a));
160.00 Independent claims in excess of three (37 C.F.R. § 1.16(b));
1,116.00 Claims in excess of twenty (37 C.F.R. § 1.16(c));
270.00 Multiple dependent claim (37 C.F.R. § 1.16(d)); and
40.00 Assignment recordation fee (37 C.F.R. § 1.21(h)).


Commissioner for Patents
November 6, 2000
Page 3

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

RWE/BEC/dab
P:\USERS\DENISEB\1735\0412appcov
Enclosures

2025 RELEASE UNDER E.O. 14176

Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof

5

Background of the Invention

Cross Reference to Related Applications

10 This application claims the benefit of Provisional Application No. 60/185,211, filed February 24, 2000, and Provisional Application No. 60/163,584, filed November 5, 1999, the contents of which are fully incorporated by reference herein.

Field of the Invention

15 This invention is in the field of medicinal chemistry. In particular, the invention relates to substituted 4H-chromene and analogs, and the discovery that these compounds are activators of caspases and inducers of apoptosis. The invention also relates to the use of these compounds as therapeutically effective anti-cancer agents.

Description of Background Art

25 Organisms eliminate unwanted cells by a process variously known as regulated cell death, programmed cell death or apoptosis. Such cell death occurs as a normal aspect of animal development as well as in tissue homeostasis and aging (Glucksmann, A., *Biol. Rev. Cambridge Philos. Soc.* 26:59-86 (1951); Glucksmann, A., *Archives de Biologie* 76:419-437 (1965); Ellis, *et al.*, *Dev.* 112:591-603 (1991); Vaux, *et al.*, *Cell* 76:777-779 (1994)).
30 Apoptosis regulates cell number, facilitates morphogenesis, removes harmful or otherwise abnormal cells and eliminates cells that have already performed their function. Additionally, apoptosis occurs in response to various

physiological stresses, such as hypoxia or ischemia (PCT published application WO96/20721).

There are a number of morphological changes shared by cells experiencing regulated cell death, including plasma and nuclear membrane blebbing, cell shrinkage (condensation of nucleoplasm and cytoplasm), organelle relocalization and compaction, chromatin condensation and production of apoptotic bodies (membrane enclosed particles containing intracellular material) (Orrenius, S., *J. Internal Medicine* 237:529-536 (1995)).

Apoptosis is achieved through an endogenous mechanism of cellular suicide (Wyllie, A.H., in *Cell Death in Biology and Pathology*, Bowen and Lockshin, eds., Chapman and Hall (1981), pp. 9-34). A cell activates its internally encoded suicide program as a result of either internal or external signals. The suicide program is executed through the activation of a carefully regulated genetic program (Wyllie, *et al.*, *Int. Rev. Cyt.* 68:251 (1980); Ellis, *et al.*, *Ann. Rev. Cell Bio.* 7:663 (1991)). Apoptotic cells and bodies are usually recognized and cleared by neighboring cells or macrophages before lysis. Because of this clearance mechanism, inflammation is not induced despite the clearance of great numbers of cells (Orrenius, S., *J. Internal Medicine* 237:529-536 (1995)).

It has been found that a group of proteases are a key element in apoptosis (see, e.g., Thornberry, *Chemistry and Biology* 5:R97-R103 (1998); Thornberry, *British Med. Bull.* 53:478-490 (1996)). Genetic studies in the nematode *Caenorhabditis elegans* revealed that apoptotic cell death involves at least 14 genes, two of which are the pro-apoptotic (death-promoting) *ced* (for *cell death abnormal*) genes, *ced-3* and *ced-4*. CED-3 is homologous to interleukin 1 beta-converting enzyme, a cysteine protease, which is now called caspase-1. When these data were ultimately applied to mammals, and upon further extensive investigation, it was found that the mammalian apoptosis system appears to involve a cascade of caspases, or a system that behaves like a cascade of caspases. At present, the caspase family of cysteine proteases comprises 14 different members, and more may be discovered in the future. All known caspases are synthesized as zymogens that require cleavage at an

DRAFT-2002-02-06


aspartyl residue prior to forming the active enzyme. Thus, caspases are capable of activating other caspases, in the manner of an amplifying cascade.

Apoptosis and caspases are thought to be crucial in the development of cancer (*Apoptosis and Cancer Chemotherapy*, Hickman and Dive, eds., Humana Press (1999)). There is mounting evidence that cancer cells, while containing caspases, lack parts of the molecular machinery that activates the caspase cascade. This makes the cancer cells lose their capacity to undergo cellular suicide and the cells become immortal-they become cancerous. In the case of the apoptosis process, control points are known to exist that represent points for intervention leading to activation. These control points include the CED-9-BCL-like and CED-3-ICE-like gene family products, which are intrinsic proteins regulating the decision of a cell to survive or die and executing part of the cell death process itself, respectively (see, Schmitt, *et al.*, *Biochem. Cell. Biol.* 75:301-314 (1997)). BCL-like proteins include BCL-xL and BAX-alpha, which appear to function upstream of caspase activation. BCL-xL appears to prevent activation of the apoptotic protease cascade, whereas BAX-alpha accelerates activation of the apoptotic protease cascade.

It has been shown that chemotherapeutic (anti-cancer) drugs can trigger cancer cells to undergo suicide by activating the dormant caspase cascade. This may be a crucial aspect of the mode of action of most, if not all, known anticancer drugs (Los, *et al.*, *Blood* 90:3118-3129 (1997); Friesen, *et al.*, *Nat. Med.* 2:574 (1996)). The mechanism of action of current antineoplastic drugs frequently involves an attack at specific phases of the cell cycle. In brief, the cell cycle refers to the stages through which cells normally progress during their lifetimes. Normally, cells exist in a resting phase termed G₀. During multiplication, cells progress to a stage in which DNA synthesis occurs, termed S. Later, cell division, or mitosis occurs, in a phase called M. Antineoplastic drugs such as cytosine arabinoside, hydroxyurea, 6-mercaptopurine, and methotrexate are S phase specific, whereas antineoplastic drugs such as vincristine, vinblastine, and paclitaxel are M phase specific. Many slow growing tumors, for example colon cancers, exist primarily in the G₀ phase, whereas rapidly proliferating normal tissues, for

example bone marrow, exist primarily in the S or M phase. Thus, a drug like 6-mercaptopurine can cause bone marrow toxicity while remaining ineffective for a slow growing tumor. Further aspects of the chemotherapy of neoplastic diseases are known to those skilled in the art (see, e.g., Hardman, *et al.*, eds., *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, Ninth Edition, McGraw-Hill, New York (1996), pp. 1225-1287). Thus, it is clear that the possibility exists for the activation of the caspase cascade, although the exact mechanisms for doing so are not clear at this point. It is equally clear that insufficient activity of the caspase cascade and consequent apoptotic events are implicated in various types of cancer. The development of caspase cascade activators and inducer of apoptosis is a highly desirable goal in the development of therapeutically effective antineoplastic agents. Moreover, since autoimmune disease and certain degenerative diseases also involve the proliferation of abnormal cells, therapeutic treatment for these diseases could also involve the enhancement of the apoptotic process through the administration of appropriate caspase cascade activators and inducers of apoptosis.

EP537949 discloses derivatives of 4H-naphthol[1,2-b]pyran as antiproliferatives:



20

wherein,

each R¹ is independently halo, trifluoromethyl, C₁₋₄ alkoxy, hydroxy, nitro, C₁₋₄ alkyl, C₁₋₄ alkylthio, hydroxy-C₁₋₄alkyl, hydroxy-C₁₋₄alkoxy, trifluoromethoxy, carboxy, -COOR⁵ where R⁵ is an ester group, -CONR⁶R⁷ or -NR⁶R⁷

25


where R⁶ and R⁷ are each hydrogen or C₁₋₄ alkyl;

R² is phenyl, napthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, wherein said phenyl, napthyl and heteroaryl groups are optionally substituted, or R² is furanyl optionally substituted with C₁₋₄ alkyl;

DRAFT - CONFIDENTIAL

R³ is nitrile, carboxy, -COOR⁸ where R⁸ is an ester group, -CONR⁹R¹⁰ where R⁹ and R¹⁰ are each hydrogen or C₁₋₄ alkyl or R¹¹SO₂ where R¹¹ is C₁₋₄ alkyl or optionally substituted phenyl;


5 R⁴ is -NR¹²R¹³, -NHCOR¹², -N(COR¹²)₂ or -N=CHOCH₂R¹² where R¹² and R¹³ are each hydrogen or C₁₋₄alkyl optionally substituted with carboxy, or R⁴ is



where X is C₂₋₄ alkylene, or R⁴ is -NHSO₂R¹⁴ where R¹⁴ is C₁₋₄ alkyl or optionally substituted phenyl; and

10 n is 0-2.

US5281619 discloses naphthopyrans for therapy of diabetic complications:



wherein,

15 R¹ is C₁₋₄ alkoxy, OH or COOH;


R² is optionally substituted phenyl;

R³ is nitrile, or R³ is carboxy or -COOR⁸ when R² is phenyl substituted with 3-nitro or 3-trifluoromethyl and R⁸ is an ester group;

20 R⁴ is NR¹²R¹³, -NHCOR¹², -N(COR¹²)₂ or -N=CHOCH₂R¹², wherein R¹² and R¹³ are each H or C₁₋₄ alkyl; and

n is 0-2.


EP599514 discloses the preparation of pyranoquinoline derivatives as inhibitors of cell proliferation:



wherein R¹ is optionally substituted phenyl or optionally substituted heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, or R¹ is furanyl optionally substituted with C₁₋₄ alkyl;

R² is nitrile, carboxy, -CO₂R⁴ wherein R⁴ is an ester group, -CON(R⁵)R⁶ where R⁵ and R⁶ are independently H or C₁₋₄ alkyl, or R⁷SO₂ where R⁷ is C₁₋₄ alkyl or optionally substituted phenyl;


R³ is -NR⁸R⁹, -NHCOR⁸, -N(CO₂R⁸)₂, -N=CHOR⁸ where R⁸ and R⁹ are independently H or C₁₋₄ alkyl, or -NHSO₂R¹⁰ where R¹⁰ is C₁₋₄ alkyl or optionally substituted phenyl, or



where X is C₂₋₄ alkylene; and

the ring P represents a pyridine fused to the benzopyran nucleus.

EP618206 discloses the preparation of naphthopyran and pyranoquinoline as immunosuppressants and cell proliferation inhibitors:



wherein,

A-B is CH₂CH₂ or CH=CH;

each R¹ is independently halo, carboxy, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy-C₁₋₄alkyl, hydroxy-C₁₋₄alkoxy, nitrogen-containing heterocyclyl, nitro, trifluoromethoxy, -COOR⁵ where R⁵ is an ester group, -COR⁶, -CONR⁶R⁷ or -NR⁶R⁷ where R⁶ and R⁷ are each hydrogen or C₁₋₄ alkyl;

5 R² is phenyl, napthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, wherein said phenyl, napthyl and heteroaryl groups are optionally substituted, or R² is furanyl optionally substituted with C₁₋₄ alkyl;


10 R³ is nitrile, carboxy, -COOR⁸ where R⁸ is an ester group, -CONR⁹R¹⁰ where R⁹ and R¹⁰ are each hydrogen or C₁₋₄ alkyl, or -SO₂R¹¹ where R¹¹ is C₁₋₄ alkyl or optionally substituted phenyl-C₁₋₄alkyl;

15 R⁴ is 1-pyrrolyl, 1-imidazolyl or 1-pyrazolyl, each of which is optionally substituted by one or two C₁₋₄ alkyl, carboxyl, hydroxyl-C₁₋₄alkyl or -CHO groups, or R⁴ is 1-(1,2,4-triazolyl), 1-(1,3,4-triazolyl) or 2-(1,2,3-triazolyl), each of which is optionally substituted by a C₁₋₄ alkyl or C₁₋₄ perfluoroalkyl group, or R⁴ is 1-tetrazolyl optionally substituted by C₁₋₄ alkyl;

X is a pyridine or a benzene ring; and


n is 0-2.

20 EP619314 discloses the preparation of 4-phenyl-4H- naphtho(2,1-b)pyran derivatives:



wherein,


R₁ and R₂ are independently halo, trifluoromethyl, C₁-C₄ alkoxy, hydroxy, nitro, C₁-C₄ alkyl, C₁-C₄ alkylthio, hydroxy-C₁-C₄ alkyl, hydroxy-C₁-C₄ alkoxy, trifluoromethoxy, carboxy, -COOR₈ where R₈ is an ester group, -COR₉, -CONR₉R₁₀ or -NR₉R₁₀ where R₉ and R₁₀ are each hydrogen or C₁-C₄ alkyl; R₃ is nitrile, carboxy or -CO₂R₁₁ wherein R₁₁ is an ester group; R₄ is -NR₁₂R₁₃, -NR₁₂COR₁₃, -N(COR₁₂)₂ or -N=CHOCH₂R₁₂ where R₁₂ and R₁₃ are each hydrogen or C₁-C₄ alkyl, or R₄ is



where X is C₂-C₄ alkylene, or R₄ is optionally substituted 1-pyrrolyl; and m and n are each independently 0-2.


The compounds are said to be useful for the treatment of restenosis, immune disease, and diabetic complications.

Smith, et al., (*Bioorg. Med. Chem. Lett.* 5:2783-2788 (1995)) reported the anti-rheumatic potential of a series of 2,4-di-substituted-4H-naphtho[1,2-b]pyran-3-carbonitriles. They reported that 4-(3-nitrophenyl)-2-(N-succinimido)-4H-naphtho[1,2-b]pyran-3-carbonitrile has proved to be acid stable and still retains biological activity:



Birch, et al., (*Diabetes* 45:642-650 (1996)) reported that LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-

stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element.



LY290181

5

Panda, *et al.*, (*J. Biol. Chem.* 272: 7681-7687 (1997)) reported the suppression of microtubule dynamics by LY290181, which might be the potential mechanism for its antiproliferative action.

10

Wood, *et al.*, (*Mol. Pharmacol.* 52: 437-444 (1997)) reported that LY290181 inhibited mitosis and microtubule function through direct tubulin binding.

15

PCT published patent application WO9824427 disclosed antimicrotubule compositions and methods for treating or preventing inflammatory diseases. LY290181 was listed as an antimicrotubule agent.

Summary of the Invention

20

The present invention is related to the discovery that substituted 4H-chromene and analogs, as represented in Formula I, are activators of the caspase cascade and inducers of apoptosis. Thus, an aspect of the present invention is directed to the use of compounds of Formula I as inducers of apoptosis.

25

A second aspect of the present invention is to provide a method for treating, preventing or ameliorating neoplasia and cancer by administering a compound of Formula I to a mammal in need of such treatment.

5

Many of compounds within the scope of the present invention are novel compounds. Therefore, a third aspect of the present invention is to provide novel compounds of Formula I, and to also provide for the use of these novel compounds for treating, preventing or ameliorating neoplasia and cancer.

10

A fourth aspect of the present invention is to provide a pharmaceutical composition useful for treating disorders responsive to the induction of apoptosis, containing an effective amount of a compound of Formula I in admixture with one or more pharmaceutically acceptable carriers or diluents.

15 A fifth aspect of the present invention is directed to methods for the preparation of novel compounds of Formula I.

Brief Description of the Drawings

15

Figs. 1A-B depict fluorescent micrographs of Jurkat cells as controls and as treated with drug and stained with a fluorescent DNA probe, Syto16. Fig. 1A depicts control cells. Fig. 1B depicts cells treated with 100 nM of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene for 24 h, showing shrunken and fragmented nuclei.

20

Figs. 2A-E depict western blots of drug induced poly(ADP)ribose polymerase (PARP) cleavage in Jurkat cells. Fig. 2A: DMSO treated control cells. Fig. 2B: cells treated with 1 μ M of staurosporine for 3 h. Fig. 2C: cells treated with 2.5 μ M of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene for 5 h. Fig. 2D: cells treated with 2.5 μ M of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene for 15 h. Fig. 2E: cells treated with 2.5 μ M of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene for 30 h.

25

Fig. 3 is a graph showing mitotic arrest in Jurkat cells treated for 6 h with different concentrations of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene. Fig. 3 shows increasing

30

USCENTRE-CHENG02/680

percent mitotic arrest with increasing drug concentration up to a concentration of 1.0 μM .

5 Figs. 4A-B are graphs showing drug induced cell cycle arrest in Jurkat cells. Fig. 4A: control cells showing most of the cells in G1. Fig. 4B: cells treated with 1 μM of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene for 18 h showing progression and arrest in S/G2/M.


10 Figs. 5A-C are graphs showing drug induced cell cycle arrest in T47D cells. Fig. 5A: control cells showing most of the cells in G1. Fig. 5B: cells treated with 1 μM of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene for 18 h showing progression and arrest in G2/M. Fig. 5C: cells treated with 1 μM of 2-amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4H-chromene for 18 h showing progression and arrest in G2/M.

15 Figs. 6A-C are graphs showing drug induced cell cycle arrest in PC-3 cells. Fig. 6A: control cells showing most of the cells in G1. Fig. 6B: cells treated with 1 μM of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene for 18 h showing progression and arrest in G2/M. Fig. 6C: cells treated with 1 μM of 2-amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4H-chromene for 18 h showing progression and arrest in G2/M.

Detailed Description of the Invention


25 The present invention arises out of the discovery that substituted 4H-chromene and analogs, as represented in Formula I, are potent and highly efficacious activators of the caspase cascade and inducers of apoptosis. Therefore compounds of Formula I are useful for treating disorders responsive to induction of apoptosis.

30 Specifically, compounds useful in this aspect of the present invention are represented by Formula I:



- or pharmaceutically acceptable salts or prodrugs thereof, wherein:
- X is O, S or NR₆, wherein R₆ is hydrogen or optionally substituted alkyl;
- 5 Y is CN, COR₇, CO₂R₇ or CONR_xR_y, wherein R₇, R_x and R_y are independently hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R_x and R_y are taken together with the nitrogen to which they are attached to form a heterocycle;
- 10 Z is NR₈R₉, NHCOR₈, N(COR₈)₂, N(COR₈)(COR₉), N=CHOR₈ or N=CHR₈, wherein R₈ and R₉ are independently H, C₁₋₄ alkyl or aryl, or R₈ and R₉ are combined together with the group attached to them to form a heterocycle;
- R₅ is hydrogen or C₁₋₁₀ alkyl;
- 15 A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic, arylalkyl or heteroarylalkyl; and
- B is an optionally substituted aromatic or heteroaromatic ring.
- Preferred compounds of Formula I include compounds wherein A is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, thienyl, furyl, pyrrolyl, 2-phenylethyl or cyclohexyl, any of which is optionally substituted..
- 20 Preferably B is optionally substituted and selected from the group consisting of benzo, naphtho, indolo, quino and isoquino. Preferably, R₅ is hydrogen. Preferably, X is O or S. Most preferably, X is O. Preferably, Z is NH₂. Preferably, Y is CN.

25 Preferred structures of Formula I are substituted 4H-chromene and analogs represented by Formulae II-IV. In particular, a preferred embodiment is represented by Formula II:



(II)

or pharmaceutically acceptable salts or prodrugs thereof, wherein R₅, X, Y, Z and A are as defined previously with respect to Formula I; and R₁-R₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or

R₁ and R₂, or R₂ and R₃, or R₃ and R₄, taken together with the atoms to which they are attached form an aryl, heteroaryl, partially saturated carbocyclic or partially saturated heterocyclic group, wherein said group is optionally substituted.

Preferred are compounds of Formula II, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, taken together form a structure selected from the group consisting of -OCH₂O-, -(CH₂)₃-, -(CH₂)₄-, -OCH₂CH₂O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.


Also preferred are compounds of Formula II, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, taken together form a structure selected from the group consisting of -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- and -CH=CH-CH=N-.

Preferred compounds falling within the scope of Formula II include compounds wherein R₁-R₄ are independently hydrogen, halogen, hydroxy,

5

C_{1-10} alkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, amino, acylamido, acyloxy, alkoxy, methylenedioxy or alkylthiol. Preferably R_5 is hydrogen; X is O; Z is NH_2 and Y is CN. Preferably A is optionally substituted phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, thienyl, furyl, pyrrolyl, 2-phenylethyl or cyclohexyl.

Another preferred embodiment is represented by Formula III:



or pharmaceutically acceptable salts or prodrugs thereof, wherein R_1-R_5 are as defined previously with respect to Formulae I and II; and $R_{10}-R_{14}$ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C_{1-10} alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or R_{10} and R_{11} , or R_{11} and R_{12} , taken together with the atoms to which they are attached form an aryl, heteroaryl, partially saturated carbocyclic or partially saturated heterocyclic group, wherein said group is optionally substituted.

10

15

20


25

Preferred are compounds of Formula III, wherein R_{10} and R_{11} , or R_{11} and R_{12} , taken together form a structure selected from the group consisting of $-OCH_2O-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-OCH_2CH_2O-$, $-CH_2N(R)CH_2-$, $-CH_2CH_2N(R)CH_2-$, $-CH_2N(R)CH_2CH_2-$, $-CH=CH-CH=CH-$, $-N(R)-CH=CH-$, $-CH=CH-N(R)-$, $-O-CH=CH-$, $-CH=CH-O-$, $-S-CH=CH-$, $-CH=CH-S-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$ and $-N=CH-CH=N-$, wherein R is hydrogen, C_{1-10} alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic

group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

Preferred compounds falling within the scope of Formula III include
5 compounds wherein R₁-R₄ are independently hydrogen, halogen, hydroxy, C₁₋₁₀ alkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, amino, acylamido, acyloxy, alkoxy, methylenedioxy or alkylthiol. Preferably R₅ is hydrogen.

Another preferred embodiment is represented by Formula IV:



or pharmaceutically acceptable salts or prodrugs thereof, wherein;
10 R₃-R₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; R₅ is hydrogen or C₁₋₁₀ alkyl;
15 R₁₀-R₁₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol;
20 or
25

R₁₀ and R₁₁, or R₁₁ and R₁₂, taken together with the atoms to which they are attached form an aryl, heteroaryl, partially saturated carbocyclic or partially saturated heterocyclic group, wherein the group is optionally substituted; and D is an optionally substituted aromatic or heteroaromatic ring.

5 Preferred compounds falling within the scope of Formula IV include compounds wherein R₃-R₄ are hydrogen. Preferably R₅ is hydrogen. Another group of preferred compounds are those wherein R₁₀ and R₁₄ are hydrogen. Preferably D is an optionally substituted aromatic or heteroaromatic ring selected from the group consisting of benzo, pyrido, furo, thieno, pyrrolo, imidazo and pyrazo.

10 Exemplary preferred compounds that may be employed in the method of the invention include, without limitation:

2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylene-dioxyphenyl)-4*H*-chromene;

15 2-Amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(1-naphthyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-naphthyl)-4*H*-chromene;

20 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4-methoxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,6-dimethoxyphenyl)-4*H*-chromene;

25 2-Amino-3-cyano-7-dimethylamino-4-(4-trifluoromethylphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4-fluorophenyl)-4*H*-chromene;

30 2-Amino-3-cyano-7-dimethylamino-4-(3,4,5-trimethoxyphenyl)-4*H*-chromene;

2-Acetamido-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene;

DRAFT - CONFIDENTIAL

- 2-Di(ethoxycarbonyl)amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-diethylamino-4-(3-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-methyl-3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethylphenyl)-4*H*-chromene;
- 10 3-Cyano-7-dimethylamino-4-(4,5-methylenedioxyphenyl)-2-propionamido-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethylphenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-methoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-diethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene;
- 20 2-Benzylidenamino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-cyclohexyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-3-trifluoromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,4,5-trifluorophenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(2,3,4-trifluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-3-nitrophenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-nitrophenyl)-4*H*-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-ethylenedioxyphenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-fluoro-3-trifluoromethylphenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-6,7-methylenedioxy-4-(3-methoxy-4,5-methylene-dioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-ethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-trifluoromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-4-trifluoromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoromethylenedioxyphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoro-5-trifluoromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-furyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-thienyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-trifluoromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-6-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-nitrophenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-phenoxyphenyl)-4*H*-chromene;

DRAFT P&G 04050260

- 2-Amino-3-cyano-7-dimethylamino-4-(2-pyridyl)-4*H*-chromene;
2-Amino-3-cyano-7-dimethylamino-4-(2-phenylethyl)-4*H*-chromene;
2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-nitrophenyl)-4*H*-
chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-5-trifluoromethyl-
phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,3-difluoro-4-trifluoromethyl-
phenyl)-4*H*-chromene;
- 10 2,7-Diamino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethoxyphenyl)-4*H*-
chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-(4-methoxyphenoxy)phenyl)-
4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dichlorophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-trifluoromethyl-
phenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3-quinolyl)-4*H*-chromene;
 2-Amino-3-cyano-7-dimethylamino-4-(2-quinolyl)-4*H*-chromene;
 2-Amino-3-cyano-7-dimethylamino-4-phenylmethyl-4*H*-chromene;
 2-Amino-3-cyano-7-dimethylamino-4-(4-carboxaldehydophenyl)-4*H*-
chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(4-bromo-3,5-dimethoxy-
phenyl)-4*H*-chromene;
- 2-Amino-7-acetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
chromene;
- 2,7-Diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
chromene;
- 30 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-
6,7,8,9,10,11-hexahydro-4*H*-pyrido[3,2,1-ij]quino[5,6-b]pyran;

- 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-
indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-ethylamino-6-methyl-4-(3-methoxy-4,5-
methylenedioxyphenyl)-4*H*-chromene;
- 5 2,7-Diamino-3-cyano-8-methyl-4-(3-methoxy-4,5-methylenedioxy-
phenyl)-4*H*-chromene;
- 2-Amino-7-chloroacetamido-3-cyano-4-(3-bromo-4,5-dimethoxy-
phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4*H*-
10 indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dibromophenyl)-4*H*-
15 chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-cyanophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chlorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
20 naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
 indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4*H*-
 indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxyphenyl)-4*H*-
25 chromene;
- 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-nitrophenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-cyanophenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-difluorophenyl)-4*H*-
30 chromene;
- 2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-bis(trifluoromethyl)-
 phenyl)-4*H*-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-5-methoxyphenyl)-
4H-chromene;
- 2-Amino-3-cyano-4-(4-bromo-3,5-dimethoxyphenyl)-4H-naphtho[1,2-
b]pyran;
- 5 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-
naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-
naphtho[1,2-b]pyran;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(4-chloromethylphenyl)-4H-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloromethylphenyl)-4H-
chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-cyano-4-fluorophenyl)-4H-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-nitro-4-fluorophenyl)-4H-
chromene;
- 20 2-Amino-3-cyano-7-methoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylthiophenyl)-
4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluorophenyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3-difluoromethoxyphenyl)-4H-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-hydroxyphenyl)-4H-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethoxyphenyl)-4H-
chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-methylaminophenyl)-4H-
chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3-dimethylaminophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-4,5-dimethoxyphenyl)-4H-chromene;
- 15 2-Chloroacetamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Acrylamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 20 3-Cyano-7-dimethylamino-2-succinimido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 3-Cyano-7-dimethylamino-2-phenylureido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-2-pyridyl)-4H-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(2-bromo-4,5-methylenedioxyphenyl)-4H-chromene;

- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[2,1-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-2-nitrophenyl)-4H-chromene;
- 5 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-isoquino[5,6-b]pyran;
- 10 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[8,7-b]pyran;
- 2-Amino-3-cyano-7-ethoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 15 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8,9,10-tetrahydro-4H-naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8-dimethyl-4H-chromene;
- 20 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-quino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 25 2-Amino-6-chloro-3-cyano-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-7-methoxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-methoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-cyanophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-chlorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-nitrophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-bromophenyl)-4H-chromene;
- 30 2-Amino-3-cyano-7-methoxy-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-methoxy-3-pyridyl)-4H-chromene;

2-Amino-3-cyano-7-methoxy-4-(5-methylthio-3-pyridyl)-4H-chromene;

2-Amino-3-cyano-7-methoxy-4-(5-chloro-3-pyridyl)-4H-chromene;

2-Amino-3-cyano-7-methoxy-4-(5-bromo-3-pyridyl)-4H-chromene;

5 2-Amino-3-cyano-7-methyl-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

2-Amino-3-cyano-7-chloro-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

10 2-Amino-3-cyano-7-bromo-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

2-Amino-3-cyano-7-bromo-4-(5-methyl-3-pyridyl)-4H-chromene;

2-Amino-3-cyano-7-chloro-4-(5-methyl-3-pyridyl)-4H-chromene;

15 2-Amino-3-cyano-7-ethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

2-Amino-3-cyano-7-ethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;

and

2-Amino-3-cyano-7-hydroxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene.

20 The present invention is also directed to novel compounds within the scope of Formulae I-IV.

Exemplary preferred novel compounds of this invention include, without limitation:

25 2-Amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxophenyl)-4H-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-naphthyl)-4H-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4,5-trimethoxyphenyl)-4H-chromene;

30 2-Acetamido-3-cyano-7-dimethylamino-4-(3,4-methylenedioxophenyl)-4H-chromene;

2-Di(ethoxycarbonyl)amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxophenyl)-4H-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-methyl-3-nitrophenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethylphenyl)-4*H*-chromene;
- 3-Cyano-7-dimethylamino-4-(4,5-methylenedioxyphenyl)-2-propionamido-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-methoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-diethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene;
- 2-Benzylidenamino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-cyclohexyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-3-trifluoromethylphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(2,4,5-trifluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,3,4-trifluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-nitrophenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3,4-ethylenedioxyphenyl)-4*H*-chromene;

00000000000000000000000000000000

- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-fluoro-3-trifluoromethyl-phenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-6,7-methylenedioxy-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-ethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoromethylenedioxyphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-furyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-thienyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-6-nitrophenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-phenoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-phenylethyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-nitrophenyl)-4*H*-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,3-difluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;
- 5 2,7-Diamino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethoxyphenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-(4-methoxyphenoxy)phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dichlorophenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-quinolyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-quinolyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-phenylmethyl-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(4-carboxaldehydophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-bromo-3,5-dimethoxy-phenyl)-4*H*-chromene;
- 2-Amino-7-acetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 25 2,7-Diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-6,7,8,9,10,11-hexahydro-4*H*-pyrido[3,2,1-ij]quino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 30 2-Amino-3-cyano-7-ethylamino-6-methyl-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;

- 2,7-Diamino-3-cyano-8-methyl-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-7-chloroacetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dibromophenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-cyanophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chlorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-naphtho[1,2-b]pyran;
- 15 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxyphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-nitrophenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-cyanophenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-difluorophenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-bis(trifluoromethyl)phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-5-methoxyphenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-4-(4-bromo-3,5-dimethoxyphenyl)-4*H*-naphtho[1,2-b]pyran;

- 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(4-chloromethylphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloromethylphenyl)-4H-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-cyano-4-fluorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-nitro-4-fluorophenyl)-4H-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-methylenedioxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylthiophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-difluoromethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-hydroxyphenyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylaminophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-dimethylaminophenyl)-4H-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-4,5-dimethoxyphenyl)-4H-chromene;
- 10 2-Chloroacetamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Acylamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 15 3-Cyano-7-dimethylamino-2-succinimido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 3-Cyano-7-dimethylamino-2-phenylureido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 20 9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-3-pyridyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(2-bromo-4,5-methylenedioxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[2,1-b]pyran;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-2-nitrophenyl)-4H-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[5,6-b]pyran;

00000111000000000000000000000000

- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
isoquino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
quino[8,7-b]pyran;
- 5 2-Amino-3-cyano-7-ethoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8,9,10-
tetrahydro-4H-naphtho[1,2-b]pyran;
- 10 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8-dimethyl-4H-
chromene;
- 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-quino[5,6-b]pyran;
- 2-Amino-3-cyano-7-methoxy-4-(3,4,5-trimethoxyphenyl)-4H-
chromene;
- 15 2-Amino-3-cyano-7-methoxy-4-(3,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-methoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-cyanophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-chlorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-nitrophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-bromophenyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-methoxy-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-methoxy-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-methylthio-3-pyridyl)-4H-
chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-chloro-3-pyridyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-methoxy-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methyl-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
- 2-Amino-3-cyano-7-chloro-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
- 30 2-Amino-3-cyano-7-bromo-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
- 2-Amino-3-cyano-7-bromo-4-(5-methyl-3-pyridyl)-4H-chromene;

2-Amino-3-cyano-7-chloro-4-(5-methyl-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-ethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-
4H-chromene;
2-Amino-3-cyano-7-ethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
and
2-Amino-3-cyano-7-hydroxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene.

Useful alkyl groups include straight-chained and branched C₁₋₁₀ alkyl groups, more preferably C₁₋₆ alkyl groups. Typical C₁₋₁₀ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, 3-pentyl, hexyl and octyl groups, which can be optionally substituted.

Useful alkoxy groups include oxygen substituted by one of the C₁₋₁₀ alkyl groups mentioned above, which can be optionally substituted.

Useful alkylthio groups include sulphur substituted by one of the C₁₋₁₀ alkyl groups mentioned above, which can be optionally substituted. Also included are the sulfoxides and sulfones of such alkylthio groups.

Useful amino groups include -NH₂, -NHR₁₅ and -NR₁₅R₁₆, wherein R₁₅ and R₁₆ are C₁₋₁₀ alkyl or cycloalkyl groups, or R₁₅ and R₁₆ are combined with the N to form a ring structure, such as a piperidine, or R₁₅ and R₁₆ are combined with the N and other group to form a ring, such as a piperazine. The alkyl group can be optionally substituted.

Optional substituents on the alkyl groups include one or more halo, hydroxy, carboxyl, amino, nitro, cyano, C_{1-C₆} acylamino, C_{1-C₆} acyloxy, C_{1-C₆} alkoxy, aryloxy, alkylthio, C_{6-C₁₀} aryl, C_{4-C₇} cycloalkyl, C_{2-C₆} alkenyl, C_{2-C₆} alkynyl, C_{6-C₁₀} aryl(C_{2-C₆})alkenyl, C_{6-C₁₀} aryl(C_{2-C₆})alkynyl, saturated and unsaturated heterocyclic or heteroaryl. Optional substituents on the aryl, aralkyl and heteroaryl groups include one or more halo, C_{1-C₆} haloalkyl, C_{6-C₁₀} aryl, C_{4-C₇} cycloalkyl, C_{1-C₆} alkyl, C_{2-C₆} alkenyl, C_{2-C₆} alkynyl, C_{6-C₁₀} aryl(C_{1-C₆})alkyl, C_{6-C₁₀} aryl(C_{2-C₆})alkenyl, C_{6-C₁₀} aryl(C_{2-C₆})alkynyl, C_{1-C₆} hydroxyalkyl, nitro, amino, ureido, cyano, C_{1-C₆} acylamino, hydroxy, thiol, C_{1-C₆} acyloxy, azido, C_{1-C₆} alkoxy or carboxy.

Useful aryl groups include C₆₋₁₄ aryl, preferably C₆₋₁₀ aryl. Typical C₆₋₁₄ aryl groups include phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl groups.

5 Useful cycloalkyl groups are C₃₋₈ cycloalkyl. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

Useful saturated or partially saturated carbocyclic groups are cycloalkyl groups as described above, as well as cycloalkenyl groups, such as cyclopentenyl, cycloheptenyl and cyclooctenyl.

10 Useful halo or halogen groups include fluorine, chlorine, bromine and iodine.

Useful arylalkyl groups include any of the above-mentioned C₁₋₁₀ alkyl groups substituted by any of the above-mentioned C₆₋₁₄ aryl groups. Preferably the arylalkyl group is benzyl, phenethyl or naphthylmethyl.

15 Useful haloalkyl groups include C₁₋₁₀ alkyl groups substituted by one or more fluorine, chlorine, bromine or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, chloromethyl, chlorofluoromethyl and trichloromethyl groups.

20 Useful acylamino (acylamido) groups are any C₁₋₆ acyl (alkanoyl) attached to an amino nitrogen, e.g., acetamido, chloroacetamido, propionamido, butanoylamido, pentanoylamido and hexanoylamido, as well as aryl-substituted C₁₋₆ acylamino groups, e.g., benzoylamido, and pentafluorobenzoylamido.

25 Useful acyloxy groups are any C₁₋₆ acyl (alkanoyl) attached to an oxy (−O−) group, e.g., formyloxy, acetoxy, propionyloxy, butanoyloxy, pentanoyloxy and hexanoyloxy.

30 Useful saturated or partially saturated heterocyclic groups include tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl pyrazolinyl, tetroxyl and tetramoyl groups.

INDUSTRIAL PROPERTY

Useful heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthiinyl, 2*H*-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3*H*-indolyl, indolyl, indazolyl, purinyl, 4*H*-quinolizinyl, isoquinolyl, quinolyl, phthalzinyl, naphthyridinyl, quinozalinyl, cinnolinyl, pteridinyl, carbazolyl, β -carbolinyl, phenanthridinyl, acrindinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl, 1,4-dihydroquinoxaline-2,3-dione, 7-aminoisocoumarin, pyrido[1,2-a]pyrimidin-4-one, 1,2-benzoisoxazol-3-yl, benzimidazolyl, 2-oxindolyl and 2-oxobenzimidazolyl. Where the heteroaryl group contains a nitrogen atom in a ring, such nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N-oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide.

Certain of the compounds of the present invention may exist as stereoisomers including optical isomers. The invention includes all stereoisomers and both the racemic mixtures of such stereoisomers as well as the individual enantiomers that may be separated according to methods that are well known to those of ordinary skill in the art.

Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, phosphate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate and oxalate; and inorganic and organic base addition salts with bases such as sodium hydroxy, Tris(hydroxymethyl)aminomethane (TRIS, tromethane) and N-methyl-glucamine.


Examples of prodrugs of the compounds of the invention include the simple esters of carboxylic acid containing compounds (e.g., those obtained by condensation with a C₁₋₄ alcohol according to methods known in the art); esters of hydroxy containing compounds (e.g., those obtained by condensation with a C₁₋₄ carboxylic acid, C₃₋₆ dioic acid or anhydride thereof such as succinic and fumaric anhydrides according to methods known in the art); imines of amino containing compounds (e.g., those obtained by condensation with a C₁₋₄ aldehyde or ketone according to methods known in the art);

carbamate of amino containing compounds such as those described by Leu, *et al.*, (*J. Med. Chem.* 42:3623-3628 (1999)) and Greenwald, *et. al.*, (*J. Med. Chem.* 42:3657-3667 (1999)); and acetals and ketals of alcohol containing compounds (e.g., those obtained by condensation with chloromethyl methyl ether or chloromethyl ethyl ether according to methods known in the art).

The compounds of this invention may be prepared using methods known to those skilled in the art, or the novel methods of this invention. Specifically, the compounds of this invention with Formulae I-IV can be prepared as illustrated by exemplary reaction in Scheme 1. Reaction of a phenol with a benzaldehyde and malononitrile in the presence a base such as piperidine or *N,N*-diisopropylethylamine produced the substituted chromene. The reaction also can be run by reacting an aldehyde with malononitrile in the presence a base such as piperidine first, the intermediate was then treated with a phenol and cyclized to give the final product as shown by exemplary reactions in Scheme 2. The 2-amino group can be modified by acylation to give the amide as shown by exemplary reaction in Scheme 3.


CONFIDENTIAL

Scheme 1




5

Scheme 2



10

Scheme 3



5

An important aspect of the present invention is the discovery that compounds having Formula I-IV are activators of caspases and inducers of apoptosis. Therefore, these compounds are expected to be useful in a variety of clinical conditions in which there is uncontrolled cell growth and spread of

10

abnormal cells, such as in the case of cancer.

Another important aspect of the present invention is the discovery that compounds having Formula I-IV are potent and highly efficacious activators of caspases and inducers of apoptosis in drug resistant cancer cells, such as breast and prostate cancer cells, which enables these compounds to kill these drug resistant cancer cells. In comparison, most standard anti-cancer drugs are not effective in killing drug resistant cancer cells under the same conditions. Therefore, compounds of this invention are expected to be useful for the treatment of drug resistant cancer in animals.

15

The present invention includes a therapeutic method useful to modulate *in vivo* apoptosis or *in vivo* neoplastic disease, comprising administering to a subject in need of such treatment an effective amount of a compound, or a pharmaceutically acceptable salt or prodrug of the compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis.

20

The present invention also include a therapeutic method comprising administering to an animal an effective amount of a compound, or a pharmaceutically acceptable salt or prodrug of said compound of Formulae I-IV, wherein said therapeutic method is useful to treat cancer, which is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Such diseases include, but are not limited to, Hodgkin's disease, non-Hodgkin's lymphomas, acute and chronic lymphocytic leukemias, multiple myeloma, neuroblastoma, breast carcinomas, ovarian carcinomas, lung carcinomas, Wilms' tumor, cervical carcinomas, testicular carcinomas, soft-tissue sarcomas, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinomas, chronic granulocytic leukemia, primary brain carcinomas, malignant melanoma, small-cell lung carcinomas, stomach carcinomas, colon carcinomas, malignant pancreatic insulinoma, malignant carcinoid carcinomas, malignant melanomas, choriocarcinomas, mycosis fungoides, head and neck

25

30

DRAFT PCT/US2012/024610

carcinomas, osteogenic sarcoma, pancreatic carcinomas, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinomas, thyroid carcinomas, esophageal carcinomas, malignant hypercalcemia, cervical hyperplasia, renal cell carcinomas, endometrial carcinomas, polycythemia vera, essential thrombocytosis, adrenal cortex carcinomas, skin cancer, and prostatic carcinomas.

In practicing the therapeutic methods, effective amounts of compositions containing therapeutically effective concentrations of the compounds formulated for oral, intravenous, local and topical application, for the treatment of neoplastic diseases and other diseases in which caspase cascade mediated physiological responses are implicated, are administered to an individual exhibiting the symptoms of one or more of these disorders. The amounts are effective to ameliorate or eliminate one or more symptoms of the disorders. An effective amount of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce, the symptoms associated with the disease. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective. The amount may cure the disease but, typically, is administered in order to ameliorate the disease. Typically, repeated administration is required to achieve the desired amelioration of symptoms

In another embodiment, a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt of said compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis in combination with a pharmaceutically acceptable vehicle is provided.

Another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a compound, or a pharmaceutically acceptable salt or prodrug of said compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis, in combination with at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent. Examples of known anti-

DRAFT P-048602/60

5 cancer agents which can be used for combination therapy include, but not are limit to alkylating agents such as busulfan, cis-platin, mitomycin C, and carboplatin; antimitotic agents such as colchicine, vinblastine, paclitaxel, and docetaxel; topo I inhibitors such as camptothecin and topotecan; topo II inhibitors such as doxorubicin and etoposide; RNA/DNA antimetabolites such as 5-azacytidine, 5-fluorouracil and methotrexate; DNA antimetabolites such as 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea and thioguanine; Antibodies such as Herceptin and Rituxan. Other known anti-cancer agents which can be used for combination therapy include melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen and alanosine.

10

15 In practicing the methods of the present invention, the compound of the invention may be administered together with at least one known chemotherapeutic agent as part of a unitary pharmaceutical composition. Alternatively, the compound of the invention may be administered apart from the at least one known cancer chemotherapeutic agent. In one embodiment, the compound of the invention and the at least one known cancer chemotherapeutic agent are administered substantially simultaneously, i.e. the compounds are administered at the same time or one after the other, so long as the compounds reach therapeutic levels in the blood at the same time. On another embodiment, the compound of the invention and the at least one known cancer chemotherapeutic agent are administered according to their individual dose schedule, so long as the compounds reach therapeutic levels in the blood.

20

25 Another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a bioconjugates of said compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis, in bioconjugation with at least one known therapeutically useful antibodies, such as Herceptin or Rituxan, growth factors such as DGF, NGF, cytokines such as IL-2, IL-4, or any molecule that binds to cell surface. The antibodies and other molecules will deliver compound of

30

DE2020200760

Formulae I-V to its targets and make them effective anticancer agents. The bioconjugates also could enhance the anticancer effect of therapeutically useful antibodies, such as Herceptin or Rituxan.

Similarly, another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a compound, or a pharmaceutically acceptable salt or prodrug of said compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis, in combination with radiation therapy. In this embodiment, the compound of the invention may be administered at the same time as the radiation therapy is administered or at a different time.

Yet another embodiment of the present invention is directed to a composition effective for post-surgical treatment of cancer, comprising a compound, or a pharmaceutically acceptable salt or prodrug of said compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis. The invention also relates to a method of treating cancer by surgically removing the cancer and then treating the animal with one of the pharmaceutical compositions described herein.

A wide range of immune mechanisms operate rapidly following exposure to an infectious agent. Depending on the type of infection, rapid clonal expansion of the T and B lymphocytes occurs to combat the infection. The elimination of the effector cells following an infection is one of the major mechanisms maintaining immune homeostasis. This deletion of reactive cells has been shown to be regulated by a phenomenon known as apoptosis. Autoimmune diseases have been lately identified as a consequence of deregulated cell death. In certain autoimmune diseases, the immune system directs its powerful cytotoxic effector mechanisms against specialized cells such as oligodendrocytes in multiple sclerosis, the beta cells of the pancreas in diabetes mellitus, and thyrocytes in Hashimoto's thyroiditis (Ohsako, S. & Elkson, K.B., *Cell Death Differ.* 6:13-21 (1999)). Mutations of the gene encoding the lymphocyte apoptosis receptor Fas/APO-1/CD95 are reported to be associated with defective lymphocyte apoptosis and autoimmune lymphoproliferative syndrome (ALPS), which is characterized by chronic,

DRAFT-DO NOT CITE

histologically benign splenomegaly and generalized lymphadenopathy, hypergammaglobulinemia, and autoantibody formation. (Infante, A.J., *et al.*, *J. Pediatr.* 133:629-633 (1998) and Vaishnav, A.K., *et al.*, *J. Clin. Invest.* 103:355-363 (1999)). It was reported that overexpression of Bcl-2, which is a member of the bcl-2 gene family of programmed cell death regulators with anti-apoptotic activity, in developing B cells of transgenic mice, in the presence of T cell dependent costimulatory signals, results in the generation of a modified B cell repertoire and in the production of pathogenic autoantibodies (Lopez-Hoyos, M., *et al.*, *Int. J. Mol. Med.* 1:475-483 (1998)). It is therefore evident that many types of autoimmune disease are caused by defects of the apoptotic process, and one treatment strategy would be to turn on apoptosis in the lymphocytes that are causing autoimmune disease (O'Reilly, L.A. & Strasser, A., *Inflamm. Res.* 48:5-21 (1999)).

Fas-Fas ligand (FasL) interaction is known to be required for the maintenance of immune homeostasis. Experimental autoimmune thyroiditis (EAT), characterized by autoreactive T and B cell responses and a marked lymphocytic infiltration of the thyroid, is a good model to study the therapeutic effects of FasL. Batteux, F., *et al.*, (*J. Immunol.* 162:603-608 (1999)) reported that by direct injection of DNA expression vectors encoding FasL into the inflamed thyroid, the development of lymphocytic infiltration of the thyroid was inhibited and induction of infiltrating T cells death was observed. These results show that FasL expression on thyrocytes may have a curative effect on ongoing EAT by inducing death of pathogenic autoreactive infiltrating T lymphocytes.

Bisindolylmaleimide VIII is known to potentiate Fas-mediated apoptosis in human astrocytoma 1321N1 cells and in Molt-4T cells, and both of which were resistant to apoptosis induced by anti-Fas antibody in the absence of bisindolylmaleimide VIII. Potentiation of Fas-mediated apoptosis by bisindolylmaleimide VIII was reported to be selective for activated, rather than non-activated, T cells, and was Fas-dependent. Zhou T., *et al.*, (*Nat. Med.* 5:42-48 (1999)) reported that administration of bisindolylmaleimide VIII to rats during autoantigen stimulation prevented the development of symptoms

of T cell-mediated autoimmune diseases in two models, the Lewis rat model of experimental allergic encephalitis and the Lewis adjuvant arthritis model. Therefore the application of a Fas-dependent apoptosis enhancer such as bisindolylmaleimide VIII may be therapeutically useful for the more effective elimination of detrimental cells and inhibition of T cell-mediated autoimmune diseases. Therefore an effective amount of a compound, or a pharmaceutically acceptable salt or prodrug of the compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis, should be an effective treatment for autoimmune disease.

Psoriasis is a chronic skin disease that is characterized by scaly red patches. Psoralen plus ultraviolet A (PUVA) is a widely used and effective treatment for psoriasis vulgaris and Coven, *et al.*, *Photodermatol. Photoimmunol. Photomed.* 15:22-27 (1999), reported that lymphocytes treated with psoralen 8-MOP or TMP plus UVA displayed DNA degradation patterns typical of apoptotic cell death. Ozawa, *et al.*, *J. Exp. Med.* 189:711-718 (1999) reported that induction of T cell apoptosis could be the main mechanism by which 312-nm UVB resolves psoriasis skin lesions. Low doses of methotrexate may be used to treat psoriasis to restore a clinically normal skin. Heenen, *et al.*, *Arch. Dermatol. Res.* 290:240-245 (1998), reported that low doses of methotrexate may induce apoptosis and this mode of action could explain the reduction in epidermal hyperplasia during treatment of psoriasis with methotrexate. Therefore an effective amount of a compound, or a pharmaceutically acceptable salt or prodrug of the compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis, should be an effective treatment for psoriasis.

Synovial cell hyperplasia is a characteristic of patients with rheumatoid arthritis (RA). Excessive proliferation of RA synovial cells as well as defective in synovial cell death might be responsible for the synovial cell hyperplasia. Wakisaka, *et al.*, *Clin. Exp. Immunol.* 114:119-128 (1998), found that although RA synovial cells could die via apoptosis through Fas/FasL pathway, apoptosis of synovial cells was inhibited by proinflammatory cytokines present within the synovium, and suggested that inhibition of

apoptosis by the proinflammatory cytokines may contribute to the outgrowth of synovial cells, and lead to pannus formation and the destruction of joints in patients with RA. Therefore an effective amount of a compound, or a pharmaceutically acceptable salt or prodrug of the compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis, should be an effective treatment for rheumatoid arthritis.

There have been accumulation of convincing evidence that apoptosis plays a major role in promoting resolution of the acute inflammatory response. Neutrophils are constitutively programmed to undergo apoptosis, thus limiting their pro-inflammatory potential and leading to rapid, specific, and non-phlogistic recognition by macrophages and semi-professional phagocytes (Savill, J., *J. Leukoc. Biol.* 61:375-380 (1997)). Boirivant, *et al.*, *Gastroenterology* 116:557-565 (1999), reported that lamina propria T cells isolated from areas of inflammation in Crohn's disease, ulcerative colitis, and other inflammatory states manifest decreased CD2 pathway-induced apoptosis, and that studies of cells from inflamed Crohn's disease tissue indicate that this defect is accompanied by elevated Bcl-2 levels. Therefore an effective amount of a compound, or a pharmaceutically acceptable salt or prodrug of the compound of Formulae I-IV, which functions as a caspase cascade activator and inducer of apoptosis, should be an effective treatment for inflammation and inflammatory bowel disease.

Compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount that is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typically, the compounds may be administered to mammals, e.g., humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for apoptosis-mediated disorders. Preferably, about 0.01 to about 10 mg/kg is orally administered to treat or prevent such disorders. For intramuscular injection, the dose is generally about one-half of the oral dose. For example, a suitable

DOCUMENT P-00486002610

intramuscular dose would be about 0.0025 to about 25 mg/kg, and most preferably, from about 0.01 to about 5 mg/kg. If a known cancer chemotherapeutic agent is also administered, it is administered in an amount which is effective to achieve its intended purpose. The amounts of such known cancer chemotherapeutic agents effective for cancer are well known to those of skill in the art.

The unit oral dose may comprise from about 0.01 to about 50 mg, preferably about 0.1 to about 10 mg of the compound of the invention. The unit dose may be administered one or more times daily as one or more tablets each containing from about 0.1 to about 10, conveniently about 0.25 to 50 mg of the compound or its solvates.

In a topical formulation, the compound may be present at a concentration of about 0.01 to 100 mg per gram of carrier.

In addition to administering the compound as a raw chemical, the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically. Preferably, the preparations, particularly those preparations which can be administered orally and which can be used for the preferred type of administration, such as tablets, dragees, and capsules, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally, contain from about 0.01 to 99 percent, preferably from about 0.25 to 75 percent of active compound(s), together with the excipient.

Also included within the scope of the present invention are the non-toxic pharmaceutically acceptable salts of the compounds of the present invention. Acid addition salts are formed by mixing a solution of the particular apoptosis inducers of the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, and the like. Basic salts are formed by mixing a solution of the particular apoptosis inducers of the present invention

with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, Tris, N-methyl-glucamine and the like.

The pharmaceutical compositions of the invention may be administered to any animal which may experience the beneficial effects of the compounds of the invention. Foremost among such animals are mammals, e.g., humans and veterinary animals, although the invention is not intended to be so limited.

The pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

The pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.

Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and

DOCUMENT NUMBER

lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropymethyl-cellulose phthalate, are used.

5 Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.

Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.

Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.

Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered.

B6592456.1

Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400) or cremophor, or cyclodextrins. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.

In accordance with one aspect of the present invention, compounds of the invention are employed in topical and parenteral formulations and are used for the treatment of skin cancer.

The topical compositions of this invention are formulated preferably as oils, creams, lotions, ointments and the like by choice of appropriate carriers. Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C₁₂). The preferred carriers are those in which the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired. Additionally, transdermal penetration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Patent Nos. 3,989,816 and 4,444,762.

Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil such as almond oil, is admixed. A typical example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.

Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool. A typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.

5

The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.

Examples

Example 1

10 **2-Amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxophenyl)-4H-chromene**

To a mixture of 3-dimethylaminophenol (489 mg, 3.56 mmol), piperonal (535 mg, 3.56 mmol), and malononitrile (233 mg, 3.53 mmol) in ethanol (20 ml) was added piperidine (0.70 ml, 7.1 mmol). The mixture was stirred at room temperature for 2 h and the resulting solid was collected by filtration, washed with methanol and dried in vacuo to yield the title compound as a yellow solid (940 mg, 2.80 mmol, 79%). ^1H NMR (DMSO- d_6): 6.83-6.77 (m, 4H), 6.66-6.64 (m, 2H), 6.47-6.44 (m, 1H), 6.21 (s, 1H), 5.96 (s, 1H), 5.95 (s, 1H), 4.53 (s, 1H), 2.85 (s, 6H).

Example 2

25 **2-Amino-3-cyano-7-dimethylamino-4-(2-naphthyl)-4H-chromene**

The title compound was prepared as a tan solid from 2-naphthylaldehyde in 73% yield as described in Example 1. ^1H NMR (DMSO- d_6): 7.89-7.81 (m, 3H), 7.74 (s, 1H), 7.52-7.44 (m, 2H), 7.23-7.20 (m, 1H), 6.89 (s, 2H), 6.77 (d, J = 8.7, 1H), 6.43-6.40 (m, 1H), 6.25 (s, 1H), 4.76 (s, 1H), 2.84 (s, 6H).

30

00000000000000000000000000000000

Example 3

3-Cyano-7-dimethylamino-4-(3,4-methylenedioxypyhenyl)-2-propionamido-4H-chromene

To a solution of 2-amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxypyhenyl)-4H-chromene (102 mg, 0.30 mmol) in dichloromethane (5 ml) was added pyridine (0.7 ml) at 0 °C, followed by propionyl chloride (0.3 ml). The mixture was then stirred at room temperature for 4 h, diluted with 1:1 hexane/EtOAc (80 ml), washed with water, 2N HCl, water and brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by chromatography (4:1 hexane/EtOAc) to yield the title compound as a yellow solid (16 mg, 14%). ^1H NMR (CDCl_3): 6.85-6.76 (m, 4H), 6.51-6.48 (m, 1H), 6.31 (m, 1H), 6.00-5.95 (m, 2H), 4.80 (s, 1H), 2.95 (s, 6H), 2.31 (q, $J = 7.5$, 2H), 1.14 (t, $J = 7.5$, 3H).

Example 4

2-Amino-3-cyano-7-dimethylamino-4-(4-methyl-3-nitropheyl)-4H-chromene

The title compound was prepared as a gray solid from 4-methyl-3-nitrobenzaldehyde in 60% yield as described in Example 1. ^1H NMR (CDCl_3): 7.78 (d, $J = 2.1$, 1H), 7.40 (d, $J = 2.1$, 1H), 7.37 (d, $J = 2.1$, 1H), 6.75-6.72 (m, 1H), 6.44-6.40 (m, 1H), 6.30 (d, $J = 2.1$, 1H), 4.72 (s, 1H), 4.62 (bs, 2H), 2.94 (s, 6H), 2.56 (s, 3H).

Example 5

2-Amino-3-cyano-7-diethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene

The title compound was prepared as a yellow solid from 5-methoxypiperonal and 3-(diethylamino)phenol as described in Example 1. ^1H NMR (CDCl_3): 6.79-6.76 (m, 1H), 6.44 (d, $J = 1.2$, 1H), 6.39-6.36 (m, 1H), 6.33 (d, $J = 1.8$, 1H), 6.22 (d, $J = 2.7$, 1H), 5.93-5.91 (m, 2H), 4.54 (s, 2H), 4.53 (s, 1H), 3.90 (s, 3H), 3.31 (q, $J = 7.2$, 4H), 1.14 (t, $J = 7.2$, 6H).

Example 6

2-Amino-3-cyano-7-dimethylamino-4-(4-carboxyphenyl)-4H-chromene

The title compound was prepared as a brown solid from 4-carboxybenzaldehyde as described in Example 1. ^1H NMR (DMSO- d_6): 7.80 (d, J = 8.4, 2H), 7.14 (d, J = 8.4, 2H), 6.86 (s, 2H), 6.78 (d, J = 8.4, 2H), 6.47-6.43 (m, 1H), 6.23 (d, J = 2.4, 1H), 4.63 (s, 1H), 2.86 (s, 6H).

Example 7

2-Amino-3-cyano-7-dimethylamino-4-(4-N-oxide-pyridyl)-4H-chromene

The title compound was prepared as a brown solid from 4-pyridinecarboxaldehyde N-oxide as described in Example 1. ^1H NMR (CDCl_3): 8.14 (d, J = 7.2, 2H), 7.11 (d, J = 7.2, 2H), 6.74 (d, J = 9.0, 1H), 6.48-6.44 (m, 1H), 6.30 (d, J = 2.7), 4.69 (s, 2H), 4.67 (s, 1H), 2.96 (s, 6H).

Example 8

2-Amino-3-cyano-7-dimethylamino-4-(2-imidazolyl)-4H-chromene

The title compound was prepared as a gray solid from imidazole-2-carboxaldehyde as described in Example 1. ^1H NMR (DMSO- d_6): 6.96 (s, 1H), 6.86-6.84 (m, 3H), 6.74 (s, 1H), 6.48-6.44 (m, 1H), 6.20 (d, J = 2.4, 1H), 4.74 (s, 1H), 2.85 (s, 6H).

Example 9

2-Amino-3-cyano-7-dimethylamino-4-(3-pyridyl)-4H-chromene

The title compound was prepared as a brown solid from 3-pyridinecarboxaldehyde as described in Example 1. ^1H NMR (CDCl_3): 8.49-8.47 (m, 2H), 7.52-7.49 (m, 1H), 7.26-7.22 (m, 1H), 6.75 (d, J = 8.7, 1H), 6.45-6.41 (m, 1H), 6.30 (d, J = 2.4, 1H), 4.69 (s, 1H), 4.62 (s, 2H), 2.93 (s, 6H).

Example 10

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene

The title compound was prepared as an off-white solid from 5-bromoveratraldehyde as described in Example 1. ^1H NMR (CDCl_3): 6.89 (d, $J = 1.8$, 1H), 6.79 (d, $J = 8.7$, 1H), 6.72 (d, $J = 1.8$, 1H), 6.46-6.43 (m, 1H), 6.28 (d, $J = 2.7$, 1H), 4.58 (s, 1H), 4.57 (s, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 2.94 (s, 6H).

Example 11

2-Amino-3-cyano-7-dimethylamino-4-(3,4-ethylenedioxypyphenyl)-4H-chromene

The title compound was prepared as a grey solid from 1,4-benzodioxan-6-carboxaldehyde as described in Example 1. ^1H NMR (CDCl_3): 6.83-6.77 (m, 2H), 6.71-6.67 (m, 2H), 6.45-6.41 (m, 1H), 6.27 (d, $J = 2.4$, 1H), 4.54 (s, 1H), 4.52 (s, 2H), 4.22 (s, 4H), 2.92 (s, 6H).

Example 12

2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethoxyphenyl)-4H-chromene

The title compound was prepared as an off-white solid from 3,4-dimethoxybenzaldehyde as described in Example 1. ^1H NMR (CDCl_3): 6.81 (s, 1H), 6.79 (s, 1H), 6.75 (d, $J = 1.8$, 1H), 6.69 (d, $J = 1.8$, 1H), 6.45-6.41 (m, 1H), 6.29 (d, $J = 3.0$, 1H), 4.60 (s, 1H), 4.54 (s, 2H), 3.85 (s, 3H), 3.83 (s, 3H), 2.93 (s, 6H).

Example 13

2-Amino-3-cyano-5,7-dimethoxy-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene

The title compound was prepared as a yellow solid from 5-methoxypiperonal and 3,5-dimethoxyphenol as described in Example 1. ^1H

NMR (CDCl_3): 6.43 (d, $J = 1.5$, 1H), 6.27 (d, $J = 1.5$, 1H), 6.20 (s, 2H), 5.92-5.90 (m, 2H), 4.61 (s, 1H), 4.51 (s, 2H), 3.88 (s, 3H), 3.79 (s, 3H), 3.67 (s, 3H).

5

Example 14

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxypyhenyl)-6,7-methylenedioxy-4H-chromene

10

The title compound was prepared as a light yellow solid from 5-methoxypiperonal and sesamol as described in Example 1. ^1H NMR (CDCl_3): 6.51 (s, 1H), 6.40 (d, $J = 1.2$, 1H), 6.38 (d, $J = 0.6$, 1H), 6.31 (d, $J = 1.5$, 1H), 5.95-5.91 (m, 4H), 4.55 (s, 2H), 4.52 (s, 1H), 3.90 (s, 3H).

15

Example 15

2-Amino-3-cyano-6,7-dimethoxy-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene

20

The title compound was prepared as a light yellow solid from 5-methoxypiperonal and 3,4-dimethoxyphenol as described in Example 1. ^1H NMR (CDCl_3): 6.54 (s, 1H), 6.41 (d, $J = 1.8$, 1H), 6.38 (s, 1H), 6.31 (d, $J = 1.8$, 1H), 5.95-5.94 (m, 2H), 4.57 (s, 1H), 4.54 (s, 2H), 3.90 (s, 3H), 3.87 (s, 3H), 3.74 (s, 3H).

25

Example 16

2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-3-quinolyl)-4H-chromene

30

The title compound was prepared as a yellow solid from 2-chloro-3-quinolinecarboxaldehyde as described in Example 1. ^1H NMR (CDCl_3): 8.02 (s, 1H), 7.99 (s, 1H), 7.77-7.68 (m, 2H), 7.55-7.50 (m, 1H), 6.88 (d, $J = 9.0$, 1H), 6.41-6.38 (m, 1H), 6.31 (d, $J = 2.4$, 1H), 5.36 (s, 1H), 4.70 (s, 1H), 2.93 (s, 6H).

Example 17

2-Amino-3-cyano-7-dimethylamino-4-(5-chloro-2-nitrophenyl)-4H-chromene

5 The title compound was prepared as a yellow solid from 5-chloro-2-nitrobenzaldehyde as described in Example 1. ^1H NMR (DMSO- d_6): 7.95 (d, J = 8.7, 1H), 7.59-7.55 (m, 1H), 7.26 (d, J = 2.1, 1H), 7.05 (s, 2H), 6.79 (d, J = 8.7, 1H), 6.50-6.46 (m, 1H), 6.26 (d, J = 3.0, 1H), 5.19 (s, 1H), 2.89 (s, 6H).

10 **Example 18**

2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-nitrophenyl)-4H-chromene

15 The title compound was prepared as a yellow solid from 2-chloro-5-nitrobenzaldehyde as described in Example 1. ^1H NMR (CDCl₃): 8.03-8.00 (m, 2H), 7.55 (d, J = 9.6, 1H), 6.78 (d, J = 8.7, 1H), 6.42-6.39 (m, 1H), 6.31 (d, J = 2.4, 1H), 5.41 (s, 1H), 4.70 (s, 2H), 2.94 (s, 6H).

Example 19

2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene

20 To a mixture of 3-dimethylaminophenol (761 mg, 5.5 mmol), 5-methoxypiperonal (1.0 g, 5.5 mmol), and malononitrile (367 mg, 5.5 mmol) in ethanol (20 ml) was added piperidine (1.2 ml, 11.1 mmol). The mixture was stirred at room temperature overnight and the solvent was evaporated. The resulting solid was collected by filtration, and washed with diethyl ether. The solid was recrystallized in DMSO/water to give the title compound as a light brown solid (1.5 g, 4.1 mmol, 74%). ^1H NMR (DMSO-d₆): 6.85 (s, 1H), 6.82 (s, 2H), 6.52 (d, J = 1.5, 1H), 6.49-6.45 (m, 1H), 6.29 (d, J = 1.5, 1H), 6.21 (d, J = 2.7, 1H), 5.94 (d, J = 6.3, 2H), 4.54 (s, 1H), 3.81 (s, 3H), 2.86 (s, 6H).

Example 20

2-Amino-3-cyano-7-dimethylamino-4-(2-bromo-4,5-dimethoxyphenyl)-4H-chromene

The title compound was prepared from 6-bromoveratraldehyde as described in Example 19. ^1H NMR (DMSO-d₆): 7.10 (s, 1H), 6.87 (s, 2H), 6.72 (d, J = 9.0, 1H), 6.66 (s, 1H), 6.47-6.43 (m, 1H), 6.21 (d, J = 2.4, 1H), 5.03 (s, 1H), 3.77 (s, 3H), 3.63 (s, 3H), 2.86 (s, 6H).

Example 21

2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-4,5-methylenedioxophenyl)-4H-chromene

The title compound was prepared from 6-chloropiperonal in a yield of 80% as described in Example 1. ^1H NMR (DMSO-d₆): 7.03 (s, 1H), 6.87 (s, 2H), 6.72 (d, J = 8.7, 1H), 6.59 (s, 1H), 6.48-6.44 (m, 1H), 6.22 (d, J = 2.4, 1H), 6.05 (s, 1H), 6.01 (s, 1H), 5.04 (s, 1H), 2.86 (s, 6H).

Example 22

2-Amino-3-cyano-7-dimethylamino-4-(2,4,5-trimethoxyphenyl)-4H-chromene

The title compound was prepared from 2,4,5-trimethoxybenzaldehyde as described in Example 19. ^1H NMR (DMSO-d₆): 6.80 (d, J = 8.7, 1H), 6.71 (s, 2H), 6.68 (s, 1H), 6.55 (s, 1H), 6.44-6.40 (m, 1H), 6.20 (d, J = 2.4, 1H), 4.88 (s, 1H), 3.76 (d, J = 3.9, 6H), 3.59 (s, 3H), 2.84 (s, 6H).

Example 23

2-Amino-3-cyano-7-dimethylamino-4-(2,3,4-trimethoxyphenyl)-4H-chromene

The title compound was prepared from 2,3,4-trimethoxybenzaldehyde as described in Example 19. ^1H NMR (DMSO-d₆): 6.73-6.71 (m, 5H), 6.45-6.41 (m, 1H), 6.22 (d, J = 2.4, 1H), 4.74 (s, 1H), 3.74 (d, J = 5.1, 6H), 3.66 (s, 3H), 2.85 (s, 6H).

Example 24

2-Amino-3-cyano-7-dimethylamino-4-(3,4,5-trimethoxyphenyl)-4H-chromene

5

The title compound was prepared from 3,4,5-trimethoxybenzaldehyde in a yield of 78% as described in Example 1. ^1H NMR (DMSO-d₆): 6.90-6.84 (m, 3H), 6.48-6.46 (m, 3H), 6.23 (s, 1H), 4.57 (s, 1H), 3.72 (s, 3H), 2.87 (s, 6H).

10

Example 25

2-Amino-3-cyano-7-dimethylamino-4-(2,3-dimethoxyphenyl)-4H-chromene

15

The title compound was prepared from 2,3-dimethoxybenzaldehyde as described in Example 19. ^1H NMR (DMSO-d₆): 6.98 (t, J = 7.2, 1H), 6.88 (d, J = 7.5, 1H), 6.77 (s, 2H), 6.72 (d, J = 8.4, 1H), 6.61 (d, J = 7.2, 1H), 6.44-6.40 (m, 1H), 6.22 (d, J = 1.8, 1H), 4.86 (s, 1H), 3.79 (s, 3H), 3.65 (s, 3H), 2.85 (s, 6H).

20

Example 26

2-Amino-3-cyano-7-dimethylamino-4-(2,4-dimethoxyphenyl)-4H-chromene

25

The title compound was prepared from 2,4-dimethoxybenzaldehyde as described in Example 19. ^1H NMR (DMSO-d₆): 6.85 (d, J = 8.4, 1H), 6.80 (d, J = 8.7, 1H), 6.71 (s, 2H), 6.54 (d, J = 2.4, 1H), 6.47-6.40 (m, 2H), 6.19 (d, J = 2.1, 1H), 4.88 (s, 1H), 3.78 (s, 3H), 3.72 (s, 3H), 2.84 (s, 6H).

30

Example 27

2-Amino-3-cyano-7-dimethylamino-4-(4-tert-butylphenyl)-4H-chromene

The title compound was prepared from 4-tert-butylbenzaldehyde in a yield of 50% as described in Example 1. ^1H NMR (DMSO-d₆): 7.31 (d, J =

8.1, 2H), 7.07 (d, J = 8.7, 1H), 6.82 (s, 2H), 6.78 (s, 1H), 6.47-6.46 (m, 1H),
6.23 (d, J = 2.1, 1H), 4.55 (s, 1H), 2.86 (s, 6H), 1.24 (s, 9H).

Example 28

5 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethylphenyl)-4H-chromene

The title compound was prepared from 3,4-dimethylbenzaldehyde in a yield of 29% as described in Example 1. ^1H NMR (DMSO-d₆): 7.04 (d, J = 7.5, 1H), 6.90-6.86 (m, 2H), 6.77 (d, J = 3.3, 2H), 6.73 (s, 1H), 6.45-6.42 (m, 1H), 6.21 (d, J = 2.7, 1H), 4.50 (s, 1H), 2.85 (s, 6H), 2.16 (s, 6H).

Example 29

10 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethylphenyl)-4H-chromene

The title compound was prepared from 3,5-dimethylbenzaldehyde as described in Example 19. ^1H NMR (DMSO-d₆): 6.82-6.75 (m, 6H), 6.46-6.42 (m, 1H), 6.22 (d, J = 2.4, 1H), 4.50 (s, 1H), 2.86 (s, 6H), 2.22 (s, 6H).

Example 30

15 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-methoxyphenyl)-4H-chromene

The title compound was prepared from 2-fluoro-5-methoxybenzaldehyde. The resulting reaction solution was purified by column chromatography to give the title compound as light yellow solid. ^1H NMR (DMSO-d₆): 7.07 (t, J = 9.9, 1H), 6.90 (s, 2H), 6.84-6.78 (m, 2H), 6.71-6.68 (m, 1H), 6.48-6.45 (m, 1H), 6.23 (d, J = 1.8, 1H), 4.81 (s, 1H), 3.69 (s, 3H), 2.86 (s, 6H).

Example 31

2-Amino-3-cyano-7-dimethylamino-4-phenyl-4H-chromene

The title compound was prepared from benzaldehyde in a yield of 74%
as described in Example 1. ^1H NMR (DMSO-d₆): 7.32-7.27 (m, 2H), 7.22-
7.14 (m, 3H), 6.82 (s, 2H), 6.78 (d, J = 8.7, 1H), 6.47-6.43 (m, 1H), 6.23 (d, J
= 2.4, 1H), 4.59 (s, 1H), 2.86 (s, 6H).

Example 32

2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-3-trifluoromethylphenyl)-4H-chromene

The title compound was prepared from 2-fluoro-3-trifluoromethylbenzaldehyde with *N,N*-diisopropylethylamine and was isolated as a pale yellow solid in a yield of 84% as described in Example 30. ^1H NMR (DMSO-d₆): 7.66 (t, J = 7.2, 1H), 7.54 (t, J = 7.2, 1H), 7.38 (t, J = 7.2, 1H), 6.99 (s, 2H), 6.79 (d, J = 8.7, 1H), 6.50-6.46 (m, 1H), 6.25 (d, J = 2.4, 1H), 5.02 (s, 1H), 2.88 (s, 6H).

Example 33

2-Amino-3-cyano-7-dimethylamino-4-(4-fluoro-3-trifluoromethylphenyl)-4H-chromene

The title compound was prepared from 4-fluoro-3-trifluoromethylbenzaldehyde as a light yellow solid in a yield of 4% as described in Example 32. ^1H NMR (DMSO-d₆): 7.59 (d, J = 7.8, 1H), 7.50-7.44 (m, 2H), 6.99 (s, 2H), 6.79 (d, J = 8.4, 1H), 6.49-6.46 (m, 1H), 6.24 (d, J = 2.1, 1H), 4.83 (s, 1H), 2.87 (s, 6H).

Example 34

2-Amino-3-cyano-7-dimethylamino-4-(2,4,5-trifluorophenyl)-4H-chromene

The title compound was prepared from 2,4,5-trifluorobenzaldehyde as a pale yellow solid in a yield of 14% as described in Example 32. ^1H NMR

(DMSO-d₆): 7.55-7.46 (m, 1H), 7.34-7.25 (m, 1H), 6.95 (s, 2H), 6.79 (d, J = 8.7, 1H), 6.49-6.45 (m, 1H), 6.23 (d, J = 2.4, 1H), 4.87 (s, 1H), 2.87 (s, 6H).

Example 35

5 **2-Amino-3-cyano-7-dimethylamino-4-(2,3,4-trifluorophenyl)-4H-chromene**

The title compound was prepared from 2,3,4-trifluorobenzaldehyde as a white solid in a yield of 14% as described in Example 32. ¹H NMR (DMSO-d₆): 7.32-7.24 (m, 1H), 7.07-7.02 (m, 1H), 6.99 (s, 2H), 6.80 (d, J = 8.4, 1H), 6.49-6.46 (m, 1H), 6.23 (d, J = 2.4, 1H), 4.94 (s, 1H), 2.87 (s, 6H).

10

Example 36

15 **2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-nitrophenyl)-4H-chromene**

The title compound was prepared from 2-fluoro-5-nitrobenzaldehyde as a yellow solid in a yield of 13% as described in Example 32. ¹H NMR (DMSO-d₆): 8.23-8.17 (m, 1H), 8.13-8.10 (m, 1H), 7.48 (t, J = 9.9, 1H), 7.04 (s, 2H), 6.83 (d, J = 8.7, 1H), 6.49-6.45 (m, 1H), 6.26 (d, J = 2.4, 1H), 5.07 (s, 1H), 2.88 (s, 6H).

20

Example 37

25 **2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-3-nitrophenyl)-4H-chromene**

25

The title compound was prepared from 4-chloro-3-nitrobenzaldehyde as a yellow solid in a yield of 25% as described in Example 1. ¹H NMR (CDCl₃): 7.65 (d, J = 1.8, 1H), 7.49 (d, J = 8.1, 1H), 7.42-7.38 (m, 1H), 6.72 (d, J = 8.4, 1H), 6.45-6.42 (m, 1H), 6.30 (d, J = 2.4, 1H), 4.73 (s, 1H), 4.68 (s, 2H), 2.95 (s, 6H).

30

Example 38

2-Amino-3-cyano-7-dimethylamino-4-(3-nitrophenyl)-4H-chromene

The title compound was prepared from 3-nitrobenzaldehyde as a yellow solid in a yield of 46% as described in Example 1. ¹H NMR (DMSO-d₆): 8.10 (d, J = 7.2, 1H), 8.02 (s, 1H), 7.65-7.63 (m, 2H), 7.03 (s, 2H), 6.83 (d, J = 8.7, 1H), 6.49-6.46 (m, 1H), 6.26 (d, J = 2.1, 1H), 4.89 (s, 1H), 2.87 (s, 6H).

10

Example 39

2-Amino-3-cyano-7-dimethylamino-4-cyclohexyl-4H-chromene

15

The title compound was prepared from cyclohexanecarboxaldehyde as a pale yellow solid in a yield of 31% as described in Example 30. ¹H NMR (DMSO-d₆): 6.96 (d, J = 8.4, 1H), 6.72 (s, 2H), 6.53-6.49 (m, 1H), 6.20 (d, J = 2.4, 1H), 3.19 (d, J = 3.3, 1H), 2.87 (s, 6H), 2.82 (s, 1H), 1.65-0.86 (m, 10H).

20

Example 40

2-Amino-7-dimethylamino-3-ethoxycarbonyl-4-(3-methoxy-4,5-methylenedioxy)phenyl-4H-chromene

25

The title compound was prepared as a tan solid from ethyl cyanoacetate in 25% yield as described in Example 1. ¹H NMR (DMSO-d₆): 6.94 (d, J = 8.4, 1H), 6.45-6.23 (m, 6H), 5.88-5.86 (m, 2H), 4.75 (s, 1H), 4.08 (q, J = 7.0, 2H), 3.87 (s, 3H), 2.91 (s, 6H), 1.20 (t, J = 7.0, 3H).

30

Example 41

2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-4-trifluoromethylphenyl)-4H-chromene

The title compound was prepared from 3-fluoro-4-trifluoromethylbenzaldehyde as a yellow solid as described in Example 19. ¹H NMR (DMSO-d₆): 7.75 (t, J = 7.65, 1H), 7.33 (d, J = 11.4, 1H), 7.20 (d, J = 8.4, 1H),

7.02 (s, 2H), 6.83 (d, J = 8.7, 1H), 6.50-6.46 (m, 1H), 6.24 (d, J = 2.4, 1H),
4.81 (s, 1H), 2.87 (s, 6H).

Example 42

5 **2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoro-5-trifluoromethylphenyl)-4H-chromene**

The title compound was prepared from 3,4-difluoro-5-trifluoromethylbenzaldehyde as a white solid in a yield of 50% as described in Example 1. ¹H NMR (DMSO-d₆): 7.65-7.60 (m, 1H), 7.44 (d, J = 5.1, 1H), 7.05 (s, 2H), 6.83 (d, J = 8.7, 1H), 6.51-6.47 (m, 1H), 6.24 (d, J = 2.7, 1H), 4.86 (s, 1H), 2.88 (s, 6H).

10 *Example 43*

15 **2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-trifluoromethylphenyl)-4H-chromene**

The title compound was prepared from 2-chloro-5-trifluoromethylbenzaldehyde as a light pink solid in a yield of 22% as described in Example 1. ¹H NMR (DMSO-d₆): 7.71-7.66 (m, 2H), 7.55 (s, 1H), 7.00 (s, 2H), 6.72 (d, J = 8.7, 1H), 6.45 (d, J = 7.5, 1H), 6.25 (s, 1H), 5.23 (s, 1H), 2.87 (s, 6H).

20 *Example 44*

25 **2-Amino-3-cyano-7-dimethylamino-4-(3,4-dibenzylxyphenyl)-4H-chromene**

The title compound was prepared from 3,4-dibenzylxybenzaldehyde as a white solid in a yield of 38% as described in Example 1. ¹H NMR (DMSO-d₆): 7.44-7.31 (m, 10H), 6.99 (d, J = 8.4, 1H), 6.92 (d, J = 1.8, 1H), 6.79 (s, 1H), 6.75 (d, J = 9.0, 1H), 6.69-6.65 (m, 1H), 6.44-6.40 (m, 1H), 6.21 (d, J = 2.4, 1H), 5.06-5.05 (m, 4H), 4.52 (s, 1H), 2.86 (s, 6H).

Example 45

2-Amino-3-cyano-7-dimethylamino-4-(3-phenoxyphenyl)-4H-chromene

The title compound was prepared from 3-phenoxybenzaldehyde as a yellow solid in a yield of 10% as described in Example 30. ¹H NMR (DMSO-d₆): 7.41-7.36 (m, 2H), 7.30 (t, J = 7.8, 1H), 7.17-7.11 (m, 1H), 7.01-6.98 (m, 2H), 6.93 (d, J = 7.5, 1H), 6.86 (s, 3H), 6.83 (d, J = 8.4, 1H), 6.79-6.76 (m, 1H), 6.50-6.46 (m, 1H), 6.22 (d, J = 2.7, 1H), 4.62 (s, 1H), 2.87 (s, 6H).

10

Example 46

2-Amino-3-cyano-7-dimethylamino-4-(4-n-octyloxyphenyl)-4H-chromene

The title compound was prepared from 4-n-octyloxybenzaldehyde as a white solid in a yield of 14% as described in Example 1. ¹H NMR (DMSO-d₆): 7.05 (d, J = 8.7, 2H), 6.84 (d, J = 8.7, 2H), 6.77 (s, 2H), 6.76 (d, J = 9.0, 1H), 6.47-6.43 (m, 1H), 6.22 (d, J = 2.4, 1H), 4.53 (s, 1H), 3.90 (t, J = 6.6, 2H), 2.86 (s, 6H), 1.70-1.65 (m, 2H), 1.38-1.26 (m, 10H), 0.854 (t, J = 6.6, 3H).

15
20
25

Example 47

2-Amino-3-cyano-7-dimethylamino-4-(4-n-dodecyloxyphenyl)-4H-chromene

The title compound was prepared from 4-n-dodecyloxybenzaldehyde as a yellow solid in a yield of 65% as described in Example 1. ¹H NMR (DMSO-d₆): 7.04 (d, J = 8.4, 2H), 6.85-6.74 (m, 5H), 6.46-6.43 (m, 1H), 6.21 (d, J = 2.1, 1H), 4.53 (s, 1H), 3.90 (t, J = 6.3, 2H), 2.85 (s, 6H), 1.67-1.65 (m, 2H), 1.24 (s, 18H), 0.84 (t, J = 3.6, 3H).

Example 48

2-Amino-3-cyano-7-dimethylamino-4-(5-fluoro-2-nitrophenyl)-4H-chromene

5 The title compound was prepared from 5-fluoro-2-nitrobenzaldehyde as a yellow solid in a yield of 7% as described in Example 30. ^1H NMR (DMSO-d₆): 8.05-8.00 (m, 1H), 7.39-7.33 (m, 1H), 7.09-7.04 (m, 1H), 7.02 (s, 2H), 6.79 (d, J = 8.7, 1H), 6.50-6.46 (m, 1H), 6.25 (d, J = 2.4, 1H), 5.23 (s, 1H), 2.88 (s, 6H).

10

Example 49

2-Amino-3-cyano-7-dimethylamino-4-(4-(4-fluorobenzoyloxy)-3-nitrophenyl)-4H-chromene

15 The title compound was prepared from 4-(4-fluorobenzoyloxy)-3-nitrobenzaldehyde as a yellow solid in a yield of 31% as described in Example 30. ^1H NMR (DMSO-d₆): 7.69 (d, J = 2.1, 1H), 7.52-7.39 (m, 4H), 7.27-7.21 (m, 2H), 6.92 (s, 2H), 6.80 (d, J = 9.0, 1H), 6.49-6.46 (m, 1H), 6.23 (d, J = 2.4, 1H), 5.25 (s, 2H), 4.74 (s, 1H), 2.87 (s, 6H).

20

Example 50

2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-3-trifluoromethylphenyl)-4H-chromene

25 The title compound was prepared from 4-chloro-3-trifluoromethylbenzaldehyde as a white solid in a yield of 46% as described in Example 1. ^1H NMR (DMSO-d₆): 7.68 (d, J = 8.4, 2H), 7.46 (d, J = 8.4, 1H), 6.98 (s, 2H), 6.80 (d, J = 8.7, 1H), 6.49-6.46 (m, 1H), 6.24 (d, J = 2.7, 1H), 4.84 (s, 1H), 2.87 (s, 6H).

30

DEPARTMENT OF CHEMISTRY

Example 51

2-Amino-3-cyano-7-dimethylamino-4-(2,3-difluoro-4-trifluoromethylphenyl)-4H-chromene

5 The title compound was prepared from 2,3-difluoro-4-trifluoromethylbenzaldehyde as a brown solid in a yield of 92% as described in Example 19. ^1H NMR (DMSO-d₆): 7.60 (t, J = 7.5, 1H), 7.21 (t, J = 7.2, 1H), 7.06 (s, 2H), 6.83 (d, J = 8.7, 1H), 6.50-6.46 (m, 1H), 6.26 (d, J = 2.4, 1H), 5.07 (s, 1H), 2.88 (s, 6H).

10

Example 52

2-Amino-3-cyano-7-dimethylamino-4-(2-carboxyphenyl)-4H-chromene

15 The title compound was prepared from 2-carboxybenzaldehyde as a white solid in a yield of 52% as described in Example 1. ^1H NMR (DMSO-d₆): 7.57 (d, J = 6.9, 1H), 7.21-7.14 (m, 2H), 7.07 (t, J = 6.9, 1H), 6.99 (d, J = 7.8, 1H), 6.66 (s, 2H), 6.40-6.36 (m, 1H), 6.18 (d, J = 2.1, 1H), 5.99 (s, 1H), 2.83 (s, 6H).

20

Example 53

2-Amino-3-cyano-7-dimethylamino-4-(3-carboxyphenyl)-4H-chromene

25 The title compound was prepared from 3-carboxybenzaldehyde as a yellow solid in a yield of 80% as described in Example 1. ^1H NMR (DMSO-d₆): 7.72-7.68 (m, 1H), 7.64 (s, 1H), 7.29-7.25 (m, 2H), 6.84 (s, 2H), 6.76 (d, J = 9.0, 1H), 6.47-6.43 (m, 1H), 6.23 (d, J = 2.7, 1H), 4.62 (s, 1H), 2.86 (s, 6H).

30

Example 54

2-Amino-3-cyano-7-dimethylamino-4-(3,5-dibenzylxyphenyl)-4H-chromene

The title compound was prepared from 3,5-dibenzylxybenzaldehyde as a white solid in a yield of 58% as described in Example 1. ^1H NMR

(DMSO-d₆): 7.45-7.32 (m, 10H), 6.83-6.80 (m, 3H), 6.54-6.53 (m, 1H), 6.46-6.41 (m, 3H), 6.21 (d, J = 2.7, 1H), 5.02 (s, 4H), 4.52 (s, 1H), 2.86 (s, 6H).

Example 55

5 2-Amino-3-cyano-7-dimethylamino-4-(3-(4-methoxyphenoxy)phenyl)-4H-chromene

The title compound was prepared from 3-(4-methoxyphenoxy)-benzaldehyde as a white solid in a yield of 12% as described in Example 30.

10 ¹H NMR (DMSO-d₆): 7.24 (t, J = 7.8, 1H), 7.01-6.93 (m, 4H), 6.86-6.78 (m, 5H), 6.68-6.64 (m, 1H), 6.50-6.46 (m, 1H), 6.22 (d, J = 2.4, 1H), 4.59 (s, 1H), 3.75 (s, 3H), 2.86 (s, 6H).

Example 56

15 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethoxyphenyl)-4H-chromene

The title compound was prepared from 3,5-dimethoxybenzaldehyde as a white solid in a yield of 38% as described in Example 1. ¹H NMR (DMSO-d₆): 6.85 (d, J = 8.7, 1H), 6.81 (s, 2H), 6.48-6.44 (m, 1H), 6.36-6.34 (m, 1H), 6.31 (d, J = 2.1, 2H), 6.22 (d, J = 2.4, 1H), 4.52 (s, 1H), 3.70 (s, 6H), 2.86 (s, 6H).

Example 57

25 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dichlorophenyl)-4H-chromene

The title compound was prepared from 3,5-dichlorobenzaldehyde as a sandy solid in a yield of 24% as described in Example 19. ¹H NMR (DMSO-d₆): 7.47 (t, J = 1.8, 1H), 7.20 (d, J = 2.1, 2H), 6.98 (s, 2H), 6.83 (d, J = 8.7, 1H), 6.51-6.47 (m, 1H), 6.24 (d, J = 2.4, 1H), 4.73 (s, 1H), 2.88 (s, 6H).

Example 58

2-Amino-3-cyano-7-dimethylamino-4-(3-benzyloxyphenyl)-4H-chromene

The title compound was prepared from 3-benzyloxybenzaldehyde in a
5 yield of 76% as described in Example 1. ^1H NMR (DMSO-d₆): 7.46-7.33 (m,
5H), 7.22 (t, J = 7.8, 1H), 6.87-6.74 (m, 6H), 6.46-6.43 (m, 1H), 6.22 (d, J =
2.1, 1H), 5.04 (s, 2H), 4.56 (s, 1H), 2.86 (s, 6H).

Example 59

**2-Amino-3-cyano-7-dimethylamino-4-(5-fluoro-2-trifluoromethylphenyl)-
4H-chromene**

The title compound was prepared from 5-fluoro-2-trifluoromethyl-
15 benzaldehyde as a brown solid in a yield of 21% as described in Example 19.
 ^1H NMR (DMSO-d₆): 7.84-7.79 (m, 1H), 7.32-7.27 (m, 1H), 7.01 (s, 2H),
6.98-6.94 (m, 1H), 6.59 (d, J = 9.0, 1H), 6.49-6.45 (m, 1H), 6.28 (d, J = 2.4,
1H), 4.95 (s, 1H), 2.88 (s, 6H).

Example 60

2-Amino-3-cyano-7-dimethylamino-4-(3-dodecyloxyphenyl)-4H-chromene

The title compound was prepared from 3-dodecyloxybenzaldehyde as a
white solid in a yield of 54% as described in Example 1. ^1H NMR (DMSO-
25 d₆): 7.19 (t, J = 7.8, 1H), 6.83-6.69 (m, 6H), 6.47-6.43 (m, 1H), 6.22 (d, J =
2.7, 1H), 4.55 (s, 1H), 3.90 (t, J = 6.3, 2H), 2.86 (s, 6H), 1.70-1.65 (m, 2H),
1.38-1.24 (m, 18H), 0.85 (t, J = 6.6, 3H).

Example 61

**2-Amino-3-cyano-7-dimethylamino-4-(4-carboxaldehydophenyl)-4H-
chromene**

The title compound was prepared from terephthaliccarboxaldehyde as
a yellow solid in a yield of 2% as described in Example 30. ^1H NMR (DMSO-
d₆): 9.96 (s, 1H), 7.86 (d, J = 8.1, 2H), 7.39 (d, J = 7.8, 2H), 6.93 (s, 2H), 6.79

(d, J = 8.7, 1H), 6.48-6.44 (m, 1H), 6.25 (d, J = 2.7, 1H), 4.75 (s, 1H), 2.87 (s, 6H).

Example 62

5 2-Amino-3-cyano-7-dimethylamino-4-(2-quinolyl)-4H-chromene

The title compound was prepared from 2-quinolinecarboxaldehyde as a pale pink solid in a yield of 31% as described in Example 1. ¹H NMR (DMSO-d₆): 8.29 (d, J = 8.7, 1H), 8.02 (d, J = 8.4, 1H), 7.93 (d, J = 8.4, 1H), 7.76 (t, J = 7.5, 1H), 7.58 (t, J = 7.8, 1H), 7.28 (d, J = 8.4, 1H), 7.02 (s, 1H), 6.83 (d, J = 8.4, 1H), 6.44-6.40 (m, 1H), 6.28 (d, J = 2.4, 1H), 4.89 (s, 1H), 2.86 (s, 6H).

Example 63

15 2-Amino-3-cyano-7-dimethylamino-4-(3-quinolyl)-4H-chromene

The title compound was prepared from 3-quinolinecarboxaldehyde as a yellow solid in a yield of 69% as described in Example 1. ¹H NMR (DMSO-d₆): 8.71 (d, J = 2.1, 1H), 8.12 (d, J = 2.1, 1H), 8.01-7.97 (m, 2H), 7.76-7.70 (m, 1H), 7.61 (t, J = 7.5, 1H), 6.99 (s, 2H), 6.81 (d, J = 8.7, 1H), 6.48-6.44 (m, 1H), 6.28 (d, J = 8.7, 1H), 6.48-6.44 (m, 1H), 6.28 (d, J = 2.4, 1H), 4.91 (s, 1H), 2.87 (s, 6H).

Example 64

25 2-Amino-3-cyano-7-dimethylamino-4-(phenylmethyl)-4H-chromene

The title compound was prepared from phenylacetaldehyde as a yellow solid in a yield of 3% as described in Example 30. ¹H NMR (DMSO-d₆): 7.15-7.12 (m, 3H), 6.94 (d, J = 8.7, 1H), 6.86-6.83 (m, 2H), 6.56 (s, 2H), 6.50-6.47 (m, 1H), 6.03 (d, J = 2.4, 1H), 3.57 (t, J = 4.8, 1H), 2.94-2.88 (m, 1H), 2.85 (s, 6H), 2.80-2.74 (m, 1H).

Example 65

3-Cyano-2,7-diamino-4-(3-methoxy-4,5-methylenedioxophenyl)-4H-chromene

5 The title compound was prepared from 3-aminophenol and 5-methoxypiperonal as a yellow-brown solid in a yield of 29% as described in Example 19. ^1H NMR (DMSO-d₆): 6.79 (s, 2H), 6.67 (d, J = 8.1, 1H), 6.49 (d, J = 1.2, 1H), 6.29-6.25 (m, 2H), 6.18 (d, J = 2.4, 1H), 5.94 (d, J = 5.1, 2H), 5.25 (s, 2H), 4.46 (s, 1H), 3.80 (s, 3H).

10

Example 66

2-Amino-3-cyano-7-dimethylamino-4-(2-pyridyl)-4H-chromene

15 The title compound was prepared from 2-pyridinecarboxaldehyde as a red-brown solid in a yield of 35% as described in Example 19. ^1H NMR (DMSO-d₆): 8.48-8.45 (m, 1H), 7.76-7.70 (m, 1H), 7.23-7.20 (m, 2H), 6.88 (s, 2H), 6.85 (d, J = 9.0, 1H), 6.46-6.42 (m, 1H), 6.23 (d, J = 3.0, 1H), 4.70 (s, 1H), 2.85 (s, 6H).

20

Example 67

2-Amino-3-cyano-7-dimethylamino-4-(2-phenylethyl)-4H-chromene

25

The title compound was prepared from hydrocinnamaldehyde as a yellow solid in a yield of 17% as described in Example 30. ^1H NMR (DMSO-d₆): 7.36-7.08 (m, 6H), 6.75 (s, 2H), 6.58-6.54 (m, 1H), 6.21 (d, J = 2.4, 1H), 3.58 (t, J = 6.9, 1H), 2.87 (s, 6H), 2.34-2.24 (m, 2H), 1.97-1.79 (m, 2H).

30

Example 68

2-Amino-3-cyano-7-dimethylamino-4-(4-methoxycarbonylphenyl)-4H-chromene

The title compound was prepared from methyl 4-formylbenzoate as a pale pink solid in a yield of 73% as described in Example 1. ^1H NMR (DMSO-d₆): 7.91 (d, J = 8.1, 2H), 7.32 (d, J = 8.1, 2H), 6.93 (s, 2H), 6.78 (d, J

= 8.7, 1H), 6.48-6.44 (m, 1H), 6.24 (d, J = 2.4, 1H), 4.73 (s, 1H), 3.83 (s, 3H), 2.86 (s, 6H).

Example 69

5 **2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoromethylenedioxypyphenyl)-4H-chromene**

The title compound was prepared from 2,2-difluoro-5-formylbenzodioxole and N,N-diisopropylethylamine as a white solid in a yield of 29% as described in Example 1. ¹H NMR (DMSO-d₆): 7.34 (d, J = 8.1, 1H), 7.19 (d, J = 1.8, 1H), 7.04-7.01 (m, 1H), 6.91 (s, 2H), 6.79 (d, J = 8.7, 1H), 6.48-6.45 (m, 1H), 6.23 (d, J = 2.4, 1H), 4.70 (s, 1H), 2.86 (s, 6H).

10 **Example 70**

15 **2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-thienyl)-4H-chromene**

The title compound was prepared from 5-nitro-2-thiophen-carboxaldehyde and N,N-diisopropylethylamine as described in Example 30. ¹H NMR (DMSO-d₆): 8.00 (d, J = 5.1, 1H), 7.19 (s, 2H), 7.16 (d, J = 4.2, 1H), 7.07 (d, J = 8.4, 1H), 6.56-6.53 (m, 1H), 6.24 (d, J = 2.4, 1H), 5.11 (s, 1H), 2.89 (s, 6H).

20 **Example 71**

25 **2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-furyl)-4H-chromene**

The title compound was prepared from 5-nitro-2-furaldehyde and N,N-diisopropylethylamine as a brown solid as described in Example 30. ¹H NMR (DMSO-d₆): 7.63 (d, J = 3.6, 1H), 7.15 (s, 2H), 7.00 (d, J = 8.4, 1H), 6.65 (d, J = 3.6, 1H), 6.56-6.53 (m, 1H), 6.25 (d, J = 2.7, 1H), 5.00 (s, 1H), 2.89 (s, 6H).

Example 72

2-Amino-3-cyano-7-ethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene

The title compound was prepared from 3-ethylaminophenol and 5-methoxypiperonal as a pale yellow solid in a yield of 34% as described in Example 30. ^1H NMR (DMSO-d₆): 6.79 (s, 2H), 6.72 (d, J = 9.0, 1H), 6.50 (d, J = 1.5, 1H), 6.31-6.28 (m, 2H), 6.10 (d, J = 2.1, 1H), 5.95-5.93 (m, 2H), 5.77-5.74 (m, 1H), 4.48 (s, 1H), 3.80 (s, 3H), 2.99-2.95 (m, 2H), 1.12 (t, J = 7.2, 3H).

10

Example 73

2-Amino-3-cyano-7-dimethylamino-4-(4-bromo-3,5-dimethoxyphenyl)-4H-chromene

15

The title compound was prepared from 4-bromo-3,5-dimethoxybenzaldehyde as a white solid in a yield of 48% as described in Example 1. ^1H NMR (DMSO-d₆): 6.89-6.86 (m, 3H), 6.57 (s, 2H), 6.48-6.44 (m, 1H), 6.23 (d, J = 2.7, 1H), 4.66 (s, 1H), 3.78 (s, 6H), 2.86 (s, 6H).

20

Example 74

2-Amino-3-cyano-7-dimethylamino-4-(4-pyridinyl)-4H-chromene

25

The title compound was prepared as a brown solid from 4-pyridinecarboxaldehyde as described in Example 1. ^1H NMR (CDCl₃): 8.54-8.52 (m, 2H), 7.13-7.11 (m, 2H), 6.75 (d, J=8.7, 1H), 6.45-6.42 (m, 1H), 6.30 (d, J=2.7, 1H), 4.64 (s, 1H), 4.63 (s, 2H), 2.94 (s, 6H).

30

Example 75

2-amino-3-cyano-4-(3-methoxy-4,5-methylenedioxypyhenyl)-5-methyl-pyrazo[5,4-b]-4H-pyran

A solution of 5-methoxypiperonal (180.2 mg, 1 mmol), malononitrile (66 mg, 1 mmol) and *N,N*-diisopropylethylamine (155 mg, 1.2 mmol) in

ethanol (10 ml) was stirred at room temperature for 2 h, than 3-methyl-3-pyrazolin-5-one was added. It was heated to reflux for 1 h, concentrated, and the residue was purified by column chromatography (silica gel, EtOAc/Hexane = 1:1) to give 201 mg (61%) of the title compound. ^1H NMR (DMSO-d₆): 12.1 (s, 1H), 6.90 (s, 2H), 6.51 (s, 1H), 6.31 (s, 1H), 5.97 (d, 2H), 4.54 (s, 1H), 3.79 (s, 3H), 1.85 (s, 3H).

Example 76

2-Imino-3-benzoyl-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-chromane

A solution of 5-methoxypiperonal (180.2 mg, 1 mmol), benzoylacetonitrile (66 mg, 1 mmol) and *N,N*-diisopropylethylamine (155 mg, 1.2 mmol) in ethanol (8 ml) was stirred at room temperature for 2 h, than 3-dimethylaminophenol was added to the solution. It was stirred at room temperature for 18 h, concentrated, and the residue was purified by column chromatography (silica gel, EtOAc/Hexane = 1:1) to give 305 mg (68%) of the title compound. ^1H NMR (CDCl₃): 7.80-7.77 (m, 2H), 7.50-7.42 (m, 3H), 6.88-6.30 (m, 5H), 5.95-5.94 (m, 2H), 4.73 (d), 4.45 (d, 1H), 3.88 (s, 3H), 3.35 (d), 3.05 (d, 1H), 2.86 (s, 6H).

Example 77

2-Amino-3-benzoyl-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene

A solution of 2-imino-3-benzoyl-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-chromane (26 mg, 0.059 mmol) and triethylamine (0.1 ml) in ethanol (5 ml) was refluxed for 12 h. It was concentrated, and the residue was purified by column chromatography (silica gel, EtOAc/Hexane = 1:5) to give 18 mg (72%) of the title compound. ^1H NMR (CDCl₃): 7.40-7.30 (m, 2H), 7.18-7.14 (m, 2H), 6.86 (d, 1H), 6.50-6.34 (m, 2H), 6.00 (d, 1H), 5.85-5.81 (m, 2H), 5.73 (d, 1H), 4.73 (s, 1H), 3.67 (s, 3H), 2.91 (s, 6H).

Example 78

2-Imino-3-(2,2-dimethylpropanoyl)-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-chromane

5

A solution of 5-methoxypiperonal (180.2 mg, 1 mmol), 4,4-dimethyl-3-oxopentanenitrile (125.2 mg, 1 mmol) and *N,N*-diisopropylethylamine (155.1 mg, 1.2 mmol) in ethanol (8 ml) was stirred at room temperature for 3 h, than 3-dimethylaminophenol was added to the solution. It was stirred at room temperature for 24 h, concentrated, and the residue was purified by column chromatography (silica gel, EtOAc/Hexane = 1:1) to give 101 mg (24%) of the title compound. ^1H NMR (CDCl_3): 6.64–6.16 (m, 5H), 5.98 (s, 2H), 4.70 (d) and 4.30 (d, 1H), 3.91 (s, 3H), 3.20 (d) and 3.02 (q, 1H), 2.91 (s, 6H), 1.30 (s, 9H).

10

15

Example 79

2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-trifluoromethylphenyl)-4H-chromene

20

The title compound was prepared from 2-fluoro-5-trifluoromethylbenzaldehyde as an orange solid in a yield of 56% as described in Example 30.
¹H NMR (DMSO-d₆): 7.73-7.70 (m, 1H), 7.62-7.60 (m, 1H), 7.41 (t, J = 9.45, 1H), 6.99 (s, 2H), 6.80 (d, J = 8.7, 1H), 6.48-6.45 (m, 1H), 6.25 (d, J = 2.7, 1H), 5.00 (s, 1H), 2.87 (s, 6H).

25

Example 80

2-Acetamido-3-cyano-7-dimethylamino-4-(methylenedioxy)phenyl-4H-chromene

30

To a solution of 2-amino-3-cyano-7-dimethylamino-4-(methylenedioxy)phenyl-4*H*-chromene (43 mg, 0.13 mmol) in pyridine (1 ml) was added acetic anhydride (0.25 ml, 2.6 mmol) at room temperature. The mixture was stirred at room temperature for 3 days, then diluted with 1:1 hexane/EtOAc (40 ml), washed with water, 2N HCl, water, 2N NaOH, water and brine. The

organic phase was dried over sodium sulfate and concentrated in vacuo. The residue was purified by chromatography (3:2 hexane/EtOAc) to yield the title compound as a yellow solid (4 mg, 8%). ^1H NMR (CDCl_3): 6.84-6.73 (m, 4H), 6.50-6.46 (m, 1H), 6.31 (m, 1H), 5.95,5.94 (2s, 2H), 4.79 (s, 1H), 2.94 (s, 6H), 2.18 (s, 3H).

5

Example 81

3-Cyano-2-di(ethoxycarbonyl)amino-7-dimethylamino-4-(methylenedioxy)phenyl-4H-chromene

10

To a solution of 2-amino-3-cyano-7-dimethylamino-4-(methylenedioxy)phenyl-4H-chromene (53 mg, 0.16 mmol) in methylenechloride (3 ml) was added pyridine (0.06 ml, 0.74 mmol), followed by ethylchloroformate (0.045 ml, 0.47 mmol). The mixture was stirred at room temperature overnight, then diluted with 1:1 hexane/EtOAc (45 ml), washed with water, 2N HCl, water and brine. The organic phase was dried over sodium sulfate and concentrated in vacuo. The residue was purified by chromatography (3:1 hexane/EtOAc) to yield the title compound as a yellow solid (5 mg, 7%). ^1H NMR (CDCl_3): 6.84-6.61 (m, 4H), 6.49-6.42 (m, 1H), 6.30 (m, 1H), 5.93,5.92 (2s, 2H), 4.74 (s, 1H), 4.36 (m, 4H), 2.93 (s, 6H), 1.31 (t, $J = 7.2, 6\text{H}$).

15

20

Example 82

2,7-Diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene

25

The title compound was prepared from 5-bromoveratraldehyde as a white solid in a yield of 37% by a procedure similar to that described for Example 19. ^1H NMR (DMSO-d_6): 6.92 (d, $J = 1.8, 1\text{H}$), 6.85 (s, 2H), 6.83 (d, $J = 1.8, 1\text{H}$), 6.70 (d, $J = 8.1, 1\text{H}$), 6.31-6.27 (m, 1H), 6.20 (d, $J = 2.1, 1\text{H}$), 5.28 (s, 2H), 4.54 (s, 1H), 3.80 (s, 3H), 3.70 (d, $J = 0.6, 3\text{H}$).

30

Example 83

2-Amino-7-chloroacetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene

To a solution of 2,7-diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene (50 mg, 0.124 mmol) in dichloromethane (2 ml) was added N,N-diisopropylethylamine (0.043ml, 0.247 mmol). The flask was cooled in iced water and a solution of chloroacetyl chloride (14 mg, 0.124 mmol) in dichloromethane (1 ml) was added dropwise. The reaction mixture was stirred for 3 h, diluted with ethyl acetate, then washed with water, brine and dried over anhydrous sodium sulfate, and evaporated. The resulting solid was washed with a small amount of dichloromethane to yield the title compound as a white solid in a yield of 24%. ^1H NMR (DMSO- d_6): 10.45 (s, 1H), 7.56 (s, 1H), 7.14-7.12 (m, 1H), 7.07 (s, 1H), 7.05 (s, 2H), 6.97 (s, 1H), 6.89 (d, $J = 0.9$, 1H), 4.74 (s, 1H), 4.24 (s, 2H), 3.80 (s, 3H), 3.70 (s, 3H).

Example 84

2-Amino-3-cyano-7-phenylamino-4-(3-methoxy-4,5-methylenedioxophenyl)-4H-chromene

The title compound was prepared from 5-methoxypiperonal and 3-hydroxydiphenylamine as a yellow solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO- d_6): 8.31 (s, 1H), 7.26 (t, $J = 10.5$, 2H), 7.07 (d, $J = 7.8$, 2H), 6.91-6.88 (m, 4H), 6.77-6.73 (m, 1H), 6.65 (d, $J = 2.7$, 1H), 6.55 (d, $J = 1.5$, 1H), 6.34 (d, $J = 1.5$, 1H), 5.95 (d, $J = 4.5$, 2H), 4.57 (s, 1H), 3.82 (s, 3H).

Example 85

2-Amino-3-cyano-7-ethylamino-6-methyl-4-(3-methoxy-4,5-methylenedioxophenyl)-4H-chromene

The title compound was prepared from 5-methoxypiperonal and 3-ethylamino- ρ -cresol as a light yellow solid in a yield of 21% by a procedure similar to that described for Example 30. ^1H NMR (DMSO- d_6): 6.75 (s, 2H),

6.59 (s, 1H), 6.49 (d, $J = 1.2$, 1H), 6.27 (d, $J = 1.2$, 1H), 6.05 (s, 1H), 5.94 (d, $J = 5.1$, 2H), 4.94 (t, $J = 5.1$, 1H), 4.46 (s, 1H), 3.81 (s, 3H), 3.07-3.01 (m, 2H), 1.95 (s, 3H), 1.170 (t, $J = 6.9$, 3H).

5

Example 86

3-Cyano-2,7-diamino-8-methyl-4-(3-methoxy-4,5-methylenedioxypyphenyl)-4H-chromene

10

The title compound was prepared from 5-methoxypiperonal and 3-amino-*o*-cresol as a yellow solid in a yield of 18% by a procedure similar to that described for Example 30. ^1H NMR (DMSO- d_6): 6.80 (s, 2H), 6.57 (d, $J = 8.1$, 1H), 6.48 (d, $J = 1.5$, 1H), 6.34 (d, $J = 8.4$, 1H), 6.26 (d, $J = 1.5$, 1H), 5.93 (d, $J = 4.8$, 2H), 4.98 (s, 2H), 4.46 (s, 1H), 3.80 (s, 3H), 2.00 (s, 3H).

15

Example 87

2-Amino-3-cyano-7-dimethylamino-4-(3-bromophenyl)-4H-chromene

20

The title compound was prepared from 3-bromobenzaldehyde as a yellow solid in a yield of 62% by a procedure similar to that described for Example 30. ^1H NMR (DMSO- d_6): 7.43-7.39 (m, 1H), 7.33 (t, $J = 1.8$, 1H), 7.29 (t, $J = 10.2$, 1H), 7.20-7.17 (m, 1H), 6.92 (s, 2H), 6.81 (d, $J = 8.4$, 1H), 6.49-6.45 (m, 1H), 6.24 (d, $J = 2.7$, 1H), 4.66 (s, 1H), 2.87 (s, 6H).

25

Example 88

2-Amino-3-cyano-7-dimethylamino-4-ethyl-4H-chromene

30

The title compound was prepared from propionaldehyde as a sticky yellow solid in a yield of 5% by a procedure similar to that described for Example 30. ^1H NMR (DMSO- d_6): 7.02 (d, $J = 8.7$, 1H), 6.67 (s, 2H), 6.55-6.51 (m, 1H), 6.18 (d, $J = 2.4$, 1H), 3.45 (t, $J = 4.5$, 1H), 2.87 (s, 6H), 1.63-1.57 (m, 2H), 0.66 (t, $J = 7.5$, 3H).

Example 89

2-Amino-3-cyano-7-dimethylamino-4-(3,5-dibromophenyl)-4H-chromene

The title compound was prepared from 3,5-dibromobenzaldehyde as a yellow solid in a yield of 9% by a procedure similar to that described for Example 19. ^1H NMR (DMSO-d₆): 7.70 (s, 1H), 7.36 (d, J = 1.2, 2H), 7.00 (s, 2H), 6.83 (d, J = 8.7, 1H), 6.51-6.47 (m, 1H), 6.23 (d, J = 2.7, 1H), 4.71 (s, 1H), 2.88 (s, 6H).

Example 90

2-Amino-3-cyano-7-dimethylamino-4-(3-cyanophenyl)-4H-chromene

The title compound was prepared from 3-cyanobenzaldehyde as a yellow solid in a yield of 25% by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.70 (d, J = 7.5, 1H), 7.65 (s, 1H), 7.56-7.50 (m, 2H), 6.96 (s, 2H), 6.79 (d, J = 8.4, 1H), 6.49-6.45 (m, 1H), 6.24 (d, J = 2.4, 1H), 4.75 (s, 1H), 2.87 (s, 6H).

Example 91

2-Amino-3-cyano-7-dimethylamino-4-(3-methoxyphenyl)-4H-chromene

The title compound was prepared from *m*-anisaldehyde as a yellow solid in a yield of 19% by a procedure similar to that described for Example 30. ^1H NMR (CDCl₃): 7.19 (t, J = 0.6, 1H), 6.82-6.72 (m, 4H), 6.44-6.40 (m, 1H), 6.28 (d, J = 2.7, 1H), 4.61 (s, 1H), 4.54 (s, 2H), 3.77 (s, 3H), 2.92 (s, 6H).

Example 92

2-Amino-3-cyano-7-dimethylamino-4-(3-chlorophenyl)-4H-chromene

The title compound was prepared from 3-chlorobenzaldehyde as a yellow solid in a yield of 33% by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.35 (t, J = 7.5, 1H), 7.29-7.25 (m, 1H),

7.19 (t, $J = 1.8$, 1H), 7.16-7.13 (m, 1H), 6.91 (s, 2H), 6.81 (d, $J = 8.4$, 1H),
6.49-6.45 (m, 1H), 6.23 (d, $J = 2.7$, 1H), 4.66 (s, 1H), 2.87 (s, 6H).

Example 93

5 **2-Amino-3-cyano-7-dimethylamino-4-(3-methylphenyl)-4H-chromene**

The title compound was prepared from *m*-tolualdehyde as a white solid
in a yield of 24% by a procedure similar to that described for Example 1. ^1H
NMR (DMSO- d_6): 7.18 (t, $J = 7.5$, 1H), 7.00 (d, $J = 7.2$, 1H), 6.95 (d, $J = 2.1$,
10 2H), 6.80 (s, 2H), 6.78 (d, $J = 8.7$, 1H), 6.46-6.43 (m, 1H), 6.22 (d, $J = 2.4$,
1H), 4.54 (s, 1H), 2.86 (s, 6H), 2.26 (s, 3H).

Example 94

15 **2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxypyphenyl)-4H-indolo[4,5-
b]pyran**

The title compound was prepared from 5-methoxypiperonal and 4-
hydroxyindole as a light yellow solid by a procedure similar to that described
for Example 30. ^1H NMR (CDCl_3): 8.34 (s, 1H), 7.21 (t, $J = 2.7$, 1H), 7.10 (d,
20 $J = 8.7$, 1H), 6.76 (d, $J = 8.4$, 1H), 6.64 (d, $J = 2.4$, 1H), 6.46 (d, $J = 1.2$, 1H),
6.34 (d, $J = 1.5$, 1H), 5.91 (d, $J = 5.7$, 2H), 4.74 (s, 1H), 4.68 (s, 2H), 3.88 (s,
3H).

Example 95

25 **2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-*b*]pyran**

The title compound was prepared from 6-bromoveratraldehyde and 4-
hydroxyindole as a yellow solid in a yield of 38% by a procedure similar to
that described for Example 30. ^1H NMR (DMSO- d_6): 11.31 (s, 1H), 7.35 (t, J
30 = 2.7, 1H), 7.11 (s, 1H), 7.09 (d, $J = 9.6$, 1H), 6.94 (s, 2H), 6.67 (s, 1H), 6.62
(d, $J = 8.4$, 1H), 6.46 (s, 1H), 5.23 (s, 1H), 3.77 (s, 3H), 3.59 (s, 3H).

Example 96

2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-8-methyl-4H-indolo[4,5-b]pyran

The title compound was prepared from 6-bromoveratraldehyde and 4-hydroxy-2-methylindole as a yellow solid in a yield of 53% by a procedure similar to that described for Example 1. ^1H NMR (DMSO-d₆): 11.13 (s, 1H), 7.10 (s, 1H), 6.96 (d, J = 8.4, 1H), 6.90 (s, 2H), 6.64 (s, 1H), 6.52 (d, J = 8.4, 1H), 6.15 (s, 1H), 5.20 (s, 1H), 3.77 (s, 3H), 3.58 (s, 3H), 2.37 (s, 3H).

Example 97

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran

The title compound was prepared from 5-bromoveratraldehyde and 4-hydroxyindole as a pale yellow solid in a yield of 10% by a procedure similar to that described for Example 19. ^1H NMR (DMSO- d_6): 11.33 (s, 1H), 7.36 (t, J = 2.4, 1H), 7.12 (d, J = 8.4, 1H), 7.00 (s, 2H), 6.98 (s, 1H), 6.87 (d, J = 1.8, 1H), 6.74 (d, J = 8.7, 1H), 6.46 (s, 1H), 4.80 (s, 1H), 3.80 (s, 3H), 3.69 (s, 3H).

Example 98

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4H-indolo[4,5-b]pyran

The title compound was prepared from 5-bromoveratraldehyde and 4-hydroxy-2-methylindole as a white solid in a yield of 48% by a procedure similar to that described for Example 1. ^1H NMR (DMSO-d₆): 11.15 (s, 1H), 6.99 (d, J = 8.7, 1H), 6.97 (s, 1H), 6.94 (s, 2H), 6.85 (d, J = 1.8, 1H), 6.64 (d, J = 8.4, 1H), 6.16 (s, 1H), 4.77 (s, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 2.38 (s, 3H).

Example 99

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-indolo[4,5-b]pyran

The title compound was prepared from 3,4,5-trimethoxybenzaldehyde and 4-hydroxyindole as a white solid in a yield of 43% by a procedure similar to that described for Example 1. ^1H NMR (DMSO-d₆): 11.29 (s, 1H), 7.35 (t, J = 2.7, 1H), 7.10 (d, J = 9.0, 1H), 6.90 (s, 2H), 6.76 (d, J = 8.4, 1H), 6.52 (s, 2H), 6.46-6.45 (m, 1H), 6.75 (s, 1H), 3.70 (s, 6H), 3.62 (s, 3H).

10

Example 100

2-Amino-3-cyano-4-(3-nitrophenyl)-4H-indolo[4,5-b]pyran

The title compound was prepared from 3-nitrobenzaldehyde and 4-hydroxyindole as a yellow solid in a yield of 17% by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 8.30 (s, 1H), 8.12-8.08 (m, 1H), 8.05 (t, J = 2.1, 1H), 7.64-7.61 (m, 1H), 7.49 (t, J = 7.8, 1H), 7.24 (d, J = 2.7, 1H), 7.13-7.10 (m, 1H), 6.69-6.66 (m, 2H), 4.99 (s, 1H), 4.78 (s, 2H).

15

Example 101

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran

20

The title compound was prepared from 3,5-dimethoxybenzaldehyde and 4-hydroxyindole as a yellow solid in a yield of 12% by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 11.30 (s, 1H), 7.35 (t, J = 2.7, 1H), 7.09 (d, J = 8.7, 1H), 6.91 (s, 2H), 6.73 (d, J = 8.4, 1H), 6.45 (s, 1H), 6.34 (s, 3H), 4.70 (s, 1H), 3.68 (s, 6H).

25

Example 102

2-Amino-3-cyano-4-(3-cyanophenyl)-4H-indolo[4,5-b]pyran

30

The title compound was prepared from 3-cyanobenzaldehyde and 4-hydroxyindole as a pale yellow solid in a yield of 33% by a procedure similar

to that described for Example 30. ^1H NMR (DMSO-d₆): 11.34 (s, 1H), 7.71-7.68 (m, 2H), 7.54-7.52 (m, 2H), 7.37 (t, J = 3.9, 1H), 7.11 (d, J = 8.4, 1H), 7.04 (s, 2H), 6.67 (d, J = 8.7, 1H), 6.47 (s, 1H), 4.93 (s, 1H).

5

Example 103

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran

10

The title compound was prepared from 5-bromoveratraldehyde and 1-naphthol as a white solid in a yield of 20% by a procedure similar to that described for Example 1. ^1H NMR (DMSO-d₆): 8.23 (d, J = 8.1, 1H), 7.91 (d, J = 8.1, 1H), 7.67-7.59 (m, 3H), 7.23 (s, 2H), 7.20 (d, J = 8.4, 1H), 7.06 (s, 1H), 6.95 (d, J = 1.8, 1H), 4.93 (s, 1H), 3.80 (s, 3H), 3.70 (s, 3H).

15

Example 104

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-naphtho[1,2-b]pyran

20

The title compound was prepared from 3,4,5-trimethoxybenzaldehyde and 1-naphthol as a white solid in a yield of 8% by a procedure similar to that described for Example 19. ^1H NMR (DMSO-d₆): 8.23 (d, J = 8.1, 1H), 7.90 (d, J = 8.4, 1H), 7.66-7.55 (m, 3H), 7.20 (d, J = 8.7, 1H), 7.15 (s, 2H), 6.58 (s, 2H), 4.87 (s, 1H), 3.71 (s, 6H), 3.63 (s, 3H).

25

Example 105

2-Amino-3-cyano-4-(4-bromo-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran

30

The title compound was prepared from 4-bromo-3,5-dimethoxybenzaldehyde and 1-naphthol as a white solid in a yield of 32% by a procedure similar to that described for Example 1. ^1H NMR (DMSO-d₆): 8.24 (d, J = 7.8, 1H), 7.91 (d, J = 7.5, 1H), 7.67-7.56 (m, 3H), 7.21 (s, 2H), 7.19 (d, J = 8.4, 1H), 6.67 (s, 2H), 4.97 (s, 1H), 3.78 (s, 6H).

Example 106

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-naphtho[1,2-b]pyran

The title compound was prepared from 5-methoxypiperonal and 1-naphthol as a white solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO- d_6): 8.22 (d, $J = 7.8$, 1H), 7.90 (d, $J = 8.1$, 1H), 7.66-7.55 (m, 3H), 7.16 (d, $J = 8.7$, 1H), 7.15 (s, 2H), 6.62 (s, 1H), 6.40 (s, 1H), 5.94 (d, $J = 8.7$, 2H), 4.84 (s, 1H), 3.81 (s, 3H).

Example 107

2-Amino-3-cyano-7-dimethylamino-4-(3,5-difluorophenyl)-4H-chromene

The title compound was prepared from 3,5-difluorobenzaldehyde as a light yellow solid in a yield of 21% by a procedure similar to that described for Example 19. ^1H NMR (DMSO- d_6): 7.12-7.04 (m, 1H), 6.96 (s, 2H), 6.90-6.83 (m, 3H), 6.50-6.46 (m, 1H), 6.23 (d, $J = 2.7$, 1H), 4.72 (s, 1H), 2.87 (s, 6H).

Example 108

2-Amino-3-cyano-7-dimethylamino-4-(3,5-bis(trifluoromethyl)phenyl)-4H-chromene

The title compound was prepared from 3,5-bis(trifluoromethyl)-benzaldehyde as a white solid in a yield of 13% by a procedure similar to that described for Example 19. ^1H NMR (DMSO- d_6): 8.01 (s, 1H), 7.86 (s, 2H), 7.06 (s, 2H), 6.83 (d, J = 8.4, 1H), 6.51-6.48 (m, 1H), 6.26 (d, J = 2.1, 1H), 5.01 (s, 1H), 2.88 (s, 6H).

Example 109

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-5-methoxyphenyl)-4H-chromene

The title compound was prepared from 3-bromo-5-methoxybenzaldehyde as a white solid in a yield of 50% by a procedure similar to that

described for Example 1. ^1H NMR (DMSO-d₆): 6.99 (s, 1H), 6.91 (s, 2H), 6.85 (s, 1H), 6.84 (d, J = 8.7, 1H), 6.77 (s, 1H), 6.49-6.46 (m, 1H), 4.61 (s, 1H), 3.75 (s, 3H), 2.87 (s, 6H).

5

Example 110

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxypyphenyl)-6,7,8,9,10,11-hexahydro-4H-pyrido[3,2,1-ij]quino[5,6-b]pyran

10

The title compound was prepared from 8-hydroxyjulolidine and 5-methoxypiperonal as a yellow solid by a procedure similar to that described for Example 19. ^1H NMR (CDCl₃): 6.43 (d, J = 1.5, 1H), 6.37 (s, 1H), 6.32 (d, J = 1.5, 1H), 5.93-5.91 (m, 2H), 4.50 (s, 2H), 4.47 (s, 1H), 3.91 (s, 3H), 3.11-3.06 (m, 4H), 2.72 (t, J = 6.6, 2H), 2.60 (t, J = 6.6, 2H), 2.01-1.86 (m, 4H).

15

Example 111

2-Amino-3-cyano-7-dimethylamino-4-(4-chloromethylphenyl)-4H-chromene

20

The title compound was prepared from 4-chloromethylbenzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.36 (d, J = 8.1, 1H), 7.16 (d, J = 7.8, 1H), 6.84 (s, 2H), 6.77 (d, J = 8.7, 1H), 6.47-6.43 (m, 1H), 6.22 (d, J = 2.7, 1H), 4.72 (s, 2H), 4.62 (s, 1H), 2.86 (s, 6H).

25

Example 112

2-Amino-3-cyano-7-dimethylamino-4-(3-chloromethylphenyl)-4H-chromene

30

The title compound was prepared from 3-chloromethylbenzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.31 (d, J = 7.8, 1H), 7.28 (s, 1H), 7.22 (s, 1H), 7.15 (d, J = 6.9, 1H), 6.85 (s, 2H), 6.78 (d, J = 8.7, 1H), 6.47-6.44 (m, 1H), 6.23 (d, J = 2.4, 1H), 4.73 (s, 1H), 4.63 (s, 1H), 2.86 (s, 6H).

Example 113

2-Amino-3-cyano-7-dimethylamino-4-(3-cyano-4-fluorophenyl)-4H-chromene

5 The title compound was prepared from 2-fluoro-5-formylbenzonitrile as a yellow solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.78-7.75 (m, 1H), 7.58-7.52 (m, 1H), 7.48 (t, J = 9.0, 1H), 6.93 (s, 2H), 6.79 (d, J = 9.0, 1H), 6.49-6.45 (m, 1H), 6.23 (d, J = 2.7, 1H), 4.77 (s, 1H), 2.87 (s, 6H).

10

Example 114

2-Amino-3-cyano-7-dimethylamino-4-(3-nitro-4-fluorophenyl)-4H-chromene

15 The title compound was prepared from 3-nitro-4-fluorobenzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.97-7.95 (m, 1H), 7.60 (m, 1H), 7.56 (d, J = 11.4, 1H), 7.00 (s, 2H), 6.82 (d, J = 8.7, 1H), 6.50-6.46 (m, 1H), 6.24 (d, J = 2.4, 1H), 4.86 (s, 1H), 2.87 (s, 6H).

20

Example 115

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-methylenedioxypyhenyl)-4H-chromene

25 The title compound was prepared from 5-bromopiperonal as a light brown solid by a procedure similar to that described for Example 1. ^1H NMR (DMSO-d₆): 6.87 (s, 2H), 6.84-6.80 (m, 2H), 6.67 (d, J = 1.2, 1H), 6.50-6.46 (m, 1H), 6.22 (d, J = 2.4, 1H), 6.08 (d, J = 6.9, 2H), 4.58 (s, 1H), 2.87 (s, 6H).

30

Example 116

2-Amino-3-cyano-7-methoxy-4-(3-bromo-4,5-dimethoxypyhenyl)-4H-chromene

35 The title compound was prepared from 3-methoxyphenol and 5-bromoveratraldehyde as a yellow solid by a procedure similar to that described

for Example 30. ^1H NMR (DMSO-d₆): 7.02 (d, J = 8.7, 1H), 7.00 (s, 2H), 6.98 (d, J = 1.8, 1H), 6.87 (d, J = 1.8, 1H), 6.71-6.68 (m, 1H), 6.56 (d, J = 2.4, 1H), 4.71 (s, 1H), 3.80 (s, 3H), 3.74 (s, 3H), 3.70 (d, J = 0.6, 3H).

5

Example 117

2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylthiophenyl)-4H-chromene

10

The title compound was prepared from 3-trifluoromethylthiobenzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.58-7.46 (m, 1H), 7.39 (d, J = 8.4, 1H), 6.92 (s, 2H), 6.80 (d, J = 9.0, 1H), 6.49-6.45 (m, 1H), 6.24 (d, J = 2.4, 1H), 4.75 (s, 1H), 2.87 (s, 6H).

15

Example 118

2-Amino-3-cyano-7-dimethylamino-4-(3-fluorophenyl)-4H-chromene

20

The title compound was prepared from 3-fluorobenzaldehyde as a white solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.39-7.31 (m, 1H), 7.06-6.95 (m, 3H), 6.89 (s, 2H), 6.82 (d, J = 8.4, 1H), 6.48-6.45 (m, 1H), 6.23 (d, J = 2.1, 1H), 4.66 (s, 1H), 2.86 (s, 6H).

25

Example 119

2-Amino-3-cyano-7-dimethylamino-4-(3-difluoromethoxyphenyl)-4H-chromene

30

The title compound was prepared from 3-(difluoromethoxy)benzaldehyde as a white solid by a procedure similar to that described for Example 30. ^1H NMR (DMSO-d₆): 7.36 (t, J = 7.8, 1H), 7.05-6.91 (m, 3H), 6.88 (s, 2H), 6.82 (d, J = 9.0, 1H), 6.84-6.45 (m, 1H), 6.23 (d, J = 2.4, 1H), 4.66 (s, 1H), 2.86 (s, 6H).

Example 120

2-Amino-3-cyano-7-dimethylamino-4-(3-hydroxyphenyl)-4H-chromene

The title compound was prepared from 3-acetoxybenzaldehyde as a white solid by a procedure similar to that described for Example 30. ¹H NMR (DMSO-d₆): 9.31 (s, 1H), 7.07 (t, J = 7.8, 1H), 6.79 (t, J = 4.5, 1H), 6.64-6.55 (m, 2H), 6.52 (s, 1H), 6.48-6.44 (m, 1H), 6.22 (d, J = 2.4, 1H), 4.48 (s, 1H), 2.86 (s, 6H).

Example 121

2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethoxyphenyl)-4H-chromene

The title compound was prepared from 3-(trifluoromethoxy)-benzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ¹H NMR (DMSO-d₆): 7.45 (t, J = 7.5, 1H), 7.21-7.15 (m, 3H), 6.92 (s, 2H), 6.82 (d, J = 8.7, 1H), 6.49-6.46 (m, 1H), 6.24 (d, J = 2.7, 1H), 4.73 (s, 1H), 2.87 (s, 6H).

Example 122

2-Amino-3-cyano-7-dimethylamino-4-(3-methylaminophenyl)-4H-chromene

The title compound was prepared from 3-methylaminobenzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ¹H NMR (DMSO-d₆): 6.99 (t, J = 8.1, 1H), 6.80 (d, J = 8.4, 1H), 6.74 (s, 2H), 6.47-6.43 (m, 1H), 6.35 (s, 1H), 6.33 (d, J = 7.2, 2H), 6.21 (d, J = 2.4, 1H), 5.64-5.59 (m, 1H), 4.41 (s, 1H), 2.85 (s, 6H), 2.62 (d, J = 5.1, 3H).

Example 123

2-Amino-3-cyano-7-dimethylamino-4-(3-dimethylaminophenyl)-4H-chromene

The title compound was prepared from 3-dimethylaminobenzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ¹H

NMR (DMSO-d₆): 7.07 (t, J = 7.8, 1H), 6.83 (d, J = 8.7, 1H), 6.76 (s, 2H), 6.59 (s, 1H), 6.55-6.52 (m, 1H), 6.46-6.43 (m, 1H), 6.38 (d, J = 7.5, 1H), 6.22 (d, J = 2.4, 1H), 4.49 (s, 1H), 2.86 (d, J = 3.9, 12H).

5

Example 124

2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran

10

The title compound was prepared from 3-iodo-4,5-dimethoxybenzaldehyde as a white solid by a procedure similar to that described for Example 30. ¹H NMR (DMSO-d₆): 8.24 (d, J = 7.5, 1H), 7.91 (d, J = 7.5, 1H), 7.67-7.56 (m, 3H), 7.22 (s, 2H), 7.19 (d, J = 8.7, 1H), 7.13 (d, J = 1.2, 1H), 7.05 (d, J = 1.5, 1H), 4.90 (s, 1H), 3.78 (s, 3H), 3.67 (s, 3H).

15

Example 125

2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-chromene

20

The title compound was prepared from 3-iodo-4,5-dimethoxybenzaldehyde as a white solid by a procedure similar to that described for Example 1. ¹H NMR (DMSO-d₆): 7.02 (d, J = 1.8, 1H), 6.96 (s, 1H), 6.88 (s, 2H), 6.86 (d, J = 8.7, 1H), 6.49-6.46 (m, 1H), 6.22 (d, J = 2.4, 1H), 4.59 (s, 1H), 3.78 (s, 3H), 3.66 (s, 3H), 2.87 (s, 6H).

25

Example 126

2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-chromene

30

The title compound was prepared from 4-acetoxy-3,5-dimethoxybenzaldehyde as a yellow solid by a procedure similar to that described for Example 30. ¹H NMR (DMSO-d₆): 6.92 (d, J = 9.0, 1H), 6.86 (s, 2H), 6.56 (s, 2H), 6.50-6.46 (m, 1H), 6.23 (d, J = 2.4, 1H), 4.63 (s, 1H), 3.70 (s, 6H), 2.87 (s, 6H), 2.22 (s, 3H).

Example 127

2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran

5 The title compound was prepared from 4-acetoxy-3,5-dimethoxybenzaldehyde as a white solid by a procedure similar to that described for Example 1. ^1H NMR (DMSO-d₆): 8.24 (d, J = 8.1, 1H), 7.90 (d, J = 7.8, 1H), 7.66-7.55 (m, 3H), 7.24 (d, J = 8.7, 1H), 7.20 (s, 2H), 6.66 (s, 2H), 4.94 (s, 1H), 3.70 (s, 6H), 2.22 (s, 3H).

10

Example 128

2-Amino-3-cyano-7-dimethylamino-4-(5-methyl-3-pyridyl)-4H-chromene

15 **Step 1. 5-Methyl-3-pyridinemethanol.** To a solution of methyl 5-methyl-3-pyridinecarboxylate (0.95 g, 6.3 mmol) in THF (10 mL) was added LiAlH₄ (300 mg, 7.9 mmol) at 0°C. The mixture was stirred at room temperature for 2 h, quenched with water, and extracted with 1:1 hexane/EtOAc (80 mL). The organic phase was washed with water and brine, dried over Na₂SO₄ and concentrated in vacuo to yield the title compound as an oil (400 mg, 3.2 mmol, 51%). ^1H NMR (CDCl₃): 8.40 (s, 1H), 8.37 (s, 1H), 7.31 (s, 1H), 4.71 (s, 2H), 2.35 (s, 3H).

20

25

Step 2. 5-methyl-3-pyridinecarboxaldehyde. A mixture of 5-methyl-3-pyridinemethanol (106 mg, 0.86 mmol) and activated MnO₂ (376 mg) in methylenechloride (10 mL) was stirred at room temperature overnight. The black solid of MnO₂ was removed by filtration. The filtrate was concentrated in vacuo to yield the title compound as an oil (100 mg, 85%). ^1H NMR (CDCl₃): 10.10 (s, 1H), 8.89 (s, 1H), 8.68 (s, 1H), 7.98 (s, 1H), 2.45 (s, 3H).

30

Step 3. 2-Amino-3-cyano-7-dimethylamino-4-(5-methyl-3-pyridyl)-4H-chromene. The title compound was prepared as a yellow solid from 5-methyl-3-pyridinecarboxaldehyde in 4% yield by a procedure similar to that described for example 1. ^1H NMR (DMSO-d₆): 8.22 (d, J = 6.7, 1H), 7.29 (s,

DEPARTMENT OF CHEMISTRY
UNIVERSITY OF TORONTO LIBRARY
SERIALS SECTION

1H), 6.88 (s, 2H), 6.75 (d, J = 8.1, 1H), 6.44 (d, J = 6.7, 1H), 6.26 (s, 1H), 4.64 (s, 1H), 2.84 (s, 6H), 2.23 (s, 3H).

Example 129

5 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-4,5-dimethoxyphenyl)-4H-chromene

The title compound was prepared from 3-chloro-4,5-dimethoxybenzaldehyde as a yellow solid by a procedure similar to that described for Example 1. ^1H NMR (CDCl_3): 6.82-6.69 (m, 3H), 6.48-6.44 (m, 1H), 6.30 (d, J = 2.7, 1H), 4.59 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H), 2.85 (s, 6H).

Example 130

15 2-Chloroacetamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene

The title compound was prepared from 2-amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene and chloroacetyl chloride as a yellow solid by a procedure similar to that described for Example 80. ^1H NMR (CDCl_3): 8.26 (s, 1H), 6.97-6.80 (m, 3H), 6.50-6.46 (m, 1H), 6.33 (d, J = 2.4, 1H), 4.73 (s, 3H), 4.23 (s, 2H), 3.85 (s, 3H), 3.83 (s, 3H), 2.95 (s, 6H).

Example 131

25 2-Acrylamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene

The title compound was prepared from 2-amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene and acryloyl chloride as a yellow solid by a procedure similar to that described for Example 80. ^1H NMR (CDCl_3): 6.96-6.23 (m, 7H), 5.92 (d, J = 10.2, 1H), 4.73 (s, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 2.96 (s, 6H).

Example 132

3-Cyano-7-dimethylamino-2-succinimido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene

5 The title compound was prepared from 2-amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene and succinyl chloride as a yellow solid by a procedure similar to that described for Example 80. ^1H NMR (CDCl_3): 7.12 (d, $J = 1.8$, 1H), 6.89-6.85 (m, 2H), 6.47 (m, 1H), 6.26 (d, $J = 2.7$, 1H), 4.79 (s, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 2.96 (s, 4H), 2.92 (s, 6H).

10

Example 133

3-Cyano-7-dimethylamino-2-phenylureido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene

15 A mixture of 2-amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene (92 mg, 0.21 mmol) and phenyl isocyanate (0.1 mL) in pyridine (4 mL) was stirred at room temperature for 6 h. The mixture was diluted with 1:1 hexane/EtOAc (100 mL) then washed with water, 2N HCl, water and brine. The solution was dried over Na_2SO_4 and concentrated in vacuo. The residue was purified by chromatography to yield the title compound as a yellow solid (26 mg, 0.05 mmol, 23%). ^1H NMR (CDCl_3): 7.66 (s, 1H), 7.42-7.33 (m, 5H), 7.15 (m, 1H), 6.95 (s, 1H), 6.82-6.73 (m, 2H), 6.52-6.47 (m, 1H), 6.39 (s, 1H), 4.68 (s, 1H), 3.85 (s, 3H), 3.84 (s, 1H), 2.96 (s, 6H).

20

Example 134

9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran

25 The title compound was prepared as a yellow solid by a procedure similar to that described in Example 1 in 6% yield. ^1H NMR (DMSO-d_6): 11.07 (s, 1H), 7.25 (s, 1H), 7.15 (d, $J = 2.4$, 1H), 7.06 (d, $J = 8.1$, 1H), 7.01 (d, $J = 2.4$, 1H), 6.91 (s, 1H), 6.85 (s, 2H), 6.70 (d, $J = 8.1$, 1H), 4.78 (s, 1H), 3.81 (s, 3H), 3.69 (s, 3H), 3.66-3.65 (m, 1H).

Example 135

2-Amino-3-cyano-7-dimethylamino-4-(5-bromo-3-pyridyl)-4H-chromene

5 The title compound was prepared as a light brown solid by a procedure similar to that described in Example 128. ^1H NMR (DMSO-d₆): 8.54 (s, 1H), 8.41 (s, 1H), 7.71 (s, 1H), 6.98 (s, 2H), 6.82-6.77 (m, 2H), 6.48-6.46 (m, 1H), 6.27 (s, 1H), 4.75 (s, 1H), 2.84 (s, 6H).

10 **Example 136**

2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-3-pyridyl)-4H-chromene

15 The title compound was prepared as a tan solid by a procedure similar to that described in Example 128. ^1H NMR (DMSO-d₆): 8.25 (s, 1H), 7.39-7.18 (m, 2H), 6.85 (s, 2H), 6.75 (d, J = 8.4, 1H), 6.46-6.43 (m, 1H), 6.26 (s, 1H), 4.63 (s, 1H), 2.83 (s, 6H), 2.40 (s, 3H).

20 **Example 137**

2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-2-pyridyl)-4H-chromene

25 The title compound was prepared as a tan solid by a procedure similar to that described in Example 1 in 66% yield. ^1H NMR (CDCl₃): 7.49 (t, J = 7.5, 1H), 7.00-6.93 (m, 3H), 6.43-6.39 (m, 1H), 6.28 (s, 1H), 4.84 (s, 1H), 4.66 (s, 2H), 2.91 (s, 6H), 2.56 (s, 3H).

30 **Example 138**

2-Amino-3-cyano-7-dimethylamino-4-(2-bromo-4,5-methylenedioxypyphenyl)-4H-chromene

30 The title compound was prepared as a yellow solid by a procedure similar to that described in Example 1 in 9% yield. ^1H NMR (DMSO-d₆): 7.16 (s, 1H), 6.88 (s, 1H), 6.72 (d, J = 9.0, 1H), 6.56 (s, 1H), 6.46 (dd, J = 2.1,

9.0, 1H), 6.2 (d, J = 2.1, 1H), 6.05 (s, 1H), 6.01 (s, 1H), 5.06 (s, 1H), 2.86 (s, 6H).

Example 139

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[2,1-b]pyran

The title compound was prepared as a yellow solid by a procedure similar to that described in Example 1 in 1% yield. ^1H NMR (DMSO- d_6): 7.98-7.89 (m, 3H), 7.53-7.43 (m, 2H), 7.35 (d, J = 9.3, 1H), 7.08-7.06 (m, 3H), 6.76 (m, 1H), 5.34 (s, 1H), 7.35 (s, 3H), 3.66 (s, 3H), 2.50 (s, 6H).

Example 140

2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-2-nitrophenyl)-4H-chromene

The title compound was prepared as a yellow solid by a procedure similar to that described in Example 1 in 5% yield. ^1H NMR (DMSO- d_6): 8.03 (d, J = 2.1, 1H), 7.72 (dd, J = 2.1, 8.7, 1H), 7.30 (d, J = 8.7, 1H), 7.03 (s, 2H), 6.75 (d, J = 8.7, 1H), 6.48 (dd, J = 2.1, 8.7, 1H), 6.24 (d, J = 2.1, 1H), 5.08 (s, 1H), 2.88 (s, 6H).

Example 141

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[5,6-b]pyran

To a mixture of 5-bromoveratraldehyde (245 mg, 1 mmol) and malononitrile (66 mg, 1 mmol) in ethanol (2 ml) was added piperidine (0.1 ml, 1 mmol). The mixture was stirred at room temperature for 15 min, then refluxed for 1 h, and cooled to room temperature. To the mixture was added piperidine (0.1 ml, 1 mmol) and 5-hydroxyquinoline (145 mg, 1 mmol). The mixture was refluxed for 1 h, and the solvent was evaporated. The residue was purified by chromatography on silica gel (EtOAc / hexane, 1:2), yielding the title compound (50 mg, 11%). ^1H NMR (CDCl_3): 8.95 (s, 1H), 8.50 (d, J = 9.0,

1H), 7.82 (d, $J = 9.0$, 1H), 7.50 (brs, 1H), 7.30 (s, 1H), 6.92 (s, 1H), 6.76 (s, 1H), 4.82 (brs, 3H), 3.84 (s, 6H).

Example 142

5 **2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-isoquinol[5,6-b]pyran**

The title compound was prepared from 5-hydroxyisoquinoline by a procedure similar to that described for Example 141. ^1H NMR (CDCl_3): 9.23 (s, 1H), 8.66 (d, $J = 6.0$, 1H), 7.95 (d, $J = 5.7$, 1H), 7.69 (d, $J = 8.4$, 1H), 7.18 (d, $J = 8.7$, 1H), 6.92 (d, $J = 1.8$, 1H), 6.75 (d, $J = 1.8$, 1H), 4.85 (m, 3H), 3.84 (s, 6H).

15 **Example 143**

15 **2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[8,7-b]pyran**

The title compound was prepared from 8-hydroxyquinoline by a procedure similar to that described for Example 141. ^1H NMR (CDCl_3): 9.01 (m, 1H), 8.17 (m, 1H), 7.55-7.50 (m, 2H), 7.15 (d, $J = 8.7$, 1H), 6.98 (d, $J = 2.0$, 1H), 6.76 (d, $J = 1.8$, 1H), 5.07 (s, 2H), 4.86 (s, 1H), 3.83 (s, 6H).

20 **Example 144**

25 **2-amino-3-cyano-7-ethoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene**

To a mixture of 5-bromoveratraldehyde (245 mg, 1 mmol) and malononitrile (66 mg, 1 mmol) in ethanol (2 ml) was added piperidine (0.1 ml, 1 mmol). The mixture was stirred at room temperature for 15 min, then 3-ethoxyphenol (138 mg, 1 mmol) was added and it was stirred overnight. The solvent was evaporated and the residue was purified by chromatography on silica gel (EtOAc / Hexane, 1:2) to yield the title compound. ^1H NMR (CDCl_3): 6.84-6.82 (m, 2H), 6.70 (s, 1H), 6.61-6.65 (m, 1H), 6.53 (s, 1H), 4.62 (m, 3H), 4.0 (q, $J = 6.0$, 2H), 3.82 (s, 6H), 1.4 (t, $J = 6.0$, 3H).

Example 145

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8,9,10-tetrahydro-4H-naphtho[1,2-b]pyran

5 **Step 1:** To a mixture of 5-bromoveratraldehyde (245 mg, 1 mmol) and malononitrile (66 mg, 1 mmol) in ethanol was added piperidine (0.1 ml, 1 mmol). The mixture was stirred at room temperature for 15 min to give the product 3,4-dimethoxy-5-bromobenzylidenemalononitrile as a yellow precipitate.

10 **Step 2:** To a stirred suspension of 3,4-dimethoxy-5-bromobenzylidene-malononitrile (293 mg, 1 mmol) and 5,6,7,8-Tetrahydro-1-naphthol (148 mg, 1 mmol) in ethanol (4 ml) was added piperidine (0.1 ml, 1 mmol), and the mixture was refluxed for 2 h. The solvent was evaporated and the residue was purified by column chromatography (EtOAc/Hexane, 1:2), yielding the title compound (6 mg, 1.4%). ^1H NMR (CDCl_3): 7.89 (d, $J = 2.0$, 1H), 6.80-6.69 (m, 3H), 4.63 (s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 2.72 (m, 4H), 1.8 (m, 4H).

Example 146

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8-Dimethyl-4H-chromene

20 The title compound was prepared from 2,3-dimethylphenol by a procedure similar to that described for Example 145. ^1H NMR (CDCl_3): 6.87 (m, 2H), 6.71 (m, 2H), 4.64 (brs, 3H), 3.85-3.82 (m, 6H), 2.26 (s, 3H), 2.22 (s, 3H).

Example 147

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-quino[5,6-b]pyran

30 The title compound was prepared from 3,4,5-trimethoxybenzylidenemalononitrile (244 mg, 1 mmol) and 5-hydroxyquinoline by a procedure similar to that described for Example 145. ^1H NMR (CDCl_3): 8.96 (m, 1H), 8.52 (d, $J = 8.7$, 1H), 7.82 (d, $J = 9.0$, 1H), 7.52

(m, 1H), 7.33 (d, J = 8.7, 1H), 6.43 (s, 2H), 4.83 (m, 3H), 3.83 (s, 3H), 3.80 (s, 3H).

Example 148

5 ***Identification of 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene and Analogs as Caspase Cascade Activators and Inducers of Apoptosis in Solid Tumor Cells***

10 Human breast cancer cell lines T-47D and ZR-75-1 were grown according to media component mixtures designated by American Type Culture Collection + 10% FCS (Life Technologies, Inc.), in a 5% CO₂ -95% humidity incubator at 37 °C. T-47D and ZR-75-1 cells were maintained at a cell density between 30 and 80% confluence at a cell density of 0.1 to 0.6 x 10⁶ cells/ml. Cells were harvested at 600xg and resuspended at 0.65 x 10⁶ cells/ml into appropriate media + 10% FCS. An aliquot of 45 µl of cells was added to a well of a 96-well microtiter plate containing 5 µl of a 10% DMSO in RPMI-1640 media solution containing 0.16 to 10 µM of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene (Example 19) or other test compound (0.016 to 1 µM final). An aliquot of 45 µl of cells was added to a well of a 96-well microtiter plate containing 5 µl of a 10% DMSO in RPMI-1640 media solution without test compound as the control sample. The samples were mixed by agitation and then incubated at 37 °C for 24 h in a 5% CO₂-95% humidity incubator. After incubation, the samples were removed from the incubator and 50 µl of a solution containing 20 µM of *N*-(Ac-DEVD)-*N'*-ethoxycarbonyl-R110 fluorogenic substrate (Cytovia, Inc.; WO99/18856), 20% sucrose (Sigma), 20 mM DTT (Sigma), 200 mM NaCl (Sigma), 40 mM Na PIPES buffer pH 7.2 (Sigma), and 500 µg/ml lysolecithin (Calbiochem) was added. The samples were mixed by agitation and incubated at room temperature. Using a fluorescent plate reader (Model 1420 Wallac Instruments), an initial reading (T = 0) was made approximately 1- 2 min after addition of the substrate solution, employing excitation at 485 nm and emission at 530 nm, to determine the background fluorescence of the

control sample. After the 3 h incubation, the samples were read for fluorescence as above (T = 3 h).

Calculation:

The Relative Fluorescence Unit values (RFU) were used to calculate the sample readings as follows:

$$\text{RFU}_{(T=3\text{h})} - \text{Control RFU}_{(T=0)} = \text{Net RFU}_{(T=3\text{h})}$$

The activity of caspase cascade activation was determined by the ratio of the net RFU value for 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene or other test compound to that of control samples. The EC₅₀ (nM) was determined by a sigmoidal dose-response calculation (Prism 2.0, GraphPad Software Inc.). The caspase activity (Ratio) and potency (EC₅₀) are summarized in Table I:

Table I. Caspase Activity and Potency

Example #	T-47D		ZR-75-1	
	Ratio	EC50 (nM)	Ratio	EC50 (nM)
1	ND	ND	4.2	60
4	6.0	200	6.6	150
10	4.2	10	5.0	9
14	5.5	172	9.0	96
19	5.5	87	6.3	38
38	12.7	45	6.5	22
39	8.4	250	2.7	65
94	6.5	49	7.8	25
95	3.8	720	5.1	364
96	Inactive	Inactive	Inactive	Inactive
97	2.7	6	5.0	7
98	2.8	36	4.3	23
103	2.2	17	4.2	12

Thus, 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-chromene (Example 19) and analogs are identified as potent caspase cascade activators and inducer of apoptosis in solid tumor cells.

Example 149

Identification of 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene and Analogs as Antineoplastic Compounds that Exhibit Inhibition of Cell Proliferation (GI_{50})

5

T-47D and ZR-75-1 cells were grown and harvested as in Example 148. An aliquot of 90 μ l of cells (2.2×10^4 cells/ml) was added to a well of a 96-well microtiter plate containing 10 μ l of a 10% DMSO in RPMI-1640 media solution containing 1 nM to 100 μ M of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene (Example 19) or other test compound (0.1 nM to 10 μ M final). An aliquot of 90 μ l of cells was added to a well of a 96-well microtiter plate containing 10 μ l of a 10% DMSO in RPMI-1640 media solution without compound as the control sample for maximal cell proliferation (A_{max}). The samples were mixed by agitation and then incubated at 37 °C for 48 h in a 5% CO₂-95% humidity incubator. After incubation, the samples were removed from the incubator and 20 μ l of CellTiter 96 AQUEOUS One Solution Cell Proliferation™ reagent (Promega) was added. The samples were mixed by agitation and incubated at 37 °C for 2-4 h in a 5% CO₂-95% humidity incubator. Using an absorbance plate reader (Model 1420 Wallac Instruments), an initial reading (T=0) was made approximately 1-2 min after addition of the solution, employing absorbance at 490 nm. This determines the possible background absorbance of the test compounds. No absorbance for 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene or its analogs was found at 490 nm. After the 2-4 h incubation, the samples were read for absorbance as above (A_{Test}).

10

15

20

25

30

REDOX INTELLIGENT

Baseline for GI_{50} (dose for 50% inhibition of cell proliferation) of initial cell numbers were determined by adding an aliquot of 90 μ l of cells or 90 μ l of media, respectively, to wells of a 96-well microtiter plate containing 10 μ l of a 10% DMSO in RPMI-1640 media solution. The samples were mixed by agitation and then incubated at 37 °C for 0.5 h in a 5% CO₂-95% humidity incubator. After incubation, the samples were removed from the incubator and

20 μ l of CellTiter 96 AQUEOUS One Solution Cell ProliferationTM reagent (Promega) was added. The samples were mixed by agitation and incubated at 37 °C for 2-4 h in a 5% CO₂-95% humidity incubator. Absorbance was read as above, ($A_{T=0}$) defining absorbance for initial cell number used as baseline in
5 GI₅₀ determinations.

Calculation:

GI₅₀ (dose for 50% inhibition of cell proliferation)

$$50 = 100 \times [(A_{\text{Test}} - A_{T=0}) / (A_{\max} - A_{T=0})]$$

The GI₅₀ (nM) are summarized in Table II:

10

Table II. GI₅₀ in Cancer Cells

Cell lines	Example 19 GI ₅₀ (nM)	Example 1 GI ₅₀ (nM)
T-47D	3	100
ZR-75-1	500	10000

15 Thus, 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylene-dioxyphenyl)-4H-chromene (Example 19) and 2-amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxophenyl)-4H-chromene (Example 1) are identified as potent antineoplastic compound that inhibit cell proliferation.

Example 150

20 *2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxophenyl)-4H-chromene Induces Nuclear Fragmentation in Jurkat Cells*

20

25 The ability of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxophenyl)-4H-chromene to induce nuclear fragmentation was tested by treatment of Jurkat cells with the test compound followed by staining of the nucleus with Syto16, a fluorescent DNA dye. The nuclei of Jurkat cells treated with DMSO vehicle are round with dispersed chromatin that is moderately stained with Syto16 (Fig.1A). In contrast, Jurkat cells treated with 100 nM or higher 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-

methylenedioxypyhenyl)-4H-chromene for 24 h have shrunken and fragmented nuclei (Fig. 1B), which is a hallmark of caspase-mediated apoptosis. These results corroborate the caspase induction assays by showing that 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene can induce a key cellular marker of apoptosis.

Example 151

2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene Induces PARP Cleavage in Jurkat Cells

A wide range of natural substrates are cleaved by the caspases during apoptosis. One of these is poly(ADP)ribose polymerase (PARP), an enzyme important in genome surveillance. The ability of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene to induce PARP cleavage was tested by treating Jurkat cells with the compound at a concentration of 2.5 μ M for 5, 15 and 30 h. Control cultures were treated with DMSO vehicle or staurosporine, a known apoptosis inducer. As illustrated in Fig. 2, 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene induced PARP cleavage starting at 15 h, and by 30 h virtually all of PARP was converted into its cleaved form. These results provide additional evidence that 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene induces caspase-mediated apoptosis in intact cultured cells.

Example 152

2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene Induces Mitotic Arrest in Jurkat Cells

Jurkat cells were incubated with a range of concentrations of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyhenyl)-4H-chromene (0.02 μ M to 5 μ M) for 6 h under normal growth conditions; control cultures were treated with DMSO vehicle. The cells were then treated for 20

min. with 800 nM Syto 16. Cytospin preparations were then prepared and the samples were viewed by fluorescent microscopy using a fluorescein filter set. For each concentration of test compound, the number of mitotic figures were counted and expressed as a percentage of the total number of cells. Three fields from each condition were evaluated and the mean and SEM were calculated and plotted as a function of drug concentration (Fig. 3). The results show that 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyphenyl)-4H-chromene is an extremely effective inducer of mitotic arrest in Jurkat cells with an EC₅₀ of about 125 nM.

10

Example 153

Treatment with 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyphenyl)-4H-chromene Leads to Cell Cycle Arrest in T Leukemia and Solid Tumor Cell Lines

15

T47D, ZR-75-1 breast cancer cell lines and PC-3, an androgen-independent prostate cancer cell line were maintained and harvested as described in Example 148. Jurkat T leukemia cells were grown in RPMI 1640 media (Life Technologies, Inc.) + 10% FCS (Sigma Chemical Company) in a 5% CO₂ -95% humidity incubator at 37 °C, and maintained at a cell density between 4 and 8 x 10⁵ cells/ml. 1x10⁶ cells were induced with 1 µM of 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxypyphenyl)-4H-chromene or 2-amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxypyphenyl)-4H-chromene for 18 h at 37 °C. As a control, cells were also incubated with DMSO. Cells were harvested at 1200 rpm and washed twice with 5 mM EDTA/PBS. Cells were then resuspended in 300 µl EDTA/PBS and 700 ml of 100% ethanol, vortexed and incubated at room temperature for 1 h. Samples were spun down at 12000 rpm for 5 min and the supernatant was removed. A solution containing 100 µg/ml of propidium iodide and 1 mg/ml of RNase A (fresh) was added to the samples and incubated for 1 h at room temperature. Samples were then transferred to 12x75 mm polystyrene tubes and analysed on a flow cytometer. All flow cytometry analyses were performed on FACScalibur (Becton Dickinson) using Cell Quest analysis

DO NOT REPRODUCE


software. Figs. 4A-B show that 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene induces cell cycle arrest in Jurkat cells. Figs. 5A-C show that 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene and 2-amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene induce cell cycle arrest in T47D Cells. Figs. 6A-C show that 2-amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene and 2-amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene induce cell cycle arrest in PC-3 cells.

Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.

0000014094850260

What Is Claimed Is:

1. A method of treating a disorder responsive to the induction of apoptosis in an animal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

10 X is O or S;

Y is CN, COR₇, CO₂R₇ or CONR_xR_y, wherein R₇, R_x and R_y are independently hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or

15 R_x and R_y are taken together with the nitrogen to form a heterocycle;

Z is NR₈R₉, NHCOR₈, N(COR₈)₂, N(COR₈)(COR₉), N=CHOR₈ or N=CHR₈, wherein R₈ and R₉ are independently H, C₁₋₄ alkyl or aryl, or R₈ and R₉ are combined together with the group attached to them to form a heterocycle;

20 R₅ is hydrogen or C₁₋₁₀ alkyl;

A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; and

25 B is an optionally substituted aromatic ring or an optionally substituted heteroaromatic ring.

2. The method of claim 1, with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans and A is phenyl, napthyl, thienyl, pyridyl,


benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, then A is substituted at three or more positions by other than hydrogen.

3. The method of claim 1, wherein B is optionally substituted and selected from the group consisting of benzo, naphtho, indolo, quino and isoquino.

4. The method of claim 1, wherein X is O.

5. The method of claim 1, wherein A is optionally substituted and selected from the group consisting of phenyl, naphthyl, quinolyl, isoquinolyl, pyridyl, thienyl, furyl, pyrrolyl, 2-phenylethyl and cyclohexyl.

10 6. The method of claim 1, wherein said compound has the
15 Formula II:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R₁-R₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or R₁ and R₂, or R₂ and R₃, or R₃ and R₄, taken together with the atoms to which they are attached form an aryl, heteroaryl, partially saturated carbocyclic or partially saturated heterocyclic group, wherein said group is optionally substituted.

DRAFT - DRAFT - DRAFT - DRAFT -

7. The method of claim 6, wherein A is optionally substituted and selected from the group consisting of phenyl, naphthyl, quinolyl, isoquinolyl, pyridyl, thienyl, furyl, pyrrolyl, 2-phenylethyl and cyclohexyl.

5 8. The method of claim 6, with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans and A is phenyl, napthyl, thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, then A is substituted at three or more positions by other than hydrogen.

10 9. The method of claim 6, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -O-CH₂-O-, -(CH₂)₃-, -(CH₂)₄-, -O-CH₂CH₂-O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

15 10. The method of claim 6, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- and -CH=CH-CH=N-.

20 11. The method of claim 6, wherein said compound is a chromene, naphthopyran, quinopyran, isoquinopyran or indolopyran.

25 12. The method of claim 6, wherein X is O.


DEPARTMENT OF TRADE AND INDUSTRY

13. The method of claim 6, wherein X is O, Y is CN and Z is NH₂.

14. The method of claim 6, wherein R₅ is hydrogen.

5 15. The method of claim 6, wherein R₁-R₄ are independently hydrogen, halogen, hydroxy, C₁₋₁₀ alkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, amino, acylamido, acyloxy, alkoxy, methylenedioxy or alkylthiol.

10 16. The method of claim 6, wherein A is



and R₁₀-R₁₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or

15 R₁₀ and R₁₁, or R₁₁ and R₁₂, taken together with the atoms to which they are attached form an aryl, heteroaryl, optionally substituted carbocyclic or optionally substituted heterocyclic group, wherein said group is optionally substituted.

20 25 17. The method of claim 16, with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans, and said compound is substituted in the 4-position of the pyran with an aryl or heteroaryl group which is phenyl, naphthyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, then said

aryl or heteroaryl group is substituted at three or more positions by other than hydrogen.

18. The method of claim 16, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -OCH₂O-, -(CH₂)₃-, -(CH₂)₄-, -OCH₂CH₂O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

15 19. The method of claim 16, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- and -CH=CH-CH=N-.

20 20. The method of claim 16, wherein R₁₀ and R₁₁, or R₁₁ and R₁₂, are taken together to form a structure selected from the group consisting of -OCH₂O-, -(CH₂)₃-, -(CH₂)₄-, -OCH₂CH₂O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -CH=CH-CH=CH-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, -CH=CH-CH=N- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

00000000000000000000000000000000

21. The method of claim 16, wherein R₁ and R₂ together form an optionally substituted ring, wherein said ring is selected from the group consisting of benzo, pyrido, furo, thieno, pyrrolo, imidazolo and pyrazo.

5 22 The method of claim 21, with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans, and said compound is substituted in the 4-position of the pyran with an aryl or heteroaryl group which is phenyl, naphthyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl then said aryl or heteroaryl group is substituted at three or more positions by other than 10 hydrogen.

15 23. The method of claim 21, wherein said compound is naphthopyran, quinopyran, isoquinopyran or indolopyran.

20 24. The method of claim 21, wherein R₁₀ and R₁₁, or R₁₁ and R₁₂, are taken together to form a structure selected from the group consisting of -OCH₂O-, -(CH₂)₃-, -(CH₂)₄-, -OCH₂CH₂O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -CH=CH-CH=CH-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, -CH=CH-CH=N- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

25 25. The method of claim 21, wherein R₃, R₄ and R₅ are each hydrogen.

30 26. The method of claim 1, wherein said compound is selected from the group consisting of:

- 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylene-dioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxypyhenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(1-naphthyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-naphthyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4-methoxyphenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,6-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-trifluoromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylphenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4-fluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4,5-trimethoxyphenyl)-4*H*-chromene;
- 20 2-Acetamido-3-cyano-7-dimethylamino-4-(3,4-methylenedioxypyhenyl)-4*H*-chromene;
- 2-Di(ethoxycarbonyl)amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxypyhenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-4,5-methylenedioxypyhenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-diethylamino-4-(3-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-methyl-3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethylphenyl)-4*H*-chromene;
- 30 3-Cyano-7-dimethylamino-4-(4,5-methylenedioxypyhenyl)-2-propionamido-4*H*-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-methoxyphenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-diethylamino-4-(3-methoxy-4,5-methylenedioxy-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene;
- 2-Benzylidenamino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-cyclohexyl-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-3-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,4,5-trifluorophenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(2,3,4-trifluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-3-nitrophenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxy-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-ethylenedioxyphenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-fluoro-3-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-pyridyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-6,7-methylenedioxy-4-(3-methoxy-4,5-methylene-dioxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-ethylamino-4-(3-methoxy-4,5-methylenedioxy-phenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;

5 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoromethylenedioxy-phenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;

10

2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-furyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-thienyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-6-nitrophenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-nitrophenyl)-4*H*-chromene;

20

2-Amino-3-cyano-7-dimethylamino-4-(3-phenoxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-pyridyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-phenylethyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-nitrophenyl)-4*H*-

25

chromene;

2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2,3-difluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;

30

2,7-Diamino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(4-pyridyl)-4*H*-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-(4-methoxyphenoxy)phenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dichlorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-quinolyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(2-quinolyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-phenylmethyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-carboxaldehydophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-bromo-3,5-dimethoxy-phenyl)-4*H*-chromene;
- 15 2-Amino-7-acetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 2,7-Diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-6,7,8,9,10,11hexahydro-4*H*-pyrido[3,2,1-ij]quino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 25 2-Amino-3-cyano-7-ethylamino-6-methyl-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2,7-Diamino-3-cyano-8-methyl-4-(3-methoxy-4,5-methylenedioxy-phenyl)-4*H*-chromene;
- 2-Amino-7-chloroacetamido-3-cyano-4-(3-bromo-4,5-dimethoxy-phenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromophenyl)-4*H*-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dibromophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-cyanophenyl)-4*H*-chromene;
2-Amino-3-cyano-7-dimethylamino-4-(3-methylphenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-chlorophenyl)-4*H*-chromene;
2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
indolo[4,5-b]pyran;
- 10 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4*H*-
indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxyphenyl)-4*H*-
chromene;
- 15 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-nitrophenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-4-(3-cyanophenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-7-dimethylamino-4-(3,5-difluorophenyl)-4*H*-
chromene;
- 20 2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;
2-Amino-3-cyano-7-dimethylamino-4-(3,5-bis(trifluoromethyl)-
phenyl)-4*H*-chromene;
2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-5-methoxyphenyl)-
4*H*-chromene;
- 25 2-Amino-3-cyano-4-(4-bromo-3,5-dimethoxyphenyl)-4*H*-
naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-4-(3-methoxy-4,5-methelenedioxyphenyl)-4*H*-
naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4*H*-
naphtho[1,2-b]pyran;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(4-chloromethylphenyl)-4*H*-
chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloromethylphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-cyano-4-fluorophenyl)-4H-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-nitro-4-fluorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-methylenedioxyphenyl)-4H-chromene;
- 10 2-Amino-3-cyano-7-methoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylthiophenyl)-4H-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-fluorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-difluoromethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-hydroxyphenyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylaminophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-dimethylaminophenyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-indo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

DEPARTMENT OF INTELLIGENCE

- 2-Amino-3-cyano-7-dimethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-4,5-dimethoxyphenyl)-4H-chromene;
- 5 2-Chloroacetamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Acrylamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 10 3-Cyano-7-dimethylamino-2-succinimido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 3-Cyano-7-dimethylamino-2-phenylureido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 15 9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-3-pyridyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-2-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-bromo-4,5-methylenedioxyphenyl)-4H-chromene;
- 25 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[2,1-b]pyran;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-2-nitrophenyl)-4H-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[5,6-b]pyran;
- 30 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-isoquino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[8,7-b]pyran;

- 2-Amino-3-cyano-7-ethoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8,9,10-tetrahydro-4H-naphtho[1,2-b]pyran;
- 5 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8-dimethyl-4H-chromene;
- 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-quino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 10 2-Amino-6-chloro-3-cyano-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 2-Amino-3-cyano-7-methoxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene;
- 15 2-Amino-3-cyano-7-methoxy-4-(3-methoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-cyanophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-chlorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-nitrophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-bromophenyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-methoxy-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-methoxy-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-methylthio-3-pyridyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-methoxy-4-(5-chloro-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methyl-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-chloro-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 30 2-Amino-3-cyano-7-bromo-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-bromo-4-(5-methyl-3-pyridyl)-4H-chromene;

2-Amino-3-cyano-7-chloro-4-(5-methyl-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-ethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-
4H-chromene;
2-Amino-3-cyano-7-ethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
and
2-Amino-3-cyano-7-hydroxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene.

27. The method of claim 1, wherein said disorder is cancer.

10

28. The method of claim 27, wherein said cancer is selected from the group consisting of Hodgkin's disease, non-Hodgkin's lymphoma, acute and chronic lymphocytic leukemias, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head and neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytoysis, adrenal cortex carcinoma, skin cancer and prostatic carcinoma.

15

20

25

30

29. The method of claim 27, with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans and A is phenyl, naphthyl, thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, then A is substituted at three or more positions by other than hydrogen.

CONFIDENTIAL

30. The method of claim 27, wherein said cancer is a drug resistant cancer.

5 31. The method of claim 30, with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans and A is phenyl, naphthyl, thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, then A is substituted at three or more positions by other than hydrogen.

10

32. The method of claim 27 or 30, additionally comprising administering at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

15

33. The method of claim 32, wherein said known cancer therapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin, Rituxan and alanosine.

20

25

34. The method of claim 27 or 30, additionally comprising treating with radiation-therapy.

35. The method of claim 27 or 30, wherein said compound is administered after surgical treatment for cancer.

5 36. The method of claim 1, wherein said disorder is an autoimmune disease.


37. The method of claim 1, wherein said disorder is rheumatoid arthritis.

10 38. The method of claim 1, wherein said disorder is inflammation or inflammatory bowel disease.

39. The method of claim 1, wherein said disorder is psoriasis.

15 40. The method of claim 1, wherein said disorder is a skin disease.

41. A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound of Formula I:




or a pharmaceutically acceptable salt or prodrug thereof, wherein:

X is O or S;

25 Y is CN, COR₇, CO₂R₇ or CONR_xR_y, wherein R₇, R_x and R_y are independently hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R_x and R_y are taken together with the nitrogen to which they are attached to form a heterocycle;

- Z is NR₈R₉, NHCOR₈, N(COR₈)₂, N(COR₈)(COR₉), N=CHOR₈ or N=CHR₈, wherein R₈ and R₉ are independently H, C₁₋₄ alkyl or aryl, or R₈ and R₉ are combined together with the group attached to them to form a heterocycle;
- 5 R₅ is hydrogen or C₁₋₁₀ alkyl;
- A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; and
- B is an optionally substituted aromatic ring or an optionally substituted heteroaromatic ring;
- 10 with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans and A is phenyl, napthyl, thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, then A is substituted at three or more positions by other than hydrogen.
- 15 42. The pharmaceutical composition of claim 41, wherein B is optionally substituted and selected from the group consisting of benzo, naphtho, indolo, quino and isoquino and A is optionally substituted and selected from the group consisting of phenyl, napthyl, pyridyl, quinolyl, isoquinolyl, thienyl, furyl, pyrrolyl, 2-phenylethyl and cyclohexyl.
- 20 43. The pharmaceutical composition of claim 41, wherein X is O.
44. The pharmaceutical composition of claim 41, wherein X is O,
- 25 Y is CN and Z is NH₂.
45. The pharmaceutical composition of claim 41, wherein R₅ is hydrogen.
- 30 46. The pharmaceutical composition of claim 41, comprising a pharmaceutically acceptable excipient or carrier and a compound of Formula II:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

- 5 R_1 - R_4 are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C_{1-10} alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocy cloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or
- 10 R_1 and R_2 , or R_2 and R_3 , or R_3 and R_4 , taken together with the atoms to which they are attached form an aryl, heteroaryl, partially saturated carbocyclic or partially saturated heterocyclic group, wherein said group is optionally substituted;
- 15 X is O or S;
- 20 Y is CN, COR_7 , CO_2R_7 or $CONR_xR_y$, wherein R_7 , R_x and R_y are independently hydrogen, C_{1-10} alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocy cloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R_x and R_y are taken together with the nitrogen to which they are attached to form a heterocycle;
- 25 Z is NR_8R_9 , $NHCOR_8$, $N(COR_8)_2$, $N(COR_8)(COR_9)$, $N=CHOR_8$ or $N=CHR_8$, wherein R_8 and R_9 are independently H, C_{1-4} alkyl or aryl, or R_8 and R_9 are combined together with the group attached to them to form a heterocycle;
- 25 R_5 is hydrogen or C_{1-10} alkyl; and
- 25 A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl;

with the proviso that when said compound is selected from the group consisting of 4H-naphthopyrans, 4H-quinopyrans and 4H-isoquinopyrans and A is phenyl, napthyl, thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, then A is substituted at three or more positions by other than hydrogen.

5

47. The pharmaceutical composition of claim 46, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -OCH₂O-, -(CH₂)₃-, -(CH₂)₄-, -OCH₂CH₂O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

10

15

20

25

48. The pharmaceutical composition of claim 46, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- and -CH=CH-CH=N-.

49. The pharmaceutical composition of claim 46, wherein X is O.

50. The pharmaceutical composition of claim 46, wherein X is O, Y is CN and Z is NH₂.

30


51. The pharmaceutical composition of claim 46, wherein R₅ is hydrogen.

DRAFT EDITION 2020

52. The pharmaceutical composition of claim 46, wherein R₁-R₄ are independently hydrogen, halogen, hydroxy, C₁₋₁₀ alkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, amino, acylamido, acyloxy, alkoxy, methylenedioxy or alkylthiol.

5

53. The pharmaceutical composition of claim 46 comprising said compound or a pharmaceutically acceptable salt or prodrug thereof, wherein A is



10 and R₁₀-R₁₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or

15 R₁₀ and R₁₁, or R₁₁ and R₁₂, taken together with the atoms to which they are attached form an aryl, heteroaryl, optionally substituted carbocyclic or optionally substituted heterocyclic group, wherein said group is optionally substituted.

20

25 54. The pharmaceutical composition of claim 53, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -OCH₂O-, -(CH₂)₃-, -(CH₂)₄-, -OCH₂CH₂O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a

heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

5 55. The pharmaceutical composition of claim 53, wherein R₁ and R₂, or R₂ and R₃, or R₃ and R₄, are taken together to form a structure selected from the group consisting of -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- and -CH=CH-CH=N-.

10 56. The pharmaceutical composition of claim 53, wherein R₁₀ and R₁₁, or R₁₁ and R₁₂, are taken together to form a structure selected from the group consisting of -OCH₂O-, -(CH₂)₃-, -(CH₂)₄-, -OCH₂CH₂O-, -CH₂N(R)CH₂-, -CH₂CH₂N(R)CH₂-, -CH₂N(R)CH₂CH₂-, -CH=CH-CH=CH-, -N(R)-CH=CH-, -CH=CH-N(R)-, -O-CH=CH-, -CH=CH-O-, -S-CH=CH-, -CH=CH-S-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, -CH=CH-CH=N- and -N=CH-CH=N-, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl.

15 57. The pharmaceutical composition of claim 53, wherein R₁ and R₂ together form an optionally substituted ring, wherein said ring is selected from the group consisting of benzo, pyrido, furo, thieno, pyrrolo, imidazo and pyrazo.

20 58. The pharmaceutical composition of claim 57, wherein said ring is selected from the group consisting of benzo, pyrido and pyrrolo.

25 59. The pharmaceutical composition of claim 57, wherein R₁₀ and R₁₁, or R₁₁ and R₁₂, are taken together to form a structure selected from the

group consisting of $-\text{OCH}_2\text{O}-$, $-(\text{CH}_2)_3-$, $-(\text{CH}_2)_4-$, $-\text{OCH}_2\text{CH}_2\text{O}-$,
- $\text{CH}_2\text{N}(\text{R})\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{N}(\text{R})\text{CH}_2-$, $-\text{CH}_2\text{N}(\text{R})\text{CH}_2\text{CH}_2-$,
 $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{N}(\text{R})-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{N}(\text{R})-$, $-\text{O}-\text{CH}=\text{CH}-$,
 $-\text{CH}=\text{CH}-\text{O}-$, $-\text{S}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{S}-$, $-\text{N}=\text{CH}-\text{CH}=\text{CH}-$,
5 $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{CH}=\text{N}-$ and
 $-\text{N}=\text{CH}-\text{CH}=\text{N}-$, wherein R is hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused
aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl,
arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl,
heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or
10 aminoalkyl.

60. The pharmaceutical composition of claim 57, wherein R₃, R₄
and R₅ are each hydrogen.

15 61. The pharmaceutical composition of claim 46, wherein said
compound is selected from the group consisting of:

2-Amino-3-cyano-7-dimethylamino-4-(3-methoxy-4,5-methylene-
dioxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-
20 4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(1-naphthyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-naphthyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4-methoxyphenyl)-
25 4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,6-dimethoxy-
phenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(4-trifluoromethylphenyl)-4*H*-
chromene;

30 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylphenyl)-4*H*-
chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4-fluorophenyl)-4*H*-
chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3,4,5-trimethoxyphenyl)-4*H*-chromene;
- 2-Acetamido-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene;
- 5 2-Di(ethoxycarbonyl)amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-diethylamino-4-(3-pyridyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(4-methyl-3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethylphenyl)-4*H*-chromene;
- 15 3-Cyano-7-dimethylamino-4-(4,5-methylenedioxyphenyl)-2-propionamido-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-methoxyphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-diethylamino-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-cyclohexyl-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-3-trifluoromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,4,5-trifluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,3,4-trifluorophenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-nitrophenyl)-4*H*-chromene;

00200000000000000000000000000000

- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3,4-ethylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethoxyphenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(4-fluoro-3-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-6,7-methylenedioxy-4-(3-methoxy-4,5-methylene-dioxyphenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-ethylamino-4-(3-methoxy-4,5-methylenedioxy-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoromethylenedioxy-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-furyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-thienyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-6-nitrophenyl)-4*H*-chromene;

00000000000000000000000000000000

- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-phenoxyphenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(2-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-phenylethyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-nitrophenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,3-difluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;
- 15 2,7-Diamino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethoxyphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3-(4-methoxyphenoxy)phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dichlorophenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-quinolyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-quinolyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-phenylmethyl-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-carboxaldehydophenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(4-bromo-3,5-dimethoxy-phenyl)-4*H*-chromene;
- 2-Amino-7-acetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;

- 2,7-Diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-ethylamino-6-methyl-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 5 2,7-Diamino-3-cyano-8-methyl-4-(3-methoxy-4,5-methylenedioxyphenyl)-4*H*-chromene;
- 2-Amino-7-chloroacetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-bromophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dibromophenyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-cyanophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chlorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxyphenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3,5-difluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-bis(trifluoromethyl)phenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-5-methoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloromethylphenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-chloromethylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-cyano-4-fluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-nitro-4-fluorophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-methylenedioxyphenyl)-4*H*-chromene;

- 2-Amino-3-cyano-7-methoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylthiophenyl)-4H-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-fluorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-difluoromethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-hydroxyphenyl)-4H-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylaminophenyl)-4H-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-dimethylaminophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Chloroacetamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 25 2-Acylamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 3-Cyano-7-dimethylamino-2-succinimido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 30 3-Cyano-7-dimethylamino-2-phenylureido-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-3-pyridyl)-4H-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-2-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-bromo-4,5-methylenedioxyphenyl)-4H-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-2-nitrophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-ethoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8-dimethyl-4H-chromene;
- 15 2-Amino-3-cyano-7-methoxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-methoxyphenyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-methoxy-4-(3-cyanophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-chlorophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-nitrophenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-bromophenyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-methoxy-4-(5-methyl-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-methoxy-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-methylthio-3-pyridyl)-4H-chromene;
- 30 2-Amino-3-cyano-7-methoxy-4-(5-chloro-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-methyl-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-chloro-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

2-Amino-3-cyano-7-bromo-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

2-Amino-3-cyano-7-bromo-4-(5-methyl-3-pyridyl)-4H-chromene;

2-Amino-3-cyano-7-chloro-4-(5-methyl-3-pyridyl)-4H-chromene;

5 2-Amino-3-cyano-7-ethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;

2-Amino-3-cyano-7-ethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;

and

2-Amino-3-cyano-7-hydroxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-

10 chromene.

62. The pharmaceutical composition of claim 57, wherein said compound is selected from the group consisting of:

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-

15 6,7,8,9,10,11-hexahydro-4H-pyrido[3,2,1-ij]quino[5,6-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-4-(4-bromo-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

20 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

25 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[2,1-b]pyran;

30 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[5,6-b]pyran;

- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-isoquino[5,6-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[8,7-b]pyran;
- 5 2-Amino-3-cyano-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 2-Amino-6-chloro-3-cyano-4-(3-bromo-4-hydroxy-5-methoxyphenyl)-4H-naphtho[1,2-b]pyran;
- 10 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8,9,10-tetrahydro-4H-naphtho[1,2-b]pyran; and
- 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-quino[5,6-b]pyran.

63. The pharmaceutical composition of claim 57, wherein said compound is selected from the group consisting of:

- 15 2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
- 20 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4H-indolo[4,5-b]pyran;
- 25 2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-nitrophenyl)-4H-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3-cyanophenyl)-4H-indolo[4,5-b]pyran;
- 2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;
- and
- 30 9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran.

64. The pharmaceutical composition of claim 41, further comprising at least one known cancer chemotherapeutic agent, or a pharmaceutically acceptable salt of said agent.

5 65. The pharmaceutical composition of claim 64, wherein said known cancer chemotherapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin, Rituxan and alanosine.

10 15 66. The pharmaceutical composition of claim 41, wherein said excipient or carrier is selected from the group consisting of saccharides, starch pastes, gelatin, tragacanth, cellulose preparations, calcium phosphates and polyvinyl pyrrolidone.

20 25 67. The pharmaceutical composition of claim 66, wherein said excipient or carrier is a saccharide selected from the group consisting of lactose, sucrose, manitol and sorbitol.

25 68. The pharmaceutical composition of claim 41, wherein said excipient or carrier is a lipophilic solvent.

30 69. The pharmaceutical composition of claim 68, wherein said lipophilic solvent is selected from the group consisting of fatty oils, fatty acid esters, polyethylene glycols and paraffin hydrocarbons.

70. The pharmaceutical composition of claim 69, wherein said lipophilic solvent is selected from the group consisting of sesame oil, ethyl oleate, triglycerides, polyethylene glycol-400, cremophor and cyclodextrins.

5 71. The pharmaceutical composition of claim 41, wherein said excipient or carrier is selected from the group consisting of vegetable oils, mineral oils, white petrolatum, branched chain fats, branched chain oils, animal fats and high molecular weight alcohol (greater than C₁₂).

10 72. The pharmaceutical composition of claim 41, wherein said excipient or carrier is a saline solution.

15 73. A chromene, selected from the group consisting of:

2-Amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-

4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-naphthyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4,5-trimethoxyphenyl)-4*H*-chromene;

2-Acetamido-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene;

2-Di(ethoxycarbonyl)amino-3-cyano-7-dimethylamino-4-(3,4-methylenedioxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-4,5-methylenedioxyphenyl)-4*H*-chromene;

25 2-Amino-3-cyano-7-dimethylamino-4-(4-methyl-3-nitrophenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethylphenyl)-4*H*-chromene;

30 3-Cyano-7-dimethylamino-4-(4,5-methylenedioxyphenyl)-2-propionamido-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethylphenyl)-4*H*-chromene;

DOCUMENT NUMBER

2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-methoxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-diethylamino-4-(3-methoxy-4,5-methylenedioxy-phenyl)-4*H*-chromene;

5 2-Amino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene:

2-Benzylidenamino-3-cyano-7-dimethylamino-4-phenyl-4*H*-chromene:

2-Amino-3-cyano-7-dimethylamino-4-cyclohexyl-4*H*-chromene:

2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-3-trifluoromethyl-phenyl)-4H-chromene:

10 2-Amino-3-cyano-7-dimethylamino-4-(2,4,5-trifluorophenyl)-4*H*-chromene:

2-Amino-3-cyano-7-dimethylamino-4-(2,3,4-trifluorophenyl)-4*H*-chromene:

2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-nitrophenyl)-4H-chromene:

2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-3-nitrophenyl)-4*H*-chromene:

2-Amino-3-cyano-7-dimethylamino-4-(3-nitrophenyl)-4*H*-chromene:

2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxy-

phenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4-ethylenedioxyphenyl)-4*H*-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3,4-dimethoxyphenyl)-4H-chromene;

25 2-Amino-3-cyano-7-dimethylamino-4-(4-fluoro-3-trifluoromethyl-phenyl)-4H-chromene;

2-Amino-3-cyano-7-dimethylamino-4-(3-pyridyl)-4*H*-chromene;

2-Amino-3-cyano-6,7-methylenedioxy-4-(3-methoxy-4,5-methylene-dioxyphenyl)-4*H*-chromene;

30 2-Amino-3-cyano-7-ethylamino-4-(3-methoxy-4,5-methylenedioxy-phenyl)-4*H*-chromene:

卷之三

- 2-Amino-3-cyano-7-dimethylamino-4-(2-fluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoromethylenedioxy-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,4-difluoro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-furyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-nitro-2-thienyl)-4*H*-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-6-nitrophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-chloro-5-nitrophenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(3-phenoxyphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-phenylethyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-nitrophenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-5-trifluoromethyl-phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2,3-difluoro-4-trifluoromethyl-phenyl)-4*H*-chromene;
- 2,7-Diamino-3-cyano-4-(3-methoxy-4,5-methylenedioxophenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(4-pyridyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dimethoxyphenyl)-4*H*-chromene;

DRAFT 10/18/2020 2:50

- 2-Amino-3-cyano-7-dimethylamino-4-(3-(4-methoxyphenoxy)phenyl)-
4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dichlorophenyl)-4*H*-
chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-fluoro-6-trifluoromethyl-
phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-quinolyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-quinolyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-phenylmethyl-4*H*-chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(4-carboxaldehydophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-bromo-3,5-dimethoxy-
phenyl)-4*H*-chromene;
- 15 2-Amino-7-acetamido-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
chromene;
- 2,7-Diamino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-ethylamino-6-methyl-4-(3-methoxy-4,5-
methylenedioxyphenyl)-4*H*-chromene;
- 20 2,7-Diamino-3-cyano-8-methyl-4-(3-methoxy-4,5-methylenedioxy-
phenyl)-4*H*-chromene;
- 2-Amino-7-chloroacetamido-3-cyano-4-(3-bromo-4,5-dimethoxy-
phenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromophenyl)-4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3,5-dibromophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-cyanophenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylphenyl)-4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-chlorophenyl)-4*H*-chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-methoxyphenyl)-4*H*-
chromene;

- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-difluorophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3,5-bis(trifluoromethyl)-
phenyl)-4*H*-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-5-methoxyphenyl)-
4*H*-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloromethylphenyl)-4*H*-
chromene;
- 10 2-Amino-3-cyano-7-dimethylamino-4-(3-chloromethylphenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-cyano-4-fluorophenyl)-4*H*-
chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(3-nitro-4-fluorophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-bromo-4,5-methylenedioxy-
phenyl)-4*H*-chromene;
- 20 2-Amino-3-cyano-7-methoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylthiophenyl)-
4*H*-chromene;
- 25 2-Amino-3-cyano-7-dimethylamino-4-(3-difluoromethoxyphenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-hydroxyphenyl)-4*H*-
chromene;
- 30 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethoxyphenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-methylaminophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-dimethylaminophenyl)-4*H*-
chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-
4*H*-chromene;

DRAFT FOR INTERNAL USE

- 2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxy-phenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
- 5 2-Amino-3-cyano-7-dimethylamino-4-(3-chloro-4,5-dimethoxy-phenyl)-4H-chromene;
- 2-Chloroacetamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 10 2-Acrylamido-3-cyano-7-dimethylamino-4-(3-bromo-4,5-dimethoxy-phenyl)-4H-chromene;
- 3-Cyano-7-dimethylamino-2-succinimido-4-(3-bromo-4,5-dimethoxy-phenyl)-4H-chromene;
- 3-Cyano-7-dimethylamino-2-phenylureido-4-(3-bromo-4,5-dimethoxy-phenyl)-4H-chromene;
- 15 2-Amino-3-cyano-7-dimethylamino-4-(5-bromo-3-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-3-pyridyl)-4H-chromene;
- 20 2-Amino-3-cyano-7-dimethylamino-4-(6-methyl-2-pyridyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(2-bromo-4,5-methylenedioxy-phenyl)-4H-chromene;
- 2-Amino-3-cyano-7-dimethylamino-4-(4-chloro-2-nitrophenyl)-4H-chromene;
- 25 2-Amino-3-cyano-7-ethoxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8-dimethyl-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene;
- 30 2-Amino-3-cyano-7-methoxy-4-(3,5-dimethoxyphenyl)-4H-chromene;
- 2-Amino-3-cyano-7-methoxy-4-(3-methoxyphenyl)-4H-chromene;

2009 RELEASE UNDER E.O. 14176

2-Amino-3-cyano-7-methoxy-4-(3-cyanophenyl)-4H-chromene;
2-Amino-3-cyano-7-methoxy-4-(3-chlorophenyl)-4H-chromene;
2-Amino-3-cyano-7-methoxy-4-(3-nitrophenyl)-4H-chromene;
2-Amino-3-cyano-7-methoxy-4-(3-bromophenyl)-4H-chromene;
5 2-Amino-3-cyano-7-methoxy-4-(5-methyl-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-methoxy-4-(5-methoxy-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-methoxy-4-(5-methylthio-3-pyridyl)-4H-
chromene;
10 2-Amino-3-cyano-7-methoxy-4-(5-chloro-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-methoxy-4-(5-bromo-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-methyl-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
15 2-Amino-3-cyano-7-chloro-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
2-Amino-3-cyano-7-bromo-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene;
2-Amino-3-cyano-7-bromo-4-(5-methyl-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-chloro-4-(5-methyl-3-pyridyl)-4H-chromene;
2-Amino-3-cyano-7-ethylamino-4-(3-bromo-4,5-dimethoxyphenyl)-
20 4H-chromene;
2-Amino-3-cyano-7-ethylamino-4-(5-methyl-3-pyridyl)-4H-chromene;
and
2-Amino-3-cyano-7-hydroxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-
chromene.
25

74. A naphthopyran, quinopyran or isoquinopyran, selected from the group consisting of:

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxypyphenyl)-
6,7,8,9,10,11-hexahydro-4*H*-pyrido[3,2,1-ij]quino[5,6-b]pyran;
30 2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-
naphtho[1,2-b]pyran;

2-Amino-3-cyano-4-(4-bromo-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-4-(3-methoxy-4,5-methelenedioxophenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-7-dimethylamino-4-(3-iodo-4,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-7-dimethylamino-4-(4-acetoxy-3,5-dimethoxyphenyl)-4H-naphtho[1,2-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-naphtho[2,1-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[5,6-b]pyran;


2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-isoquino[5,6-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-quino[8,7-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-7,8,9,10-tetrahydro-4H-naphtho[1,2-b]pyran; and

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-quino[5,6-b]pyran.

75. An indolopyran of Formula I:



or a pharmaceutically acceptable salt or prodrug thereof, wherein:

B is optionally substituted indolo;

X is O;

Y is CN, COR₇, CO₂R₇ or CONR_xR_y, wherein R₇, R_x and R_y are independently hydrogen, C₁₋₁₀ alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R_x and R_y are taken together with the nitrogen to which they are attached to form a heterocycle;

Z is NR₈R₉, NHCOR₈, N(COR₈)₂, N(COR₈)(COR₉), N=CHOR₈ or N=CHR₈, wherein R₈ and R₉ are independently H, C₁₋₄ alkyl or aryl, or R₈ and R₉ are combined together with the group attached to them to form a heterocycle;

R₅ is hydrogen or C₁₋₁₀ alkyl; and

A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl.

76. The compound of claim 75, wherein said compound is an optionally substituted 4H-indolo[4,5-b]pyran.

77. The compound of claim 76, wherein A is optionally substituted phenyl.

78. The compound of claim 77, wherein said compound is selected from the group consisting of:

2-Amino-3-cyano-4-(3-methoxy-4,5-methylenedioxyphenyl)-4H-indolo[4,5-b]pyran;

2-Amino-3-cyano-4-(2-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[4,5-b]pyran;

2-Amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-8-methyl-4H-indolo[4,5-b]pyran;

2-Amino-3-cyano-4-(3,4,5-trimethoxyphenyl)-4H-indolo[4,5-b]pyran;

2-Amino-3-cyano-4-(3-nitrophenyl)-4*H*-indolo[4,5-b]pyran;

2-Amino-3-cyano-4-(3-cyanophenyl)-4*H*-indolo[4,5-b]pyran;

2-Amino-3-cyano-4-(3,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran;

and


5 9-Acetamide-2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-indolo[4,5-b]pyran.

Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof

5

Abstract

The present invention is directed to substituted 4H-chromene and analogs thereof, represented by the general Formula I:



10

wherein A, B, X, Y, Z and R₅ are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

15

Figure 1A




Figure 1B




Figure 2





Figure 3



0.00 0.05 0.10 0.15 0.20




Fig.4A




Fig.4B

0.9705840 = 4.406500




Fig.5A




Fig.5B




Fig.5C




Fig.6A




Fig.6B




Fig.6C

Declaration for Patent Application

Docket Number: 1735.0410002/RWE/BEC

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled
Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof,
the specification of which is attached hereto unless the following box is checked:

- was filed on _____;
as United States Application Number or PCT International Application Number _____; and
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)	Priority Claimed
(Application No.)	(Country)
(Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Application No.)	(Country)
(Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

<u>60/185,211</u> (Application No.)	<u>February 24, 2000</u> (Filing Date)
<u>60/163,584</u> (Application No.)	<u>November 5, 1999</u> (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application No.)	(Filing Date)	(Status - patented, pending, abandoned)
(Application No.)	(Filing Date)	(Status - patented, pending, abandoned)



Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	John A. Drewe
Signature of sole or first inventor	 11/3/00 Date X
Residence	Costa Mesa, California Carlsbad, California X
Citizenship	United States of America
Post Office Address	2175 Pacific Avenue, B+ 7069 Murillo Lane X Costa Mesa, California 92627 Carlsbad, California 92009 X
Full name of second inventor	Sui Xiong Cai
Signature of second inventor	 11/3/00 Date X
Residence	San Diego, California
Citizenship	United States of America
Post Office Address	3623 Berryfield Court San Diego, California 92130
Full name of third inventor	Yan Wang
Signature of third inventor	 11/3/00 Date X
Residence	San Diego, California
Citizenship	People's Republic of China
Post Office Address	12760 Rancho Penasquitos Boulevard, #67 9218 Balcones Club Dr. #2514 San Diego, California 92129 Austin, TX 78750

(Supply similar information and signature for subsequent joint inventors, if any)

POWER OF ATTORNEY FROM ASSIGNEE

Cytovia, Inc., a corporation of Delaware, having a principal place of business at 6650 Nancy Ridge Drive, San Diego, California 92121, is assignee of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee executed on November 3, 2000 of an invention known as Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof (Attorney Docket No. 1735.0410002/RWE/BEC), which is disclosed and claimed in a patent application of the same title by the inventor(s) John A. Drewe, Sui Xiong Cai and Yan Wang (said application filed on (herewith) at the U.S. Patent and Trademark Office, having Application Number (to be assigned)).

The Assignee hereby appoints the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; Samuel L. Fox, Esq., Reg. No. 30,353; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; John M. Covert, Esq., Reg. No. 38,759; and Linda E. Alcorn, Esq., Reg. No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Cytovia, Inc.

SIGNATURE: 

BY: Prasad Sunkara, PhD

TITLE: Sr Vice President, Research & Development

DATE: 4/5/00 11-3-00